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1 Abstract 
Impaired insulin signaling due to peripheral insulin resistance and failure of pancreatic 
insulin secretion is a key factor for the onset and manifestation of type 2 diabetes 
mellitus (T2D). Insulin receptor (IR) agonists are being developed to restore insulin 
signaling via direct activation of the cytoplasmic insulin receptor tyrosine kinase activity. 
Two classes of such compounds have been developed by the pharmaceutical 
companies Merck & Co., Inc., and Telik, Inc., but in patents and literature there is no 
data as to how these compounds activate the IR kinase activity.  
Attempts to solve the crystal structures of dimeric human IR kinase domains and 
complexes of these with IR agonists within this thesis failed. However, biophysical 
characterization of the full-length intracellular part of the IR containing the kinase 
domain demonstrated an intrinsic ability to dimerize independently of the enzyme-
substrate type of interaction seen in IR autophosphorylation. This dimer formation was 
found to be enhanced in the presence of a distinct IR agonist. 
Crystals of various constructs and isoforms of the key antidiabetic target AMP-activated 
protein kinase (AMPK) were obtained. Despite substantial optimization trials these 
crystals were not sufficient for solving the structure of AMPK.  
However, the crystal structure of carnitine palmitoyltransferase 2 (CPT-2), a protein 
downstream of the metabolite signaling initiated by AMPK, was solved. CPT-1 and -2 
facilitate the import of long-chain fatty acids into mitochondria. Modulation of the 
catalytic activity of the CPT system is currently under investigation for the development 
of novel drugs against diabetes mellitus. The crystal structure of the full-length 
mitochondrial membrane protein CPT-2 was solved at a resolution of 1.6 Å. The 
structure of CPT-2 in complex with the generic CPT-inhibitor ST1326 [(R)-N-
tetradecylcarbamoyl-aminocarnitine], a substrate analog mimicking palmitoylcarnitine 
and currently in clinical trials for T2D treatment, was solved at 2.5 Å resolution. These 
structures of CPT-2 provide insight into the function of residues involved in substrate 
binding and determination of substrate specificity, thereby facilitating the rational design 
of novel antidiabetic drugs. A sequence insertion uniquely found in CPT-2 was identified 
that mediates membrane localization. Mapping of mutations described for CPT-2 
deficiency, a hereditary disorder of lipid metabolism, implies effects on substrate 
recognition and structural integrity of CPT-2. 
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2 Introduction 
2.1 Type 2 diabetes mellitus: an increasing health burden 
The peptide hormone insulin released from the β-cells of the pancreas is a major 
regulator of glucose homeostasis and responsible for the uptake of glucose from blood 
plasma into cells. Type 2 diabetes mellitus (T2D) is a metabolic disorder characterized 
by resistance of peripheral target tissues, especially skeletal muscle, adipose tissue and 
liver, to insulin and concomitant relative insulin deficiency. More than 90 % of the 
diabetics worldwide have the T2D form of the disease as opposed to app. 5 % type 1 
(T1D) diabetics, where an absolute insulin deficiency is elicited by destruction of 
pancreatic β-cells due to autoimmune processes. These two major presentations of 
diabetes were historically differentiated as non-insulin-dependent vs. insulin-dependent 
diabetes mellitus (NIDDM and IDDM, respectively). However, according to the 
recommendations of the Expert Committee on the Diagnosis and Classification of 
Diabetes Mellitus of the American Diabetes Association (ADA, 2003) this terminology 
should now be regarded as obsolete. T2D patients may eventually become dependent 
on insulin supplementation due to β-cell failure as a consequence of prolonged 
compensation stress. The remaining < 5% of diabetes cases can be attributed to 
gestational (BUCHANAN and XIANG, 2005) and mitochondrial (MAASSEN et al., 2004) 
diabetes mellitus as well as rare monogenic presentations such as maturity-onset 
diabetes of the young (MODY; SHIH and STOFFEL, 2002). In addition, various 
endocrinopathies (e.g., Cushing's syndrome) and genetic syndromes (e.g., Down's 
syndrome, Friedreich's ataxia) may be associated with diabetes mellitus depending on 
the severity of the symptomology (ADA, 2003). 
The diverse metabolic abberations underlying T2D are of multifactorial etiology and 
render T2D a clinically heterogenous disease (O'RAHILLY et al., 2005). The common 
symptoms relevant for the diagnosis of diabetes mellitus are casual peaks in the plasma 
glucose concentration above 200 mg/dl (11.1 mM) combined with polyuria, polydipsia 
and weight loss. Alternatively, diabetes mellitus is diagnosed if the fasting plasma 
glucose concentration is raised to more than 126 mg/dl (7 mM) or when an impaired 
glucose clearance from plasma is detected during an oral glucose tolerance test [i.e., 
plasma glucose levels above 200 mg/dl (11.1 mM) 2 h after oral administration of 75 g 
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glucose dissolved in water; ADA, 2003]. The increasingly impaired fasting glucose and 
glucose tolerance precede the manifestation of overt diabetes mellitus (STUMVOLL et 
al., 2005) and are frequently accompanied by visceral obesity, dyslipidemia (i.e., 
hypertriglyceridemia and decreased plasma high density lipoprotein) and hypertension. 
This constellation of risk factors is referred to as the metabolic syndrome (syndrome X; 
ALBERTI et al., 2005). The highest prevalance of the metabilic syndrome is found in the 
US population (app. 39 %; FORD, 2005), but affects an increasing part of the population 
worldwide. As an effect of this, the number of T2D patients is expected to raise from 
currently app. 190 million to more than 300 million worldwide within the next 20 years 
(Figure 2.1-1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1-1: Number of type 2 diabetics worldwide, in millions.The increase in patient number since 
1985 (squares, continuous line) is linearly extrapolated to the year 2025 in order to visualize a "prognosis 
cone" together with the prospective least patient numbers in 2010 and 2025 (triangles, dashed line; data 
compiled from KING et al., 1998; ZIMMET et al., 2001; RONDINONE, 2005; STUMVOLL et al., 2005; 
http://www.who.int/topics/diabetes_mellitus/en/). 
 
Therefore, diabetes mellitus represents a growing health burden as its occurence is 
highly correlated with an increased risk of cardiovascular disease (atherosclerosis, heart 
disease, diabetic retinopathy), neuropathy (sensory loss, diabetic foot disease), and 
nephropathy (kidney failure rendering patients dependent on hemodialysis). These 
complications emerge due to chronic hyperglycemia which causes tissue damage by 
nonenzymatic glycation of proteins, lipids and DNA (ADA, 2003).  
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2.2 Pharmacological treatment of diabetes mellitus 
The vastly growing incidence of T2D worldwide (diabetes epidemic; ZIMMET et al., 
2001) and its severe health consequences have to be met by pharmacologic 
intervention. The lack of endogeneous insulin in T1D can be effectively treated by 
application of the proper insulin preparations (VAJO and DUCKWORTH, 2000). For 
T2D, several treatments are established today that are applied depending on desease 
progression and severity of symptoms. Clinically mild presentations of T2D can be 
treated by established antidiabetic drugs such as insulin secretagogues, insulin 
sensitizing thiazolidinediones (TZDs), which are agonists of the nuclear hormone 
receptor PPARγ, and metformin (reviewed in WAGMAN and NUSS, 2001). Advanced 
T2D requires administration of exogeneous insulin. The mechanism of action of insulin 
is well established and has been extensively reviewed (KAHN and PESSIN, 2002; 
WHITE, 2003).  
Several members of the TZD class of compounds were approved for the treatment of 
T2D. However, some TZDs had to be withdrawn from clinical development and the use 
of approved substances had to be restricted due to hepatotoxicity issues (WAGMAN 
and NUSS, 2001).  
The possibility to mimic the insulin-mediated activation of the insulin receptor (IR) by 
orally available pharmaceutical substances was confirmed by the discovery of small-
molecules that either directly activate the IR (ZHANG et al., 1999) or do so 
synergistically with insulin (insulin enhancer; MANCHEM et al., 2001). To our 
knowledge, none of these small-molecule IR agonsits has entered the clinical phase of 
development, and results of this thesis demonstrate why this may be the case. 
Metformin decreases plasma glucose levels by inhibition of hepatic gluconeogenesis 
and increasing glucose consumption in peripheral tissues. This effect can at least 
partially be attributed to (indirect) activation of the 5'-AMP-activated protein kinase 
(AMPK), which is physiologically activated upon an increase in the [AMP]/[ATP] ratio 
due to exercise, hypoxia or hormonal stimuli (reviewed in HARDIE and HAWLEY, 2001; 
CARLING, 2004; KAHN et al., 2005; Figure 2.3-1). Metformin fails to directly activate 
purified AMPK in vitro, even in the presence of AMP (U. Riek, ETH Zurich, personal 
communication), but, like TZDs, stimulates AMPK kinase activity in isolated hepatocytes 
and cultures muscle cells (ZHOU et al., 2001; FRYER et al., 2002; SAHA et al., 2004). 
___________________________________________________________Introduction 
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Although metformin was shown to inhibit complex 1 of the respiratory chain, thereby 
increasing the [AMP]/[ATP] ratio, the metformin-mediated activation of AMPK can 
proceed in both adenin nucleotide-dependent and -independent manner (FRYER et al., 
2002; HAWLEY et al., 2002; ZOU et al., 2004).  
However, there is strong experimental evidence that the controlled direct 
pharmacological activation of AMPK could prevent the progression from a pre-diabetic 
state with impaired glucose tolerance to the manifestation of overt T2D and would also 
ameliorate the key symptoms of T2D (HARDIE and HAWLEY, 2001). The adenine 
nucleotide analog 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) is 
converted into its 5'-monophosphorylated form, ZMP, by adenosine kinase upon 
entering cells. ZMP mimics AMP and is an allosteric activator of AMPK both in vitro and 
in vivo. Impaired insulin sensitivity was found to be highly correlated with reduced 
enzymatic activity of AMPK and ZMP was shown to effectively improve the glucose 
tolerance, hyperglycemia and dyslipidemia in animal models of insulin resistance and 
diabetes (HARDIE and HAWLEY, 2001; YE et al., 2005). These effects of AMPK 
activation are due to the normalization of substrate flux into catabolic, energy-generating 
metabolic pathways with simultaneous down-regulation of anabolic pathways. AMPK 
phosphorylates and inactivates acetyl-CoA carboxylase (ACC) which catalyzes the 
commited step of fatty acid (FA) synthesis, the formation of malonyl-CoA from acetyl-
CoA (CARLING et al., 2003; Figure 2.3-1). The production of FA and triglycerides in 
lipogenic tissues and ectopic lipid disposal in skeletal muscle, both of which are 
causative for peripheral insulin resistance and impaired glucose tolerance (lipotoxicity), 
are decreased by AMPK (CARLING et al., 2003; SCHINNER et al., 2005). Thus, 
activation of AMPK reduces the FA-dependent serine phosphorylation of insulin 
receptor substrate 1 (IRS-1) by various PKC isoforms which impaires the insulin-
dependent glucose uptake by the glucose transporter GLUT4 (ZICK, 2003 and 2005).  
Malonyl-CoA is an inhibitor of carnitine palmitoyltransferase 1 (CPT-1) and diminishing 
malonyl-CoA levels upon AMPK activation allow an increased import of FA into 
mitochondria via CPT-1 which supports the mobilization of excess lipid depots in 
skeletal muscle and adipocytes. In the liver the acetyl-CoA derived from β-oxidation is a 
potent allosteric activator of pyruvate carboxylase (PC, Figure 2.3-1), which initiates 
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gluconeogenesis (JITRAPAKDEE and WALACE, 1999), but here AMPK inhibits 
substrate flux into hepatic gluconeogenesis (HARDIE et al., 2003).  
Therefore, both the pharmacologic activation of (muscle) AMPK and the inhibition of 
liver CPT-1 are rational, novel means for reestablishing normoglycemia in T2D patients, 
by reversing peripheral insulin resistance and normalization of the hepatic 
gluconeogenesis rate, respectively. 
 
2.3 Molecular aspects of IR and AMPK signaling 
Insulin elicits its effects on metabolism via the insulin receptor (IR, Figure 2.3-1). The IR 
is a type II receptor tyrosine kinase with additional intrinsic dual kinase activity 
(TENNAGELS et al., 2001) and is expressed in liver, muscle, adipose tissue and 
neurons, among other tissues. Insulin binds to the extracellular α-subunits of the (αβ)2-
heterotetrameric IR, thereby inducing a change in conformation of and activating the 
intracellular kinase domain of the transmembrane β-subunits of (VAN OBBERGHEN et 
al., 2001; DE MEYTS and WHITTAKER, 2002; DE MEYTS, 2004). 
Two isoforms of the IR have been described (SEINO and BELL, 1989). The α-subunit of 
IR-A lacks 12 amino acids at the carboxy-terminus compared to isoform IR-B as a result 
of alternative splicing of exon 11. Thus, two nomenclature conventions exist: 1. IR-A, 
ULLRICH et al. (1985) and 2. IR-B, EBINA et al. (1985), which was adopted in this 
thesis in accordance with the residue numbering used for the structure of IR core kinase 
domain (HUBBARD et al., 1994). 
It has been demonstrated that the two isoforms have different properties with regard to 
insulin affinity, receptor endocytosis and recycling as well as expression patterns 
(YAMAGUCHI et al., 1993, and references therein). A change in expression rate and 
isoform-ratio has been implicated in the compensatory mechanism during insulin 
resistance, but it has not been conclusively shown whether this process is involved in 
the pathogenesis of T2D or might be exploited for the treatment of diabetic patients 
(HARING et al., 1994; DE MEYTS and WHITTAKER, 2002). 
Several lines of evidence demonstrated the existence of hybrid receptors consisting of 
an IR (αβ)-protomer covalently linked to an (αβ)-protomer of the insulin-like growth 
factor 1 receptor (IGF-1R). Depending on the isoform of the IR protomer, these hybrid 
receptors have different affinity for insulin and IGF-1 as well as distinct signaling 
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properties (PANDINI et al., 2002). The physiological functions in health and disease of 
the hybrid receptors and that of the insulin-receptor-related receptor (IRR; KLAMMT et 
al., 2005) remain to be established. 
The subunits of the IR are transcribed from a single gene and translation yields a pre-
pro-receptor, which is processed to the functional, glycosylated IR in the endoplasmatic 
reticulum and Golgi-compartment (WILLIAMS et al., 1990). The IR associates with 
multiple adaptor, substrate and effector proteins that modulate its catalytic activity and 
signaling properties (KAHN and PESSIN, 2002; PIROLA, 2004).  
 
Figure 2.3-1: The interrelation of the insulin signaling response (dashed box) with two key regulators of 
glucose homeostasis and fatty acid metabolism, AMPK and the CPT-system. Abbreviations as outlined in 
the text, CACT = carnitine/acylcarnitine translocase. Enzymes examined in this thesis are the IR (green), 
AMPK (blue) and CPT-2 (magenta). Green arrows indicate activation, red arrows denote inhibition. 
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For the experiments documented in this thesis the focus was put on the intracellular 
tyrosine kinase domain of the insulin receptor (IRTK; HERRERA et al., 1988) as well as 
fusion proteins of IRTK or the core kinase of the IR (IRK; HUBBARD et al., 1994) with 
the constitutively dimeric glutathione S-transferase from Schistosoma japonicum (GST; 
BAER et al., 2001). 
As the concerted regulation of IR effector proteins is abrogated in insulin resistance and 
diabetes and no clinically save small-molecule IR-agonists exist to date, AMPK and the 
CPT system have been identified as candidate drug targets for restoring glucose 
homeostasis. 
AMPK is a heterotrimeric protein, consisting of a catalytic α- subunit (two isoforms) and 
two regulatory β- and γ-subunits (two and three isoforms, respectively). The 12 isoforms 
combinations can be further modified by alternative promoter usage, splicing, tissue 
specific expression and post-translational modification, including multiple 
phosphorylation (α- and β-subunits) and myristoylation (β-subunit; FRYER and 
CARLING, 2003; CARLING, 2004). The physiological allosteric activator AMP binds to 
the CBS-domains of the γ-subunit (SCOTT et al., 2004; KEMP et al., 2003) which 
renders the activation-loop of the α-subunit a better substrate for the upstream kinases 
LKB1 and Ca2+/calmodulin-activated protein kinase kinase (CAMKK; WOODS et al., 
2003 and 2005). The β-subunit tethers the α- and γ-subunits and also contains a 
glycogen binding domain which might serve to target AMPK to substrates associated 
with glycogen-particles (POLEKHINA et al., 2005B). This is in-line with the finding that 
AMPK phosphorylates and inactivates glycogen synthase, thereby inhibiting 
glycogenesis (HARDIE et al., 2003). As AMPK also inhibits lipid synthesis its effects 
may seem to partialy oppose those of insulin. While this is indeed the case in a healthy 
metabolic setting (AMPK is considered a fuel-gauge that senses and counteracts 
nutrient shortfall, while insulin regulates post-prandial nutrient storage), the enzymatic 
activity of AMPK is supressed as an effect of excess dietary calory intake, obesity and 
physical inactivity (YE et al., 2005). In patients with metabolic syndrome and/or T2D the 
activation of AMPK would allow dissipation of excess energy stores and plasma 
glucose. This is emphasized by the observation that AMPK promotes the translocation 
of GLUT4 from intracellular compartments to the cell surface in an IRS-1 dependent 
___________________________________________________________Introduction 
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manner (JAKOBSEN et al., 2001), which provides a point of convergence with signaling 
of the IR. 
In the liver an increased substrate flux via the CPT-system results in substantial 
upregulation of gluconeogenesis due to prevailing glucagonergic effects and via 
stimulation of pyruvate carboxylase by acetyl-CoA. In T2D patients, whose insulin-
sensitive tissues are deprived of glucose, lipogenesis in the adipose tissue and β-
oxidation in the liver is highly upregulated, which further suppresses glycolysis. The 
forced formation of ketone bodies from FA aggravates the diabetic state because these 
metabolites promote the insulin resistance in skeletal muscle. If not treated properly this 
metabolic imbalance can eventually lead to diabetic ketoacidosis.  
 
It should be emphasized that the metabolic regulation and potential pharmaceutical 
approaches described so far are restricted to peripheral tissues. However, the IR, 
AMPK as well as CPT enzymes are also expressed in the central nervous system 
(CNS) with high abundance in the hypothalamus (ISGANAITIS and LUSTIG, 2005; 
KAHN et al., 2005; PLUM et al., 2005; OBICI et al., 2003). Here these proteins regulate 
systemically food intake and energy homeostasis via the efferent pathways of the 
autonomous nervous system (sympathetic and parasympathetic signals).  
The peripheral tissues signal to the hypothalamus by means of the release of peptide 
hormones (insulin, adipokines, gut hormones) into the blood. Interestingly, the AMPK 
and the CPT-system are reciprocally regulated in the hypothalamus vs. periphery. 
Insulin and leptin dependent inhibition of hypothalamic AMPK activity constitutes an 
anorexigenic signal in experimental animal models (KAHN et al., 2005). Food intake is 
also diminished by pharmacological inhibition of the CPT-system in the CNS, either 
directly by adminstration of the competetive pseudosubstrate ST1326 (OBICI et al., 
2003) or indirectly by inhibition of fatty acid synthase by the compound C75 (KIM et al., 
2004). The latter results in accumulation of the allosteric CPT-1 inhibitor malonyl-CoA. 
In addition, defects in insulin as well as IGF-1 signaling have been implicated in the 
progression of central neurodegenerative diseases (especially Alzheimer's disease; 
PLUM et al., 2005) which suggests a neuroprotective function of these peptide 
hormones. 
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2.4 Specific aims 
During the course of this thesis three projects were followed up with the purpose to 
1) assess the crystallizability and to solve the crystal structure of a GST-dimerized IR (or 
alternatively IGF-1R) construct and to evaluate its interaction with published agonists. 
2) assess the crystallizability of and to solve the crystal structure of AMPK or truncated 
constructs thereof. 
3) assess the crystallizability and to solve the crystal structure of CPT-2. 
 
Projects 1 and 2 were terminated because no crystals suitable for solving the crystal 
structures were obtained and the published IR agonists had adverse effects on the 
integrity of the intracellular part of the IR in vitro. The aim of project 3 was successfully 
accomplished. 
__________________________________________________Results: IR and IGF-1R 
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3 Results 
3.1 Characterization and crystallization of IR and IGF-1R 
constructs 
3.1.1 Summary of literature data 
The kinase domain of the IR was the first tyrosine kinase whose structure was solved by 
X-ray crystallography (HUBBARD et al., 1994). Since then a number of mechanistic 
studies on the enzymology of the IR and IGF-1R kinase activities were accompanied by 
crystallographic examinations of intrinsically monomeric kinase domains (Table 3.1.1-1). 
 
Receptor PDB code Author (Publication) Comment 
1irk HUBBARD et al., 1994 apo, 0-P 
1ir3 HUBBARD et al., 1997 AMP-PNP, 3-P 
1gag Parang et al., 2001 bisubstrate inhibitor 
1i44 Till et al., 2001 Asp1161Ala in A-loop 
1p14 Li et al., 2003 role of Tyr984 in JM 
IR 
1rqq Hu et al., 2003 complex with SH2 of APS 
1k3a FAVELYUKIS et al. 2001 AMP-PCP, 3-P 
1jqh PAUTSCH et al., 2001 AMP-PNP, 2-P 
1m7n MUNSHI et al., 2002 apo, 0-P, dimer? 
IGF-1R 
1p4o MUNSHI et al., 2003 apo, 0-P, hinge mutant, dimer? 
Table 3.1.1-1: Compilation of IR and IGF-1R related entries in the PDB. No PDB entry has been released 
for a study by ABLOOGLU et al., 2000, where peptide substrates containing a fluorinated tyrosine residue 
were used to investigate the mechanism of phosphotransfer. 
 
Despite the low resolution structure of the IR with bound insulin determined by electron 
microscopy (LUO et al., 1999), only in the two crystal structures of the 
unphosphorylated kinase domain of the highly homologous IGF-1R (PDB codes 1m7n 
and 1p4o) the formation of dimers can be observed. In both structures the contents of 
the asymmetric unit consists of a dimer with the active sites facing each other, while a 
second dimer with the αD-helices as interface is generated via crystallographic 
symmetry (MUNSHI et al., 2003).  
However, from these structures it cannot be inferred how autophosphorylation occurs. 
The activation loop (A-loop) adopts a similar conformation as seen in the structure of the 
unphosphorylated IRK (PDB code 1irk) with Tyr1135 forming a tight hydrogen bond 
(2.57 Å in chain A) with the catalytic Asp1105. This conformation of the A-loop does not 
allow the simultaneous binding of ATP and autophosphorylation. Here it should be 
noted that the conformation of the A-loop in the structures of the unphosphorylated IRK 
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and IGFK is not a means of autoinhibition because physiological concentrations of ATP 
or dimerization can readily displace the A-loop (MADDUX and GOLDFINE, 1991; 
FRANKEL et al., 1999 and 2001; BAER et al., 2001).  
Moreover, the A-loop of IRK was classified as non-gated (ADAMS, 2003), i.e., 
phosphorylation of A-loop tyrosines enhances the phosphoryl transfer step but not 
substrate (ATP and peptide) binding. The amino-terminal peptide of one monomer of 
IGFK (including the autophosphorylation site Tyr950) is reciprocally situated in the 
active site cleft of the second monomer in the asymmetric unit of the high resolution 
structure of IGFK (PDB code 1p4o). This conformation is also not compatible with 
autophosphorylation. The hydroxy group of Tyr950 (chain B) is 5.38 Å away from the 
nearest side chain oxygen of the catalytic residue ASP1105 of chain A.  
Therefore, these residues are not positioned within hydrogen-bonding distance, which is 
a prerequisite for the phosphotransfer reaction to occur (ADAMS, 2001). Moreover, the 
amino-terminus of IGFK occupies the space taken by the A-loop in the active 
conformation of IGFK (PDB code 1k3a) and phosphorylation of the juxtamembrane has 
been shown to occur in cis, i.e., in an intramolecular reaction,  for the highly homolgous 
IR (CANN and KOHANSKI, 1997).  
 
3.1.2 Crystallization experiments on dimeric IR and IGF-1R constructs 
In order to elucidate the crystal structures of functional dimeric IR and IGF-1R kinase 
domains the full-length intracellular domains or truncated kinase domains of these 
receptors were expressed as fusion proteins  with the constitutively dimeric protein GST 
(by K. Baer, M. Gompert, L. Thiebach; Table 3.1.2-1; BAER et al., 2001). This thesis 
assignment comprised purification of these constructs (Figure 3.1.2-1) and subjection to 
crystallization trials.  
 
Construct AA Source Comment 
His6_IRTK R953- S1355 Sf9, in-house, H-J. Schönfeld monomer 
GST-IRTK R953- S1355 Sf9, lysate & cells, Klein group dimer 
GST-IRTK_D1120A R953 - 1355 Sf9, lysate & cells, Klein group dimer, inacive 
GST-IRTK_∆NT/CT 
(GST-IRK) V978 - K1283 Sf9, lysate & cells, Klein group dimer, NT and CT deletion 
GST-IGFK_∆NT/CT V986 - K1286 Sf9, lysate & cells, Klein group dimer, NT and CT deletion 
Table 3.1.2-1: Constructs of human IR and IGF-1R used for characterization and crystallization. The 
monomeric hexahistidine-tagged construct His6_IRTK was used for the investigation of the effect of IR-
agonists on dimerization (see 3.1.3). AA = amino acids of IR or IGF-1 fused to GST. 
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The GST-tag and purification by GST affinity chromatography increased the stability and 
yield of the tagged vs. untagged kinase domains, respectively. In addition to GST-
mediated dimerization, these constructs also allowed the exploitation of carrier protein 
(i.e., GST) driven crystallization (CARTER et al., 1994; LIM et al., 1994; MCTIGUE et 
al., 1995A and 1995B; KUGE et al., 1997; TANG et al., 1998; HAN et al., 2001; ZHAN 
et al., 2001; SMYTH et al., 2003). 
A two step purification protocol [1. GSH-sepharose affinity chromatography, 2. size 
exclusion chromatography (SEC)] yielded 10 - 15 mg of purified fusion protein from app. 
109 Sf9 cells. While the solubilization and the affinity chromatography were performed 
with DTT as reducing agent, tris-(2-carboxyethyl)phosphine (TCEP, GETZ et al., 1999) 
was used during the final SEC in order to avoid any covalent modification on cysteine 
residues of the enzyme by DTT or glutathione, which was used for elution from the 
GST-affinity column. The post-translational modification of proteins, including the IR, 
with thiol-reactive compounds is now recognized as a reversible means of regulating 
their activity in response to oxidative stress (SCHMID et al., 1998; O'BRIEN and CHU, 
2005). As a change in activity is generally accompanied by a change in conformation, 
any heterogeneity with respect to redox-modifications was sought to be avoided during 
preparation and crystallization of the GST-tagged IR and IGF-1R constructs.  
Physiological as well as exogenous redox reagents had been described to alter the 
activity of the holo-IR (SCHMID et al., 1998 and 1999A/B; SWEET et al. 1986; WILDEN 
et al., 1986; WILDEN and PESSIN, 1987; ENGL et al. 1994; HOTZ-WAGENBLATT and 
DROGE, 2002). While redox reagents could have multiple effects on the IR in cellular 
assays or the purified IR (e.g., modification of phosphatase activity, reviewd by TONKS, 
2005; IR quarternary structure or insulin binding), SCHMITT et al. (2005) observed a 
modulation of the enzymatic activity of purified GST-IRTK_∆NT/CT (GST-IRK) by 
changes in the redox status. Glutathione, which was used in millimolar quantities for the 
elution of the fusion proteins from the affinity column, could exert modification of the IR 
(SCHMITT et al., 2005). Covalent modification and regulation of kinase activity by S-
glutathionylation was also shown for PKA (HUMPHRIES et al., 2002 and 2005).  
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A                                               GST-IRTK 
 
 
 
 
 
 
B                                              GST-IRTK
 
C                                 GST-IRTK_∆NT/CT
 
 
 
 
 
D                               GST-IRTK_∆NT/CT 
 
F                       GST-IRTK (Rh = 5.5 nm; Polydisp. = 14.1%)
 
 
 
 
 
E 
 
 
 
 
 
Assay Max.  
32P-
Incorporation 
■   Autophosphorylation 4.0 ± 0.2 
▲ Substrate Phosphorylation 1.6 ± 0.3 
G      GST-IRTK_∆NT/CT (Rh = 4.6 nm; Polydisp. = 10.7%) 
 
Figure 3.1.2-1: Purification and characterization of GST-tagged kinase domains of the IR and IGF-1R as 
examplified by GST-IRTK and GST-IRTK_∆NT/CT (GST-IRK). A, SEC elution profile and B, SDS-PAGE 
of GST-IRTK (theoretical MW = 72 kDa, the red arrow indicates the peak fraction of A used for 
characterization and crystallization). C, SEC elution profile and D, SDS-PAGE of GST-IRTK_∆NT/CT 
(theoretical MW = 61 kDa, lane 4 depicts the peak fraction of C). The sizes of molecular weight marker 
proteins are indicated for C and D. The minor peaks in the SEC profiles are residual free GST, which 
could be completely separated from the fusion proteins. E, activity assay, i.e., time course of 
autophosphorylation (squares) and substrate (GST_IRS-1_p30) phosphorylation (triangles), of GST-IRTK 
in the presence of 2 mM TCEP. The data from a single experiment were fit to a monophasic exponential 
association curve. The values for the maximal phosphate incorporation are in-line with those determined 
for preparations containing DTT (BAER et al., 2001). The results from DLS indicate monodisperse 
preparations for the concentrated samples (10 mg/ml of peak fraction from A and C, respectively) of F, 
GST-IRTK and G, GST-IRTK_∆NT/CT. 
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Along these lines, non-modifying protease inhibitors (Roche Complete) instead of 
phenylmethylsulphonylfluoride (PMSF), which is generally known to covalently modify 
serine residues, were used. GST-IRTK retained full activity when purified in the 
presence of the reducing agent TCEP and was found to be devoid of any covalent 
modifications as determined by mass spectrometry. This also confirmed the absence of 
phosphorylation, which might interfere with crystallization. All preparations of GST-
tagged IR and IGF-1R kinase domains were found to be monodisperse when examined 
by dynamic light scattering (DLS; Figure 3.1.2-1). 
The purified GST-fusion proteins were subjected to crystallization trials using the 
modified microbatch method (D'ARCY et al., 2003 and 2004) with various sets of 
screening solutions. Crystals were obtained from assays containing GST-IRTK or GST-
IRTK_∆NT/CT (GST-IRK), but not with GST-IGFK or GST-IGFK_∆NT/CT (Figure 3.1.2-
2).  
 
Construct Condition Crystal 
H
01
 
 (i
n-
ho
us
e)
 
25 % (w/v) PEG 1500 
-no diffraction 
 
#   2 0.2 M KF, 20 % PEG 3350, pH 7.2 
- no diffraction 
 
# 14 0.2 M KSCN, 20 % PEG 3350, pH 7.0 
- no diffraction 
  
# 21 0.2 M NaCHO2, 20 % PEG 3350,  pH 7.2 
- no diffraction 
 
# 27 0.2 M NaOAc, 20 % PEG 3350, 7.9 
- no diffraction 
  
GST-IRTK 
P
E
G
/Io
n 
S
cr
ee
n™
 (H
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 R
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# 31 0.2 M Li2SO4, 20 % PEG 3350, pH 6.4 
- complete dataset collected (2.5 Å resolution) * 
 
# 45 0.2 M tri-Li citrate, 20 % PEG 3350, pH 8.1 
- no diffraction 
  
GST-IRKD 
∆NT/CT 
(GST-IRK) 
 Index Screen™ (Hampton Research) 
# 42 0.1 M BisTris pH 5.5, 25 % PEG 3350 
 
Stura Footprint Screen 2 (Molecular Dimensions) 
#20 0.1 M NaOAc, pH5.5, 36 % PEG MME 5000 
 
Fragment (GST) crystallized and structure solved 
(Rufer et al., 2005; see Appendix 7.1) 
no picture 
Figure 3.1.2-2: Crystallization hits from assays containing GST-IRTK or GST-IRTK_∆NT/CT (GST-IRK). 
* Data statistics are summerized in Table 3.1.2-2. 
 
#2 #14
#27#21
#31
10 µm
#45
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Preincubation of the GST-fusion proteins with the generic kinase inhibitor staurosporine 
(FUJITA-YAMAGUCHI and KATHURIA, 1988; RUEGG and BURGESS, 1989) or the 
IGF-1R-specific inhibitors genistein or tyrphostin AG1024 did not improve the 
crystallization behavior. 
A dataset could be collected from a single crystal grown from an assay containing GST-
IRKD (10 mg/ml) with condition 31 of the PEG/Ion Screen™, Hampton Research, as 
precipitant (Table 3.1.2-1). 
Data Collection 
Program  
XDS / XSCALE DENZO / SCALEPACK 
Space group I222 (or I212121) § I222 (or I212121) § 
Cell dimensions 
a, b, c [Å] 
α, β, γ [°] 
 
93.6, 98.8, 102.4 
90.0, 90.0, 90.0 
 
93.6, 98.8, 102.4 
90.0, 90.0, 90.0 
Resolution [Å] * 70.0 - 2.5 (2.65 - 2.50) 70.0 - 2.5 (2.61 - 2.50) 
Rsym [%] 11.6 (29.0) 9.1 (18.2) 
I/σI 16.9 (7.8) 13.8 (6.0) 
Completeness [%] 98.9 (94.1) 94.4 (92.5) 
Redundancy 4.4 (4.4) 4.0 (4.0) 
Mattews' Parameter Calculation 
MW [kDa] Nmol / AU Matthew's Coefficient Solvent Content 
72 (GST-IRTK) 1 1.6 24.6 
46 (IRTK) 1 2 
2.6 
1.3 
51.8 
3.7 
26 (GST) 
1 
2 
3 
4.6 
2.3 
1.5 
72.8 
45.6 
18.3 
Table 3.1.2-2: Data collection (SLS, 110 K) statistics of the crystal obtained from an assay containing 
GST-IRTK and PEG/Ion Screen™ solution number 31. The Matthews' parameter (VM) calculation 
(MATTHEWS, 1968) suggests that solely a fragment of GST-IRTK was crystallized as the solvent content 
of a theoretical crystal packing consisting of closely packed spheres is app. 26 % (KANTARDJEFF and 
RUPP, 2003). However, GST-IRTK is not necessarily spherical and trypsin crystals (P3121 cell) were 
reported with a solvent content between 11 % and 18 % (C. Vonrhein, Global Phasing, personal 
communication). The good resolution (2.5 Å) of the diffraction data collected from the tiny crystal indicates 
a high protein content and dense crystal packing.  According to the TRUNCATE statistics, twinning of the 
crystal and concomitant underestimation of VM due to apparent higher symmetry could be ruled out (a 50 
% twinning fraction with a diad twin symmetry would result in an VM reduced by factor 2). Calculation of 
self-rotation functions (MolRep, AMoRe) did not resolve the ambiguity of the asymmetric unit contents. 
 * Values in parentheses are for the highest resolution shell. Processing of the data with 
DENZO/SCALEPACK produced a decreased value for  Rmerge, but the number of rejected reflections was 
higher with a concomitant decrase in completeness. § The orthorhombic body-centered space groups 
cannot be distinguished based on systematic absences. Therefore, the molecular replacement trials were 
performed in both I222 and I212121. Processing the data in P1 and search for higher symetry with the 
program XPREP (SHELXTL package) confirmed the choice of these space groups. 
 
The data were processed and scaled with XDS/XSCALE as well as 
DENZO/SCALEPACK yielding similar results. Subsequent phasing trials were 
conducted with various molecular replacement programs (AMoRe, MOLREP, BEAST, 
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PHASER). Multiple structures of kinase domains from the PDB as well as all publically 
availale GST structures were used as search models. However, none of the molecular 
replacement calculations gave an indication for a correct solution with respect to 
correlation coefficients of observed and calculated amplitudes, R-factors, results of 
packing functions or maximum likelihood scores. 
Fragmentation of GST-IRTK in the crystallization trials seemed likely based on the 
Matthews' parameter analysis for the dataset. This was also found to be the case for the 
truncated construct GST-IRTK_∆NT/CT (GST-IRK; Figure 3.1.2-3).  
 
1 (intact construct) 
1  2  3  4  5  6  7  8  9 10 
S  P  I  L  G  Y  X  X  X  X      
2 (IRTK∆NT/CT = IRK) 
1  2  3  4  5  6  7  8  9 10 
G  S  V  F  P  S  S  V  F  V    
 
 
 
 
 
 
3 (released GST) 
1  2  3  4  5  6  7  8  9 10 
S  P  I  L  G  Y  X  X  X  X 
Figure 3.1.2-3: Spontaneous fragmentation of GST-IRTK_∆NT/CT (GST-IRK). Essentially homogeneous 
preparations were not stable during storage in 50 mM Tris/HCl pH 7.5, 150 mM NaCl, 2mM TCEP (A) or 
2 mM DTT (B, purified with an alternative protocol by K. Baer, University of Cologne) for 7 days at 4°C. 
The right panel shows the results of the amino-terminal (Edman) sequencing of the blotted fragments. 
The data clearly demonstrated that the construct GST-IRTK_∆NT/CT (GST-IRK) was cleaved in the linker 
(thrombin cleavage site) of the fusion protein, yielding fragment 2 (IRTK_∆NT/CT = IRK, red, plus two 
additional amino terminal residues from the linker) and fragment 3 (free GST plus six additional carboxy-
terminal residues from the linker). 
 
No contaminating protease activity could be detected using a sensitive spectroscopic 
assay with resorufin-labeled casein als generic protease substrate. Supplementing the 
storage buffer with diisopropyl fluorophosphate (5 mM f.c.) and Roche Complete 
protease inhibitor (2 Tbs/l f.c.) did not prevent the decomposition of the GST-
IRTK_∆NT/CT (GST-IRK). Therefore, it was concluded that spontaneous autocatalytic 
cleavage as described for nucleolin and myelin basic protein (CHEN et al., 1991; 
D'SOUZA et al., 2005), which also undergo degradation independent of both 
endogeneous and exogeneous protease activity, could be the reason for the instability 
of the GST-IRTK_∆NT/CT (GST-IRK; RUFER et al., 2005; Appendix 7.1). Analysis by 
mass spectrometry combined with amino-terminal sequencing of the fragments revealed 
that the cleavage occured in the linker of the fusion protein (Figure 3.1.2-3). 
 
7 d
A B
3
2
1
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Replacement of the linker between GST and IRTK_∆NT/CT (IRK) was not pursued 
because the introduction of a (Gly-Ala)5 linker resulted in significant loss of activity in 
autophosphorylation assays indicating suboptimal alignment of the kinase domains (A. 
KLOSE, 2000, Diploma thesis, University of Cologne). 
 
3.1.3 Interaction of IRTK with small-molecule agonists 
Non-peptidic small-molecule compounds that directly activate the kinase activity of the 
isolated kinase domain of the IR in vitro or elicit an insulin-sensitizing activity had been 
described by the pharmaceutical companies Merck & Co., Inc., and Telik, Inc., (Table & 
Figure 3.1.3-1; AIR et al., 2002; GURA, 1999; ZHANG et al., 1999; LIU et al., 2000; 
QURESHI et al., 2000; WEBER et al., 2000; WOOD et al., 2000; ZHANG and MOLLER, 
2000; BALASUBRAMANYAM and MOHAN, 2001; LI et al., 2001 and 2002; MANCHEM 
et al., 2001; SALITURO et al., 2001; DING et al., 2002; LABORDE and MANCHEM, 
2002; PENDER et al., 2002;  PERSAUD et al., 2002; PIRRUNG et al., 2002; WEBSTER 
et al., 2003; CHENG et al., 2004; STROWSKI et al., 2004; reviewed in DE MEYTS and 
WHITTAKER, 2002).  
The parent compound of the asterriqinone series pursued by Merck & Co., Inc., (Table 
3.1.3-1) was initially isolated from the fungus Pseudomassaria spec. This compound 
was highly potent as it could stimulate in vitro the activity of GST-IRTK, which is a 
constitutive dimer with elevated intrinsic activity (ZHANG et al., 1999; BAER et al., 
2001). 2,4-Dihydroxylation rendered the quinoid compounds insensitive to redox-
reactions and, therefore, a redox-priming type of activation of purified IR in vitro 
(SCHMID et al., 1998) or modification of other cellular components in cell-based assays 
could be excluded. Three related bioactive asterriquinones from Aspergillus sp. were 
described by ONO et al., 1991, ALVI et al., 1999 and WIJERATNE et al., 2003. These 
compounds were found to elicit diverse effects including inhibition of HIV-reverse 
transcriptase, disruption of binding of the Grb-2 SH2 domain to the phosphorylated 
epidermal growth factor receptor (EGFR) and inhibition of cell cycle progression in 
tumor cell lines, respectively.  
The insulin-sensitizing Telik1 compound (Table 3.1.3-1) was identified by screening a 
compound library for insulin receptor agonist activity in an affinity fingerprint assay 
(KAUVAR et al., 1995; MANCHEM et al., 2001). Two successor compounds with 
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decreased molecular weights and enhanced, direct agonistic potency with respect to 
activation of the IR kinase activity both in vitro and in vivo were developed by Telik.  
Interestingly, the recently identified adipokine visfatin also binds directly to the IR and 
activates the kinase activity of the IR without competing with insulin binding. The 
discovery of this physiologic insulin-mimetic emphasizes the feasability of heterologous 
activation of the IR, albeit further characterization of the exact binding mode of visfatin is 
needed (FUKUHARA et al., 2005; HUG and LODISH, 2005). 
Initial incubation and co-crystallization experiments of His6-IRTK (purified by H-J. 
Schönfeld and B. Pöschl, Roche Basel) and the GST-tagged constructs with the 
Merck1/2 and Telik3 compounds showed that the compounds tended to aggregate the 
protein as judged from analysis by DLS and increased precipitation in crystallization 
screens. In order to characterize the protein ligand interactions and the physico-
chemical properties of the compounds, limited proteolysis and analytical 
ultracentrifugation (AUC) were performed. The tryptic cleavage pattern of His6-IRTK (0.5 
mg/ml ≈ 10 µM) after incubation with Merck1 (RO0716631) was changed such that the 
A-loop was protected from tryptic cleavage (Figure 3.1.3-1). Whereas the presence of 
the Merck1 compound provoked the release of a distinct 30 kDa fragment, the formation 
of this fragment was less pronounced with the compounds Merck2 and Telik3 (all 20 
mM). AMP-PCP (100 mM), a non hydrolyzable analog of the kinase co-substrate ATP, 
rendered the activation loop highly susceptible for tryptic cleavage. 
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Compound Comment 
N
O
O
O
O
N
 
 Merck1 (RO0716631)  
L-783,281 
Demethylasterriquinone B1 
Pseudomassaria sp. 
activates GST-IRTK in vitro 
MW = 506.6  
EC50 = 5 µM 
ZHANG et al., 1999 
O
O
O
ON
 
Merck2 (RO0721705) 
2,5-Dihydroxy-3-(1-methylindol-3-yl)-3-
phenyl-1,4-benzoquinone 
synthesized as derivative of Merck1 
MW = 345.4  
EC50 = 0.3 µM 
LIU et al., 2000 
N N
NN
N N
N N
NN
O
OO
SS
SS
SS
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Telik1 
TLK16998 
MW = 1241.2 (free acid) 
EC50 = 1 µM 
MANCHEM et al., 2001 
 
N N
O
S
N
S
N
O
O
O
O
ClCl
SS
O O
O
O O
O
Na
+
 
Telik2 (RO4590422) 
TLK19780 
MW = 851.7 (free acid) 
EC50 = 0.1 µM  
PENDER et al., 2002 
N N
O
S
N
S
N
O
O
O
O
SS
O O
O
O O
O
Cl Cl
O O
Na
+
 
Telik3 (RO0731502) 
TLK19781 
MW = 883.7 (free acid) 
EC50 = 0.1 µM  
CHENG et al., 2004 
Table 3.1.3-1: 3,6-diaryl-2,5-dihydroxybenzoquinones (MERCK compounds; the generic asterriquinone, 
2,5-bis-[1-(1,1-dimethyl-2-propenyl)-indol-3-yl]-3,6-dihydroxy-1,4-benzoquinone, is shown as reference) 
and the symmetrical urea-derivatives (TELIK compounds) that were found to stimulate the tyrosine kinase 
activity of the IR in vitro. The app. in vitro EC 50 values are indicated. 
 
This suggested that the A-loop might be buried in a dimer interface, i.e., the Merck1 
compound promotes the formation of productive dimers primed for autophosphorylation. 
The formation of His6-IRTK dimers mediated by Merck1 was verified by AUC. However, 
the AUC data also clearly showed that the Merck1 compound leads to aggregation and 
sedimentation loss of His6-IRTK in a concentration dependent manner (Figure 3.1.3-
1B). 
O
O
O
ON
N
Prototype asterriquinone
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A 
 
 
 
 
 
 
 
1 His6_IRTK + Trypsin 
2 "      + Trypsin + 5 %(v/v) DMSO 
3 "      + Trypsin + Merck1 
4 "      + Trypsin + Merck2 
5 "      + Trypsin + Telik3 
6 "      + Trypsin + Mg/AMP-PCP 
7 untreated 
B 
 
D 
 
Assay EC50 (Dimerization) [µM]
w/o DMSO 11.8 
C 
 
1 % (v/v) DMSO 20.8 
Figure 3.1.3-1: Characterization of the effect of small-molecule IR agonists (and DMSO control) on the 
quarternary structure/ oligomerization of  His6_IRTK. All charaterizations were performed in 50 mM 
HEPES/ NaOH pH 7.7, 100 mM NaCl supplemented with DMSO as indicated. A, limited tryptic 
proteolysis of His6_IRTK (0.5 mg/ml + 0.006 mg/ml trypsin) in the absence (lane 1, lane 2 is DMSO 
control) or presence (lanes 3-5) of agonists. The non-hydrolyzable nucleotide-analog AMP-PCP (lane 6) 
was used as positive control for triggering the gate-open conformation of His6_IRTK. Lane 7 shows the 
untreated enzyme. Three fragments are released upon cleavage by trypsin [A (30 kDa) cleaved after 
Lys1030 of ATP binding site; B (24 kDa) cleaved at activation loop and C (16 kDa) cleaved at carboxy-
terminus; ZHANG et al., 1999; SALITURO et al., 2001; BAER et al., 2001). B, results from analytical 
ultracentrifugation of His6_IRTK (5 µM) in absence (0 µM, plus DMSO control) or presence of 5 µM (i.e., 
equimolar) and 10 µM Merck1 compound. The asterisk indicates 100 % supernatant at equilibrium speed. 
C, effect of concentration and DMSO on the quarternary structure of His6_IRTK (the asterisk indicates an 
extrapolated value), as determined by AUC. Concentrations higher than 8 µM  His6_IRTK  could not be 
investigated because of the limited dynamic range in absorption spectroscopy during AUC. D, based on 
the AUC data (bold curves, measured data) the EC50 for the association of His6_IRTK during dimer 
formation was calculated with a sigmoidal fit (thin curves, simulated; Prism 3.0, GraphPad Software). The 
inset shows the second order polynomial fit of the AUC data (up to the inflection point of the association 
curve) that was used for determining appropriate initial values for the simoidal fit. 
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Another important result of the AUC studies was the finding that the intrinsically 
monomeric His6_IRTK (unphosphorylated apo enzyme) forms dimers in a concentration 
dependent manner with an EC50 = 11.8 µM. The concentration for half-maximal dimer 
formation was shifted to EC50 = 20.8 µM in the presence of 1 % (v/v) f.c. DMSO, which 
was essential for solubilizing the hydrophobic agonists. Therefore, the DMSO interfered 
with dimer formation (Figure 3.1.3-1C), while it was simultaneously used as vehicle for 
dimerization inducing compounds in published and in-house in vitro kinase assays. 
Extrapolation of the simulated association curves (Figure 3.1.3-1) revealed that 
theoretically 100 % dimerization was reached at app. 550 µM, independent of the 
presence of DMSO. At the His6_IRTK concentration of 10 mg/ml ≈ 200 µM which was 
used for crystallization experiments, still ≥ 95 % of the protein could be expected to be 
in its dimeric form. 
In order to characterize the specificity of the Merck1, Telik1 and Telik2 compounds 
regarding their agonist activity, DLS and AUC analyses with the free compounds or in 
the presence of GST were performed. This also served as pilot study for the evaluation 
of the effect of these compounds on GST-IRTK. According to a DLS screen, the Merck1 
and Telik2/3 compounds formed particles of app. 50 - 150 nm. Surprisingly, AUC runs in 
absence of protein with free Telik2 and its derivative Telik3 in the GST-IRTK storage 
buffer (20 mM TRIS/HCl, pH7.5, 150 mM NaCl, 2 mM TCEP, 0.02 % NaN3, 1 % v/v 
DMSO) showed that these compounds formed micelles with aggregation numbers of 96 
and 92, respectively (Figure 3.1.3-2). Moreover, the compounds had an effect on the 
oligomerization state of GST which indicated unspecific protein binding. 
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Compound Particle Mass [kDa] NAgg.
Telik2 88.7 96 
Telik3 78.3 92 
0
20
40
60
80
100
none Merck1 Merck2 Telik2 Telik3
M
as
s 
di
st
rib
ut
io
n 
[%
]
Dimer
Tetramer
Octamer
Micells
Aggregates
 
 
 
 
 
 
Figure 3.1.3-2: Unspecific binding of Merck and 
Telik compounds (all 50 µM) to GST (5 µM). The 
Telik compounds form micelles of specific size 
and aggregates of micells with GST. 
 
The formation of particles and micelles of defined size was described for screening hits 
and drug-like compounds of unrelated structure (MCGOVERN et al., 2002 and 2003; 
SEIDLER et al., 2003). Regarding the experimental results and literature data it seems 
reasonable to argue that the in vitro agonistic potential of the published IRTK enhancers 
can be largely attributed to adsorbtion of IRTK molecules to particle or micelle surfaces. 
Thereby, the local concentration of the enzyme is increased, which then promotes 
autophosphorylation. The formation of aggregates by adsorbtion and/or absorbtion of 
IRTK by particles of agonist molecules also explains the sedimentation loss observed 
with increasing agonist concentrations.  
However, when administered to animal models of T2D (db/db, ob/ob and 
streptozotocin/high fat diet treated mice), both the Merck (p.o.) and the Telik (i.p.) 
compounds do possess in vivo efficacy (ZHANG et al., 1999; MANCHEM et al., 2001). 
As the Merck1 compound was also found to dimerize and activate the 
BDNF/neurotrophin receptors TrkA/B/C in cellular assays by binding to the intracellular 
kinase domains (WILKIE et al., 2001; POLLACK and HARPER, 2002A and B), the 
compound seems to possess an unspecifc agonistic activity on several receptor tyrosine 
kinase domains. Interestingly, the Trk receptors display significant sequence similarity 
(app. 60 %) and identity ( app. 45 %) to the IR based on an alignment of 270 amino 
acids of their core kinases. The highest similarity (app. 80 %) and identity (app. 70 %) is 
seen in the 30 amino acids of the activation loops, where both IR and Trk receptors 
have three autophosphorylation sites. This could imply a similar mode of activation for 
these receptors, despite the fact that the qu
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endogenous dimerization of its two kinase domains as opposed to the monomeric Trk 
receptors.  
The establishment of a preliminary structure activity relationship for the Merck 
compounds (WOOD et al., 2000) suggested that the asterriquinone series could be 
amenable to optimization with regard to its specificity and physico-chemical properties. 
Nevertheless, a cytotoxicity issue remains because the Merck1 compound and 
asterriquinones in general have been shown to intercalate into genomic DNA, thereby 
causing cell death (WILKIE et al., 2001; KAJI et al., 1997). 
The specificity of the Telik compound is also questionable because the highly related 
compound suramin (Figure 3.1.3-3) was identified as a direct activator of Trk receptors 
as well (GILL and WINDEBANK, 1998; POLLACK and HARPER, 2002A and B), 
besides having diverse effects on multiple other enzymes (EICHHORST et al., 2004, 
and references therein). 
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Figure 3.1.3-3: The structure of suramin. 
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3.2 Characterization and crystallization of AMPK 
3.2.1 Summary of literature and Roche data 
The initial focus of AMPK crystallization was put on the catalytic α-subunit for reasons of 
better biochemical tractability as opposed to the regulatory β- and γ-subunits or the 
heterotrimeric holoenzyme. Two soluble GST-fusion constructs of the rat α1-subunit, 
comprising amino acids 1-312 and 1-392, respectively,  had been described by CRUTE 
et al. (1998; see also HAMILTON et al., 2002). The lengths of these constructs had 
been determined based on their biochemical properties. Truncation of the α1-subunit at 
amino acid 392 yielded an inactive enzyme and fully abolished binding to the regulatory 
subunits. In contrast, CRUTE et al. (1998) found the AMPK_α2_1-312 construct to be 
constitutively active in the absence of the allosteric activator AMP when phosphorylated 
on T172 in the activation loop. These results implied the presence of an autoinhibitory 
sequence in amino acids 312-392 of  the AMPK α1-subunit.  
The corresponding constructs of the rat α2 isoform were cloned in-house, yielded stable 
proteins without GST-fusion and were subjected to crystallization trials. The entire work 
on the α-subunit in our laboratory was focused on constructs of the rat α2 isoform, 
which is almost identical to the clinically relevant human α2 isoform (Table 3.2.1-1). 
 
Species 
rat mouse human  
α1 α1 α2 α1 isoform1 
α1 
isoform 2 α2 
rat α2 
NP_076481 
86.4 (94.1) 
P54645 
86.1 (93.8) 
AAW79567 
99.1 (99.7) 
NP_835279 
85.3 (93.0) 
Q13131 
82.0 (89.3) 
NP_996790 
99.1 (99.7) 
P54646 
Table 3.2.1-1: Percent identity (in parentheses: similarity; calculated with Needle, EMBOSS, RICE et al., 
2000) of amino acid sequences for residues 1-339 of catalytic AMPK α-subunits in comparison to the rat 
α2-subunit used in-house (EC2.7.1.-, with accession codes). Isoform 2 of human AMPK α1 is a splice 
variant and has a 15 amino acid insert which is predicted to localize between helices αD and αE close to 
the hinge region and the lobe interface. The function of this insert had not been characterized. 
 
In addition, the activation loop mutants T172D were prepared for both the published 
constructs in order to mimic the regulatory phosphorylation by an upstream kinase and, 
thereby, populate a distinct conformation. STEIN et al. (2000) reported that introduction 
of the T172D mutation into heterotrimeric AMPK is sufficient for stimulating 
approximately 50 % of the wild-type activity. Conflicting data had been published 
regarding the activity of the construct AMPK_α2_1-312 _T172D, which was described 
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to be constitutively active by TSUBOI et al. (2003), whereas CRUTE et al. (1998) 
detected no activity. Therefore, it was not clear whether the T172D mutation was 
sufficient for mimicking phosphorylation. Further truncation of the enzyme 
(AMPK_α2_1-301) was found to destabilize the protein which could be partialy 
compensated by addition of 20 mM imidazole and 10 % (v/v) glycerol during purification. 
As screening of these constructs with commercial and in-house sets of precipitants 
(developed based on the publication by JANCARIK and KIM, 1991) and mutants did not 
yield crystals, a limited proteolytic digest of apo AMPK_α2_1-392 was performed in 
order to identify the actual domain boundary. Cleavage with subtilisin yielded a stable 
fragment, AMPK_α2_1-339, as identified by mass spectrometry (no post-translational 
modification found) and amino-terminal  sequencing (Edman microsequencing from 
blotted sample according to MATSUDAIRA, 1989) of an excised gel band (Figure 3.2.1-
1). 
  
Figure 3.2.1-1: Limited proteolysis of  apo AMPK_α2_1-392 with 
subtilisin. Lane 1: incubation for 24 h on ice. Lane 2: incubation for 
8 h at 21°C. Three major bands were excised for analysis. M: 
marker, molecular weight [kDa] is indicated. In both reactions the 
same main fragment (AMPK_α2_1-339, red arrow) was produced. 
 
This construct was found to be enzymatically inactive (M. Andjelkovic, Roche Basel), 
albeit the effect of phosphorylation of T172 in the activation loop by an upstream 
AMPKK preparation (HAMILTON et al., 2002), CAMKKβ (HAMILTON et al., 2002; 
HAWLEY et al., 2005; HURLEY et al., 2005; WOODS at al., 2005) or purified LKB1 
(HAWLEY et al. 2003; LIZCANO et al., 2004) was not investigated.  
Crystallization trials of AMPK_α2_1-339 (c = 10 mg/ml, in 20 mM Tris/HCl pH 7.8, 150 
mM NaCl, 2 mM MgCl2, 2 mM TCEP) resulted in reproducible crystals with 5 % (w/v) 
PEG 8000, 0.1 M NH4OAc, 0.02 M MgCl2 and 0.1 M HEPES pH 7.0 (Natrix Screen™ # 
39, Hampton Research) as precipitant. After refinement of the crystallization conditions 
to 2-3 % (w/v) PEG 8000, 0.4-0.5 M NH4OAc, 2-10 mM MgCl2 and 0.1 M HEPES/NaOH 
37
50
1 2 M
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pH 7.0-7.4 (depending on drop ratio), the crystals diffracted to a resolution of 6.5 Å at 
the SLS synchrotron. The space group symmetry could not be assigned due to the 
limited diffraction quality of the crystals. AMPK_α2_1-339 crystallized under similar 
conditions with and without amino-terminal His6-tag (from pET-15b expression vector).  
Amino-terminal truncation (AMPK_α2_8-339) or introduction of the activation loop 
mutant (AMPK_α2_1-339_T172D) resulted in additional crystallization conditions but 
did not improve the diffraction quality of the crystals. An AMPK homology model based 
on the structure of PKA (BOSSEMEYER et al., 1993, PDB code 1cdk) was built (B. 
Kuhn, Roche Basel) in order to allow selection of flexible surface residues which could 
be mutated in order to facilitate crystallization by improving crystal contacts (reviewed in 
DALE et al., 2003 and DEREWENDA, 2004; see PATEL et al., 2004, for example on 
p38α kinase). None of the constructs with surface mutants (K12A, R239A and K255A 
for AMPK_α2_1-312_D172D; K107A, Y237R and Y292A for AMPK_α2_1-339) 
crystallized.  
 
Addition of the nucleoside analog 5-aminoimidazole-4-carboxamide-1-β-D-
ribofuranoside (AICAR) or its phosphoric acid derivative 5`-AICAR monophosphate 
(ZMP) produced weakly diffracting crystals with AMPK_α2_1-339 and AMPK_α2_1-
339_T172D, respectively. The presence of the generic kinase inhibitor staurosporine 
(RUEGG and BURGESS, 1989) completely prevented crystallization. This could most 
likely be attributed to a pronounced change in the conformation of the AMPK catalytic 
domain, similar to that observed upon binding of staurosporine to PKA (PRADE et al., 
1997). The change from conventional protein concentration via microconcentrators to 
step elution from a 1ml anion-exchange column greatly improved the quality of the 
protein preparation in terms of avoiding aggregation. Despite purification of 
homogeneous and monodisperse proteins and various crystallization conditions, all the 
crystals had the same morphology and diffracted X-rays poorly (max. 6.5 Å resolution). 
 
A collaboration with the group of Prof. T. Wallimann, Institute of Cell Biology, ETH 
Zurich, was established which granted access to lysates from E. coli expressing 
heterotrimeric rat AMPK_α1β1γ1 and AMPK_α2β2γ1 expressed from a tricistronic 
vector (NEUMANN et al., 2003). Crystallization trials with the latter yielded needle-
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shaped crystals with 1 M Li2SO4, 0.01 M NiCl2 and 0.1 M Tris/HCl pH 8.5 (Jena 
Bioscience screen 10/B1) as precipitant. As crystals of AMPK_α2_1-339 were obtained 
under identical conditions and both the α2-subunit constructs as well as the trimeric 
AMPK were found to bind to Ni-NTA-resin even after cleavage of the His6-tag, NiCl2 was 
tested as additive. However, addition of NiCl2 during purification did not improve the 
quality of  the protein and crystals thereof. 
 
3.2.2 Crystallization and characterization of AMPK_α2 constructs  
All the following experiments were performed as part of this thesis. AMPK_α2_1-339 
(wild-type) was selected from the existing constructs of the α-subunit for further 
optimization because the purification protocol and crystallization was more reproducible 
compared to other constructs. In addition, this was the only construct for which initial 
crystallization conditions were available. For subsequent protein preparations the final 
storage buffer was changed to HEPES (instead of Tris) because AMPK_α2_1-339 
crystallized repeatedly from HEPES-buffered conditions.  
Rescreening the crystallization properties of this construct at 15°C instead of the 
established 21°C using the modified microbatch method (D'ARCY et al., 2003 and 
2004) with 25 % (v/v) silicone oil/ 75 % (v/v) paraffin oil as opposed to standard 50 % 
(v/v) silicone oil/ 50 % (v/v) paraffin oil (Al's Oil) as evaporation barrier provoked a 
slower nucleation and extended crystallization phase (CHAYEN, 1997 and 2004). This 
change in the progress along the trajectory through the crystallization phase diagram 
caused AMPK_α2-1-339 to crystallize from 15 % (v/v) Tacsimate*, 2 % (w/v) PEG 3350 
and 0.1 M HEPES pH 7.0 (Hampton Research Index Screen™ # 36). After exchanging 
the PEG 3350 to 3 % (w/v) PEG 8000 large, single orthorhombic crystals were obtained 
with 6 % (w/v) dextran sulfate as additive, whereas crystals with a hexagonal habitus 
grew under the exact same conditions with 9 mM hexamine-Co(III)-chloride as additive 
(Table 3.2.2-1).1 
                                                 
* Tacsimate is a specially formulated, proprietary salt mixture composed of neutralized organic acids 
including but not limited to malonic acid, succinic acid, and malic acid. Sam Patel, Hampton Research 
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Table 3.2.2-1: In-house preparations of AMPK that were subjected to crystallization during the course of 
this thesis. Numbers in parentheses indicate drop ratios for setting up crystallization trials from stock 
solutions [µl, protein + precipitant (+ additive, where applicable)]. 
Construct Crystals/ Comment 
 apo, 30 mg/ml (2+2+1) 
Diffraction to 6.5 Å  
orthorhombic 
15 % Tacsimate pH 7.0 
0.1 M HEPES pH 7.0 
3 % PEG 8000 
6 % Dextran Sulfate 5000 
- optimized from 
Hampton Research Index # 36 
Additive Screen 3.8 
AMPK_α2_1-339_wt *  apo, 30 mg/ml (2+2+0.4) 
Diffraction to 7.5 Å  
hexagonal 
15 % Tacsimate pH 7.0 
0.1 M HEPES pH 7.0 
3 % PEG 8000 
9 mM Hexamine-Co(III)-chloride 
- optimized from 
Hampton Research Index # 36 
Additive Screen 2.17 
AMPK_α2_1-339_T172D * no crystals 
AMPK_α2_8-339_wt * no crystals 
AMPK_α2_1-339 
 Staurosporine (5+2) 
Diffraction to 7.5 Å  
cubic 
0.2 M tri-Na-Citrate 
20 % PEG 3350 
0.16 mM n-Decyl-β-D-maltopyranside  
(1X CMC) 
- optimized from 
Hampton Research Index # 94 
Detergent Screen 1.9 
AMPK_α2_1-301 minute crystals, no optimization 
AMPK_α2_1-312 minute crystals, no optimization 
AMPK_α2_1-249 insoluble in expression test 
AMPK_α2_1-262 insoluble in expression test 
AMPK_α2_1-263 insoluble in expression test 
AMPK_α2_1-264 insoluble in expression test 
D
56
A/
R
17
1E
/T
17
2D
 
AMPK_α2_1-326 no crystals 
AMPK_β1γ1(∆1-67) * no crystals 
AMPK_β1γ1(∆1-185) * no crystals 
His6_AMPK_α1β1γ1_wt § 
 apo, 10 mg/ml (2+1) 
orthorhombic 
Diffraction to 7.5 Å 
0.2 M MgCl2 
0.1 M TRIS/HCl pH 8.5 
25 % PEG 3350 
- optimized from 
Hampton Research Index # 85 
* cloned by D. Burger, R. Thoma. § purified in-house by H-J. Schönfeld and B. Pöschl from E. coli cell 
lysate provided by Wallimann group, ETH Zurich. 
25 µm
75 µm
150 µm
25 µm
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These crystals diffracted X-rays to 6.5 Å and 7.5 Å at the SLS, respectively (see 
Appendix 7.2 for diffraction images). Indexing of the orthorhombic crystals revealed a 
very large unit cell with a = 132.1 Å,  b = 157.9 Å and c = 379.4 Å with a C centered 
Bravais lattice. In a recent survey by KANTARDJIEFF and RUPP, 2003, a median 
Matthews' coefficient (MATTHEWS, 1968) of 2.52 Å3/Da for 10,471 protein crystal 
structures in the PDB was reported. A Matthews' coefficient of 2.5 Å3/Da could be 
calculated for the orthorhombic AMPK_α2-1-339 crystals assuming 10 molecules per 
AU (51 % solvent, point group 222). If this was the true value for this crystal form, the 
solution of the structure would have been very difficult. However, if the true Matthews' 
coefficent was higher, i.e., there were fewer molecules in the asymmetric unit and the 
solvent content was higher, this could have accounted for the limited diffraction quality 
of the orthorhombic crystals.  
For the hexagonal crystals the unit cell parameters were a = b = 143.4 Å and c = 203.4 
Å, which would correspond to a Matthews' coefficient of 2.6 Å3/Da (assuming 3 
molecules per AU for point group 622 or 6 molecules per AU for point group 6; 52 % 
solvent). However, the indexing of both the orthorhombic and hexagonal crystal forms 
was not unequivocal due to limited diffraction quality, i.e., resolution limit, small number 
and limited profile quality of indexed spots.  
The usage of 25 % (v/v) silicone oil/ 75 % (v/v) paraffin oil also allowed the identification 
of crystallization conditions containing volatile ingredients like Natrix Screen™ # 20 (0.1 
M ammonium acetate, 0.015 M magnesium acetate, 10 % (v/v) i-propanol and 0.05 M 
sodium cacodylate pH 6.5), among others. A screen with the precipitant synergy screen 
(MAJEED et al., 2003) that had been designed to rationally combine mechanistically 
distinct precipitants, yielded small crystals with 1 M ammonium sulfate, 15 % (v/v) i-
propanol and 0.1 M Tris/HCl pH 8.5. This emphasized the tendency of AMPK_α2_1-339 
to crystallize from conditions containing combinations of salts of organic acids and small 
organic compounds. With these a gradual increase of the ionic strength and a 
simultaneous decrease of  the dielectricity constant in the buffer could be achieved 
during drop equilibration in order to drive salting-out and crystallization. Generally, salts 
of carbonic acids are ideally suited for obtaining high ionic strength without the formation 
of salt crystals. However, this rational way of optimizing the crystallization of 
AMPK_α2_1-339 did not result in diffraction quality crystals. 
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3.2.2.1 Biacore  
Part of the putative autoinhibitory sequence (amino acids 313-392) of the catalytic α-
subunit was contained in the construct AMPK_α2_1-339. The actual mechanism of 
inhibition had not been elucidated for AMPK_α2_1-392. Therefore, it was not known 
whether the autoinhibitory sequence would function as a pseudosubstrate (CRUTE et 
al., 1998; for review see KEMP et al., 1994) or by imposing conformational control on 
AMPK activity (reviewed in ADAMS, 2001; ENGH and BOSSEMEYER, 2002; HUSE 
and KURIYAN, 2002; NOLEN et al., 2004).  
In order to explore the accessibility of the active site and the possibility to improve the 
crystal quality by co-crystallization of active site ligands, surface plasmon resonance 
(Biacore; COOPER, 2003; HOMOLA, 2003) measurements were performed (in 
collaboration with W. Huber, Roche Basel). These measurements clearly demonstrated 
that ATP-analogs and compound C (ZHOU et al., 2001; synthesized by P. Hebeisen, 
Roche Basel) could bind to the active site of (unphosphorylated) AMPK_α2_1-339 
(Figure 3.2.2.1-1) despite the presence of part of the autoinhibitory sequence. 
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A  B  
 
 
 
 
 
C D 
 
 
Figure 3.2.2.1-1: Results of surface plasmon resonance measurements that proved the accessibility of 
the active site of AMPK_α2_1-339 for the non-hydrolyzable ATP-analog AMP-PNP and the inhibitor 
compound C. All measurements were performed in crystallization buffer, i.e., 20 mM HEPES/NaOH pH 
7.8, 2 mM MgCl2, 2 mM TCEP and 250 mM NaCl. Data were analyzed by non-linear regression assuming 
a single class of binding site in a stoichiometric 1:1 complex. A, sensorgramm and B, Langmuir 
adsorption isotherm (20°C) of AMP-PNP. C, sensorgramm and D, Langmuir adsorption isotherm of 
compound C (20°C, structure depicted in inset). Other ATP-analogs bound to AMPK_α2_1-339 with a KD 
in the mid to high micromolar range (data not shown). 
 
Interestingly, the KD = 460 nM for the binding of compound C to AMPK_α2_1-339 was 
in the range of the Ki of this compound for the inhibition of a partially purified preparation 
of the AMPK heterotrimer equilibrated with ATP (Ki = 109±16 nM, ZHOU et al., 2001). 
Although the dynamic light scattering profile was greatly improved by preincubation of 
AMPK_α2_1-339 with AMP-PCP, AMP-PNP or compound C, the addition of these 
compounds fully abolished crystallization indicating an effect of complex formation on 
conformation (Figure 3.2.2.1-2). 
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A             Rh = 6.4nm, Polydisp. = 34.6 % 
 
 
 
 
 
B            Rh = 3.9 nm, Polydisp. = 13.1 % 
 
 
 
 
 
 
 
Figure 3.2.2.1-2: Dynamic light scattering (20°C) of concentrated (20 mg/ml) A, apo AMPK_α2_1-339 
and B, material from the same preparation after overnight incubation at 4°C with a 10-fold molar excess 
of compound C. Both samples were centrifuged for 30 min at 20,000 g and 4°C prior to the measurement. 
Similar results were obtained with nucleotide analogs (data not shown). 
 
A Biacore assay was also conducted with the intact AMPK_α1β1γ1 heterotrimer as well 
as the β1γ1-dimer of regulatory subunits and the AMPK_α2_1-339 kinase domain 
construct immobilized in parallel on a three-channel chip. These experiments clearly 
showed that the physiological ligands of AMPK, AMP and ATP (the non-hydrolyzable 
analogs AMP-PNP and AMP-PCP were used), can bind to both the allosteric and 
catalytic sites (data not shown). This emphasizes the difficulties to design a robust 
assay for AMPK activity because the allosteric activator outcompetes the co-substrate 
ATP from the active site (and vice versa) in a concentration dependent manner. 
 
3.2.2.2 Thermofluor 
Pre-incubation with staurosporine completely abolished crystallization of AMPK_α2_1-
339 under all conditions investigated, which implied a pronounced effect of 
staurosporine on the conformation. Since staurosporine is too adhesive for Biacore 
measurements the Thermofluor technique was chosen to characterize the complex 
formation. This method allows analysis of the stability of protein-ligand complexes 
based on their thermal unfolding curves (PANTOLIANO et al., 2001; LO et al., 2004; 
CARVER et al., 2005, MATULIS et al., 2005; PARKS et al., 2005). For monitoring of the 
unfolding process the fluorescence probe SYPRO orange was added to the protein or 
protein ligand complexes. This dye only emits fluorescence upon binding to the 
hydrophobic core of proteins which becomes exposed to the solvent during the process 
of unfolding. The thermal stability of AMPK_α2_1-339 was examined with the apo 
enzyme and with enzyme pre-incubated with the non-hydrolyzable nucleotide analogs 
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AMP-PNP, AMP-PCP as well as staurosporine (Figure 3.2.2.2-1). These measurements 
were also performed with AMPK_α2_1-392 in order to elucidate the effect of the 
putative autoinhibitory domain on the stability of this construct. 
 
A 
B  
 
Figure 3.2.2.2-1: A, melting curves of AMPK_α2_1-339 and AMPK_α2_1-392 in the presence or 
absence of the active site inhibitors AMP-PNP (PNP), AMP-PCP (PCP) or staurosporine (Stau). Means ± 
SEM of two (PNP, Stau) or three (apo, PCP) independent experiments are presented. The base line of 
the raw data was corrected for photobleaching and thermal disintigration of the fluorescence probe 
SYPRO orange. The inset shows the pH dependency of the buffer used for the Thermofluor assays. B, 
Normalized data of A which emphasize the clustering of the melting curves in four discrete bins. See 
Material and Methods for details of data processing. 
 
310 320 330 340 350
0
50
100
150
200
250
300
350
339apo
392apo
339PNP
392PNP
339PCP
392PCP
339Stau
392Stau
T [K]
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 [A
U
]
310 320 330 340 350
0.0
0.5
1.0
339apo
392apo
339PNP
392PNP
339PCP
392PCP
339Stau
392Stau
T [K]
N
or
m
al
iz
ed
 F
lu
or
es
ce
nc
e
7
7.2
7.4
7.6
7.8
8
280 290 300 310 320 330 340 350 360
T [K]
pH
pH measured
pH theoretical
_________________________________________________________Results: AMPK 
 35
The data fully supported the results of surface plasmon resonance measurements 
(3.2.2.1) regarding the accessibility of the active site of the AMPK contructs. The melting 
curves of both AMPK_α2_1-339 and AMPK_α2_1-392 clearly showed that the 
presence of an active site inhibitor enhances the thermal stability of these constructs. 
The construct length had no significant effect on the respective melting points, which 
implied that the autoinhibitory sequence (here aa 340-392) of AMPK does not bind with 
high affinity to the catalytic core. Whereas AMP-PCP was found to be slightly more 
effective than AMP-PNP in increasing the melting points, the presence of staurosporine 
caused a pronounced shift of the melting points to higher temperatures for both 
examined constructs (Table 3.2.2.1-1). The melting point temperatures for the 
complexes of AMPK constructs with ATP analogs were found to be in the range of those 
reported for PKA equlibrated with 1 mM ATP (HERBERG et al., 1999). 
 
Construct Ligand Melting Point ± SEM [K] 
KD 
[µM] 
95 % conf. int.
[µM] 
apo 323.7 ± 0.6 n/a n/a 
AMPPNP 326.0 ± 0.3 442 (36) 237-663 
AMPPCP 326.9 ± 0.2 311 171-490 
 
AMPK_α2-1-339 
 
 Staurosporine 341.5 ± 0.2 0.0005 6E-12 - 2.8E-8 
apo 324.1 ± 0.4 n/a n/a 
AMPPNP 326.1 ± 0.2 480 322-641 
AMPPCP 327.0 ± 0.2 336 214-495 AMPK_α2-1-392 
Staurosporine 340.8 ± 0.2 0.0009 2.8E-11 - 1.7E-8 
Table 3.2.2.1-1: Melting points and dissociation constants (value in parantheses was determined by 
Biacore measurements), plus values for the 95 % confidence interval, of AMPK_α2_1-339 and 
AMPK_α2_1-392. The values were determined from the melting curves by non-linear regression using 
the equations described in Materials and Methods. 
 
The dissociation constant of the AMPK_α2_1-339•AMP-PNP complex (KD = 442 µM) 
which was determined by the Thermofluor assay was found to be one order of 
magnitude larger in comparison to the value measured by Biacore (KD = 36 µM). This 
could be due to interference of the fluorescence probe SYPRO orange with ligand 
binding to AMPK_α2_1-339 by, e.g., altering the conformation or accessibility of the 
nucleotide binding site. The 95 % confidence intervals for the dissociation constants of 
staurosporine are wide in comparison to those of AMP-PNP or AMP-PCP. This can be 
explained by the fact that the concentration of enzyme cannot be neglected during 
calculation of the KD values for the staurosporine complexes. A 1:4 molar enzyme to 
ligand ratio had to be used because of the limited solubility of staurosporine in aqueous 
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buffer. However, the order of the numeric values of the dissociation constants reflects 
well their effect on the stability of the AMPK constructs. The KD values determined for 
staurosporine (app. 1 nM) are in-line with those reported by EISINGER et al. (2003) for 
the AMPK heterotrimer. 
The pH of the buffer used in the Thermofluor assays (20 mM HEPES/NaOH pH 7.8, 2 
mM MgCl2, 150 mM NaCl and 2 mM TCEP) was found to decrease by less than 0.3 pH 
units (pH = 7.8 at 298 K / 25 °C; pH = 7.54 at 353 K / 80 °C) over the temperature range 
of the experiment. The actual change in pH is likely to be even smaller because of the 
buffer capacity of the protein, which is a polyampholyte. The pH range of the experiment 
was well above the isoelectric points and, therefore, the solubility boundary of 
AMPK_α2_1-339 (pI = 6.56) and AMPK_α2_1-392 (pI = 6.65). As HEPES has a pKa = 
7.5 the change in ionic strength of the buffer was negligible. From these observations it 
seems reasonable that the melting behavior is entirely dependent on the increase in 
temperature and the stability of the apo proteins or the protein-ligand complexes. 
The Thermofluor experiments showed that the binding of staurosporine to 
AMPK_α2_1-339 and AMPK_α2_1-392 markedly increased the thermal stability of 
these enzymes. This effect on stability could be exploited for improving the 
crystallization of an activation loop mutant of AMPK_α2_1-339 (see below). 
 
3.2.2.3 Generation of the triple mutant AMPK_α2_1-339_D56A/R171E/T172D 
As the crystals of the wild type construct , i.e., the enzyme in its inactive conformation, 
were of poor diffraction quality it was anticipated that populating the active conformation 
might facilitate better crystallization. Since AMPK does not undergo autophosphorylation 
on the activation loop and the upstream kinase was not known at the time of the study, 
a site-directed mutagenesis approach was chosen. Inspection of the homology model of 
the α-subunit suggested that in addition to the T172D mutation, a R171E and a D56A 
mutation could be introduced in order to improve the interaction of the activation loop 
with the amino-terminal lobe of AMPK (Figure 3.2.2.3-1).  
The crystal structure of PKA in its active conformation (PDB code 1cdk; BOSSEMEYER 
et al., 1993) reveals a tight  salt bridge (2.64 Å) of a phosphoryl-oxygen of pT193 in the 
activation loop with the guanidinium group of the conserved R165 of the catalytic loop. 
The respective residues in the catalytic α-subunit of AMPK are T172 and R138, 
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respectively. If a T172D mutation in AMPK_α2_1-339 was to mimic phosphorylation of 
this residue, the neighbouring R171 might compensate the single negative charge, 
thereby obstructing the interaction with R138. Therefore, a R171E mutation was 
introduced, which could support lobe closure by electrostatic interaction with K60 or R63 
in helix αC. In order to stabilize these interactions D56 at the amino-terminal end of 
helix αC was mutated to alanine (see Appendix 7.3 for sequence data). 
 
Figure 3.2.2.3-1: A, Homology model of AMPK_α2_1-339 in the standart orientation, i.e., looking down 
helix αC (amino- to carboxy terminus). The residues that were mutated are highlighted. The model is 
colored according to secondary structure (α-helices: green; β-sheets: blue). B, close-up of a 
superimposition of the activation segment of  AMPK_α2_1-339 (homology model, green) and PKA (cyan, 
PDB code 1cdk), in an orientation rotated 90° to the left with respect to the view in A. 
 
A pET-15b vector with the coding sequence of AMPK_α2_1-339_T172D was used as a 
template to generate the triple mutant, AMPK_α2_1-339_D56A/R171E/T172D, by 
means of site directed mutagenesis. The Quick Change® Multi site directed 
mutagenesis kit (Stratagene) was used according to the manufacturers specifications 
(primers listed in Appendix 7.3). Introduction of the mutants and integrity of the construct 
was verified by fluorescence-based DNA sequencing after PCR amplification 
(sequencing primers listed in Appendix 7.3). The identity of the expressed protein was 
confirmed by mass spectrometry (no post-translational modification found). The 
resulting protein was in the soluble fraction when expressed in E. coli. and could be 
purified by Ni2+-IMAC, IEX chromatography and final SEC (Figure 3.2.2.3-2; see also 
Material and Methods). 
A 
 
 
 
 
B 
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A                                               Ni2+-IMAC
 
B                                                          IEX
 
C                                                        SEC 
 
D                                IEX-Concentration 
 
E                                             SDS-PAGE Figure: 3.2.2.3-2: Purification of the construct 
AMPK_α2_1-339_D56A/R171E/T172E. A-D, 
chromatography steps as indicated. E, SDS-gel, 
lanes were deliberately overloaded in order to 
visualize residual contaminations (red circles). 
M   Marker, MW is indicated 
1    Precleared lysate 
2    Pellet 
3    Peak 1 Ni2+-IMAC 
4    Peak 2 Ni2+-IMAC, AMPK 
5    Flow-through Ni2+-IMAC 
6    AMPK after thrombin cleavage and dialysis 
7/8 IEX elution 
9    Flow-through IEX 
10  SEC elution 
11  IEX-Concentration Peak 1 
12  IEX-Concentration Peak 2, AMPK for 
      crystallization (40 µg/lane) 
13  IEX-Concentration Peak 2, AMPK for 
      crystallization (4 µg/lane ⇒ single band) 
 
AMPK_α2_1-339_D56A/R171E/T172D could be purified to homogeneity, despite traces 
of an uncharacterized ~17 kDa contamination. This contamination was most likely a 
protein from the E. coli host cells because it was shown to co-elute with AMPK 
constructs of different lengths and no signs for proteolytic degradation could be detected 
(data not shown). Most of this protein was seperated by Ni2+-IMAC (Peak 1). 
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The typical yield of 40 mg AMPK_α2_1-339_D56A/R171E/T172D per liter bacterial 
culture after scale up of the expression was 10-50 % higher compared to the previous 
constructs. Assuming unchanged mRNA and protein half-life this suggested improved 
protein stability compared to the wild-type construct. No enzymatic activity could be 
detected in a preliminary gel-shift assay with a commercial GST-tagged substrate. 
Nevertheless, the introduction of the D56A and R171E mutants had a pronounced effect 
on conformation as implied by the totally different crystallization behavior of AMPK_α2-
1-339_D56A/R171E/T172D in comparison to the wild-type construct (see below). 
 
3.2.2.4 Crystallization of AMPK_α2_1-339_D56A/R171E/T172D 
Using dynamic light scattering the mutant AMPK_α2_1-339_D56A/R171E/T172D was 
found to be monodisperse and monomeric as apo protein and in complex with active 
site inhibitors (Figure 3.2.2.4-1).  
A             Rh = 4.9 nm, Polydisp. = 16.2 %
 
 
 
 
 
B             Rh = 5.1 nm, Polydisp. = 26.6 %
  
 
 
 
 
C             Rh = 4.9 nm, Polydisp. = 23.5 %
 
 
 
 
 
D             Rh = 4.8 nm, Polydisp. = 15.9 %
 
 
 
 
 
 
Figure 3.2.2.4-1: Dynamic light scattering (DLS) profiles of AMPK_α2_1-339_D56A/R171E/T172D. DLS 
was used as quality check on the concentrated protein samples (20 mg/ml) and protein-ligand complexes 
after overnight incubation at 4°C prior to setting up the crystallization drops. All samples were measured 
in identical buffer (20 mM HEPES/NaOH pH 7.8, 2 mM MgCl2, 2 mM TCEP and 250 mM NaCl) at 20°C 
after centrifugation at 20,000 g for 30 min. The determined hydrodynamic radii (Rh) and the percent 
polydispersity (% polydisp.) are indicated. A, apo enzyme. B, complex with staurosporine (1.5 X molar 
excess). C, complex with AMP-PCP (10 mM) and D, complex with AMP-PNP (10 mM). No difference in 
the affinity and association/dissociation kinetics for small molecule active site binders was detected for the 
wild-type vs. the triple mutant enzyme (collaboration with Biacore, Uppsala, Sweden). This indicated 
unhindered access of the ligands to the active site. 
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A positive correlation of low (generally ≤ 20 %) polydispersity of a given protein sample 
and the tendency to crystallize had been described (ZULAUF and D'ARCY, 1992; 
D'ARCY, 1994). Despite high purity and the absence of aggregation, initial screens with 
apo AMPK_α2_1-339_D56A/R171E/T172D did not result in crystals as opposed to the 
wild-type construct. Staurosporine was reported to be a strong inhibitor of full-length 
AMPK with  an IC50 of  approximately 1 nM (EISINGER et al., 2003) and markedly 
stabilized the AMPK_α2_1-339 construct in the Thermofluor assay (3.2.2.2). In order 
to stabilize AMPK_α2_1-339_D56A/R171E/T172D for crystallization, a 20 (-30) mg/ml 
preparation of the protein was incubated with a 1.5 molar excess of staurosporine 
overnight at 4°C. In contrast to the wild type construct and the mutant apo protein, the 
complex of the triple mutant with staurosporine crystallized from various conditions 
(Table 3.2.2.4-1, no crystals were obtained from AMP-PCP or AMP-PNP complexes). 
 
Condition Crystallization 
Screen # precipitant solution 
63 5 % (v/v) Tacsimate, 10 % (w/v) PEGMME 5000, 0.1 M HEPES pH 7.0
74 0.2 M LiSO4, 25 % (w/v) PEG 3350, 0.1 M Bis-Tris pH 6.5 
75 0.2 M LiSO4, 25 % (w/v) PEG 3350, 0.1 M HEPES pH 7.5 
76 0.2 M LiSO4, 25 % (w/v) PEG 3350, 0.1 M Tris pH 8.5 
86 0.2 M Na/K-tartrate, 20 % (w/v) PEG 3350 
87 0.2 M Na-malonate pH 7.0, 20 % (w/v) PEG 3350 
Index Screen™1 
94 0.2 M Na/K-citrate, 20 % (w/v) PEG 3350 
10 20 % (w/v) PEGMME 2000, Tris pH 7.0 Wizard™ I + II2 15 0.2 M LiSO4, 10 % (w/v) PEG 3000, 0.1 M imidazole pH 8.0 
1/26 0.8 M Na/K-tartrate, 0.1 M HEPES pH 7.5 
Structure Screen™3 
2/3 2 % (w/v) dioxane, 10 % (w/v) PEG 20000, 0.1 M Bicine pH 9.0 
Precipitant Synergy 
Screen4 
31 0.5 M NaCl, 30 % MPD, 8 % (w/v) PEG 8000, 0.1 M Tris pH 8.5 
Table 3.2.2.4-1: Compilation of screening solutions from which crystals of the AMPK_α2_1-
339_D56A/R171E/T172D • staurosporine complex were obtained (1: Hampton Research; 2: Emerald 
Biostructures/ deCode genetics; 3: Molecular Dimensions Ltd.; 4: MAJEED et al., 2003). 
 
All crystals of the triple mutant had identical crystal morphology (Table 3.2.2-1) and unit 
cell parameters. The diffraction pattern indicated that the crystals had an I-centered 
cubic Bravais lattice with unit cell dimensions a = b = c = 177.7 Å. With a calculated MW 
of 38,942 Da for the AMPK_α2_1-339_D56A/R171E/T172D construct the Matthews' 
coefficient was determined to be 3.0 Å3/Da (assuming 2 molecules per AU for point 
group 23 or 1 molecule per AU for point group 432), which corresponds to a solvent 
content of 59 %). 
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Despite extensive optimization trials using grids of 24 conditions around the initial 
crystallization conditions of the screening hits and exploitation of four different 
crystallization methods (free interface diffusion in the Fluidigm® system, HANSEN et al., 
2002, modified microbatch with hydrophobic and hydrophilic plate surfaces, sitting and 
hanging drop) all these crystals diffracted merely to 7 Å at the SLS. The diffraction 
images recorded in-house also had a resolution limit of app. 7 Å indicating that not 
crystal size but rather dynamic disorder limited diffraction. 
As AMPK_α2_1-339_D56A/R171E/T172D recurrently crystallized under conditions 
containing salts of carboxylic acids, which had been described to improve crystal quality 
(especially sodium malonate, MC PHERSON, 2001; HOLYOAK et al., 2003; XING and 
XU, 2003), a range of salts of organic acids in combination with 20 % (w/v) PEG 3350 
were tested as precipitants. This yielded crystals with the sodium salts (unbuffered and 
solutions buffered with HEPES/NaOH pH 7-8) of acetate, malate, malonate, maleinate, 
succinate, oxalate, benzoate as well as ammonium citrate, but not with formate and had 
no effect on diffraction quality. Interestingly, large crystals could also be obtained from 
unbuffered 1 M sodium acetate alone. With acetate the counterions Mg2+, Ca2+, Zn2+ 
and NH4+ (all 1 M f.c.) abolished crystallization.  
The addition of arginine, which is commonly used in refolding protocols as stabilizing 
agent, or other amino acid (salts of proline, aspartic acid, glutamic acid) as sole 
precipitants were ineffective with regard to improving diffraction quality. Attempts to 
optimize the crystallization of AMPK_α2_1-339_D56A/R171E/T172D by using various 
redox-agents [dithitothreitol (DTT) and reduced glutathione (GSH) which might 
covalently modify the enzyme as described for PKA (HUMPHRIES et al., 2002), β-
mercaptoethanol (β-ME), L-cysteine, and tris-(carboxyethyl)-phosphine (TCEP); GETZ 
et al., 1999; BURNS et al., 1991), detergents or other additives (Hampton Research 
Detergent/ Additive Screens), heavy atom derivatives as additves for co-crystallization 
(Hampton Research Hg and Pt heavy atom kits) and in-gel crystallization in hanging 
drops (DONG et al., 1999; MORENO et al., 2002) yielded crystals under several 
conditions but did not improve diffraction quality. 
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The effect of different cryo-protocols was also investigated with regard to the choice of 
cryo-protectant and the way of cooling the crystals to the cryogenic temperature of liquid 
nitrogen for synchrotron measurements. Incubating the crystals of  AMPK_α2_1-
339_D56A/R171E/T172D for 30 s in mother liquor supplemented with 20 % (v/v) 
ethylene prior to direct mounting in the cryo-stream at 110 K was found to be a proper 
cryo-protocol. Crystals measured at room temperature (see 3.2.2.6) did not diffract X-
rays better than the cryo-cooled specimens. 
Analysis of buffer-dependent protein solubility according to JANCARIK et al. (2004) 
revealed discrete solubility optima for AMPK_α2_1-339_D56A/R171E/T172D (Figure 
3.2.2.4-1). 
 
Figure 3.2.2.4-1: Plot of the solubility (bars, 1= insoluble precipitate, 0 = clear drop) of the triple mutant 
AMPK_α2_D56A/R171E/T172D as a function of pH (triangles) and various buffer compounds (all 100 
mM). Citrate and acetate apparently stabilize the protein (red asterisks) as implied by the results of 
crystallization. Independent of the buffer compound the triple mutant remained soluble above its 
isoelectric point (calculated pI = 6.34). Solutions of different buffer species were not corrected for ionic 
strength. The inset shows the experimental determination of the pI of the triple mutant via isoelectric 
focusing (IEF), the pI values of marker proteins are indicated. The smeared band is probably due to the 
presence of TCEP, which is known to cause artifacts in IEF (Invitrogen product information). 
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The lack of precipitate with 100 mM citric acid at pH 3.2 and 100 mM sodium acetate at 
pH 4.5 emphasizes the stabilizing effect of these organic acids (salts) on AMPK_α2_1-
339_D56A/R171E/T172D. However, optimization of pH against the concentrations 
sodium citrate or sodium acetate did not result in crystals in the the pH range close to 
the respective pKa values. This might reflect the observation that acidic proteins 
generally tend to crystallize 0-2.5 pH units above their pI (KANTARDJEFF and RUPP, 
2004). 
 
3.2.2.5 Refolding 
In order to investigate the possibility that AMPK_α2_1-339_D56A/R171E/T172D might 
be misfolded due to the heterologous expression in a prokaryotic system or that micro-
impurities (e.g., small molecule contaminations or residual E. coli host proteins) might 
interfere with crystallization, it was decided to produce the protein by refolding. For this 
AMPK_α2_1-339_D56A/R171E/T172D was expressed in E. coli using a fermenter at 
37°C, which resulted in a high yield of inclusion bodies (Figure 3.2.2.5-1).  
 
A 
 
B 
 
 
C 
 
 
 
 
 
Figure 3.2.2.5-1: A, SDS-PAGE of the expression profile of the inclusion body production of 
AMPK_α2_1-339_D56A/R171E/T172D (red arrow indicates product, lane 0: before induction, lanes 2-4: 
hours of expression). After cell disruption and centrifugation the insoluble fraction was dissolved in 8 M 
urea, 100 mM Tris pH 8.5,  4% (w/v) SDS and 7 mM  β-mercaptoethanol. B, SDS-PAGE showing the 
electrophoretic homogeneity of  refolded AMPK_α2_1-339_D56A/R171E/T172D. C, elution profile from 
final size exclusion chromatography of refolded AMPK_α2_1-339_D56A/R171E/T172D in 50 mM Tris/HCl  
pH 7.5, 500 mM NaCl, 3 mM CHAPS, 10 % (v/v) glycerol and 2 mM TCEP. The arrow indicates the 
monomeric main species. 
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The inclusion bodies were subjected to a generic kinase refolding protocol, and 
electrophoretically pure, monomeric protein was obtained (M. Dangl, Roche Penzberg; 
FIGURE 3.2.2.5-1). Despite the His6-tag the preparative Ni2+-IMAC step was omitted, 
thereby excluding the possibility of oxidative modification by undergoing a redox-
reaction with Ni2+-ions of  AMPK_α2_1-339_D56A/R171E/T172D on the column. The 
refolded enzyme crystallized under identical conditions as the conventionally purified 
material but resolution was still limited to app. 7 Å. The metabolic status of the E.coli 
host cells during expression at 37°C was likely to differ from that at the established 
expression temperature of 20°C and, therefore, a different contamination profile was to 
be expected. Taken together, these results indicated that not contaminations but 
intrinsic properties (e.g., loop flexibility) of AMPK caused the observed crystallization 
behavior. This conclusion is supported by the observation that the crystal structure of 
the core kinase domain of yeast AMPK (app. 60 % amino acid identity and 75 % 
similarity) shows a high degree of disorder (RUDOLPH et al., 2005). 
 
3.2.2.6 Free Mounting system 
Since attempts to optimize the crystallization of AMPK_α2_1-339_D56A/R171E/T172D 
by conventional, chemical means were unsuccessful, the impact of physical modification 
of the crystals was investigated. Desiccation of protein crystals had been described to 
improve crystal packing and diffraction (ABERGEL, 2004). The Free Mounting system 
(KIEFERSAUER et al., 2000) allows capillary-free mounting of protein crystals at room 
temperature. The advantage of this technique is the gentle mounting of crystals directly 
from the mother liquor, i.e., mechanical forces and soaking in cryo buffer that might 
destroy crystal quality are avoided. Gradients of controlled humidity can be applied after 
mounting in order to dehydrate the crystal, which potentially improves their diffraction 
quality by rearrangement of the crystal lattice. For this the dew point of the mother liquor 
is determined by mounting a drop from the mother liquor without crystal and adjusting a 
stream of humidified air hitting the loop until the volume (as determined by integration of 
the contour area) remains constant over time. X-ray still images are taken during the 
gradient program to follow the effect on diffraction quality as a function of relative 
humidity. 
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Cubic crystals of AMPK_α2_1-339_D56A/R171E/T172D in complex with staurosporine 
grown from 0.2 M sodium/potassium tartrate or 0.2 M sodium citrate and 20 % (w/v) 
PEG 3350 (Index Screen™ 86 or 96 from Hampton Research, respectively) in hanging 
drops were subjected to optimization trials with the free mounting system (Figure 
3.2.2.6-1). 
 
 
Figure 3.2.2.6-1: A-C and 1-4 depict the contour area images of the gradual dehydration of two 
AMPK_α2_1-339_D56A/R171E/T172D crystals. Both the crystals have a similar orientation with their 
apex (D) pointing down. The change in volume is recorded by integrating the pixel number of the crystal 
profiles. The bottom panel (E) shows another crystal (mounted in a 0.4 -0.5 mm cryo-loop) during the 
proceess of dehydration. Any residual mother liquor had been completely withdrawn and the crystal 
remains attached to the loop by only one side. 
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The crystals were mounted at 96 % of the relative humity that corresponded to the 
saturated vapor pressure of the mother liquor (at 21°C and atmospheric pressure) in 
order to avoid condensation of water on the loop, which might dissolve the crystal. The 
relative humidity generated close to the crystal can be calculated by the empirical 
Magnus formula (KIEFERSAUER et al., 2000). 
 
Analyses of the contour area during dehydration revealed that the AMPK_α2_1-
339_D56A/R171E/T172D crystals changed their size in a pronounced step at a relative 
humidity between app. 91 % and 88 % (Figure 3.2.2.6-2). The differences in the curves 
can be ascribed to direction-dependent, i.e., non-isotropic, lattice forces 
(KIEFERSAUER et al., 2000). The dehydration process was fully reversible (Appendix 
7.2). 
A B 
Figure 3.2.2.6-2: Plots of the change in contour area (black curves) and relative humidity (blue curves) 
over time for two seperate crystals (A and B) harvested from the same hanging drop. 
 
Despite various dehydration protocols (steepness of gradients, initial relative humidity), 
there was no significant improvement in the diffraction quality of the AMPK_α2_1-
339_D56A/R171E/T172D crystals. In retrospective, the dehydration procedure with the 
Free Mounting system according to KIEFERSAUER et al. (2000) had a success rate 
of 15 % with cystals of app. 100 different protein crystallization projects (H. Brandstetter, 
personal communication). However, the important information that was gained from 
these experiments was that the limited quality of the crystals tested in-house and at the 
SLS was not due to adverse effects of freezing and data collection at cryogenic 
temperatures. 
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3.2.2.7 Truncated triple (D56A/R171E/T172D) mutants 
The triple mutant AMPK_α2_1-339_D56A/R171E/T172D showed strongly improved 
crystallization when compared to the corresponding wild-type construct, yet the 
diffraction limit was not sufficient for solving the structure. For this reason the effect on 
protein stability and crystallization of the introduction of the three point mutations into 
the short constructs AMPK_α2_1-301 and AMPK_α2_1-312 was investigated. Cloning 
of these mutants was performed by excising the coding region for amino acids 1 to 268 
(comprising the three point mutations) by NdeI/PmeI restriction of a pET-15b-
AMPK_α2_1-339_D56A/R171E/T172D vector and subsequent introduction of this 
fragment into vectors coding for the AMPK_α2_1-301 and AMPK_α2_1-312 constructs 
(Figure 3.2.2.7-1). 
 
A 
 
 
 
 
B 
Figure 3.2.2.7-1: A, analytical agarose gel of the NdeI/PmeI restriction of  pET-15b vectors carrying the 
coding sequence for 1, AMPK_α2_1-339_D56A/R171E/T172D, 2, AMPK_α2_1-301_wt and 3, 
AMPK_α2_1-312_wt. The three excised 805 bp fragments showed slightly increased apparent molecular 
weight. B, analytical gel of  the extracted and purified excised fragment (1, *), which was ligated as insert 
into the cut vectors (2, 3) from the gel shown in A. The integrity of the resulting vectors was confirmed by 
nucleotide sequencing and the correct identity of the resulting proteins was confirmed by mass 
spectromety (no post-translational modification found). 
 
AMPK_α2_1-301_D56A/R171E/T172D exhibited very low recovery from the preparative 
Resource Q anion exchange column that had been used in the second step of 
purification of previous constructs and mutants. Running this purification step at 
decreased pH (7.0-7.4) in order to weaken the interaction of the target protein with the 
IEX resin was not sufficient to improve the yield. Therefore, a hydrophobic interaction 
chromatography (HIC) protocol was established (see Material and Methods). A 1 ml 
phenyl sepharose high performance (34 µm bead matrix) column with a ligand density 
of 25 µmol/ml was found to be optimal in terms of purification, recovery and resolution of 
the elution peak profile (Figure 3.2.2.7-2).  
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 Figure 3.2.2.7-2: HIC elution profile of 
AMPK_α2_1-301_D56A/R171E/T172D. The red 
arrow marks a non-proteinacious contamination 
that could be completely separated by HIC. For 
longer constructs the same contamination was 
seperated with anion exchange chromatography. 
 
The AMPK_α2_1-312_D56A/R171E/T172D construct also did not elute completely 
during the preparative anion exchange chromatography but here a decrease of the pH 
to 7.4 was sufficient for optimization of the elution. This suggested that part of the 
pronounced retention of this construct could be due to the Donnan effect, which causes 
an increase in the pH of the microenvironment of the anion exchanger surface 
(SCOPES, 1993; SHEN and FREY, 2004). 
Since the shorter triple mutant constructs have a higher pI (Figure 3.2.2.7-3) and altered 
surface properties compared to AMPK_α2_1-339_D56A/R171E/T172D, the behavior 
during elution from the IEX column could be attributed to protein-protein interaction and 
possibly aggregation on the IEX column rather than increased interaction with the resin. 
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Figure 3.2.2.7-3: Theoretical 
titration curves of AMPK_α2 
triple mutants as calculated 
with EMBOSS (RICE et al., 
2000). The carboxy-terminal 
amino acids of the constructs 
and the respective pI values 
are indicated in the legend. 
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After optimization of the purification protocols both the truncated triple mutant constructs 
could be prepared in substantially higher yields compared to the wild-type constructs. 
Tiny needle-shaped crystals of AMPK_α2_1-312_D56A/R171E/T172D in complex with 
staurosporine were obtained with 10 % (w/v) PEG 3000 or 8000, 0.2 M NaCl and 0.1 M 
CHES/ NaOH pH 9.5 (Emerald Wizard Screen 1, conditions 26 or 29, respectively). The 
further truncated construct AMPK_α2_1-301_D56A/R171E/T172D also crystallized as 
tiny needles from these conditions. However, optimization trials around these conditions 
did not improve crystal size. 
The results of the crystallization trials indicated that the carboxy-terminal construct 
boundary seemed to determine crystallization behavior and crystal size. A limited 
proteolytic digest of AMPK_α2_1-339_D56A/R171E/T172D in complex with 
staurosporine was performed in order to define stable truncated constructs derived from 
the complex that crystallized best (Figure 3.2.2.7-4). 
 
  
Figure3.2.2.7-4: Limited proteolytic digest of AMPK_α2_1-
339_D56A/R171E/T172D in complex with staurosprine at 
21°C (crystallization temperature) for the indicated times. 
Proteases were: 1, subtilisin, 2, proteinase K, 3, pronase and 
4, Staphylococcus aureus protease. In lane C AMPK_α2_1-
312_D56A/R171E/T172D was used as control. Proteolysis 
with proteinase K yielded a stable fragment of approximately 
31 kDa (red arrow, corresponding to ~260 amino acids) as 
determined from the marker calibration curve. 
 
 
The results of the limited proteolysis suggested that the preparation of stable core 
kinase constructs might be feasible, especially because no precipitate of insoluble 
fragments became visible. However, a given protease could cut a target protein into two 
(insoluble) fragments which remain associated in a stable (and soluble) complex and 
are only seperated upon denaturing electrophoresis. Here, interpretation of the results 
was unambiguous because from previous experiments it was known that the amino-
terminus of the soluble constructs of the α-subunit of AMPK was resistant to proteolysis 
under the conditions employed as opposed to the presumably flexible carboxy-terminus. 
Based on the homology model of AMPK_α2_1-339 four truncation points (i.e., after 
amino acid 249 and 262/3/4, Figure 3.2.2.7-5) were selected for generating the core 
kinase constructs by mutating the consecutive codons to stop codons by site directed 
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mutagenesis. The three constructs with carboxy-terminal residues 262/3/4 were made in 
order to exploit the effect of a positively or negatively charged or an uncharged carboxy-
terminus on the biochemical properties of these constructs. 
 
 
Figure 3.2.2.7-5: Standart orientation (left) and view rotated by 180° (right) of the homology model of 
AMPK_α2_1-339. The position of  helix αC is indicated for clarity, α-helices green, β-sheets blue, despite 
amino acids 249 to 339 of the carboxy-terminus which are colored light red. The red spheres represent 
the carboxy-terminal amino-acids of the truncated constructs. 
 
 
These construct boundaries could be verified by the FoldIndex prediction tool (Figure 
3.2.2.7-6; PRILUSKY et al., 2005). For a given protein sequence this program examines 
the correlation of the mean hydrophobicity (according to KYTE and DOLITTLE, 1982) to 
the mean net charge, as described by UVERSKY et al. (2000). Generally, natively 
unfolded proteins and amino acid sequences without secondary structure are found to 
possess a relatively high net charge together with low mean hydrophobicity. This 
interferes with the mechanisms proposed to underlie protein folding, i.e., gradual 
formation of local secondary structure with subsequent formation of tertiary structure, 
hydrophobic collapse or a nucleation-condensation driven process because of the 
repulsion of homonymous charges and the lack of formation of a hydrophobic core 
(NÖLTING and ANDERT, 2000). 
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      1 MAEKQKHDGR VKIGHYVLGD TLGVGTFGKV KIGEHQLTGH KVAVKILNRQ  
  51 KIRSLAVVGK IKREIQNLKL FRHPHIIKLY QVISTPTDFF MVMEYVSGGE  
 101 LFDYICKHGR VEEVEARRLF QQILSAVDYC HRHMVVHRDL KPENVLLDAQ  
 151 MNAKIADFGL SNMMSDGEFL EDSCGSPNYA APEVISGRLY AGPEVDIWSC  
 201 GVILYALLCG TLPFDDEHVP TLFKKIRGGV FYIPEYLNRS IATLLMHMLQ  
 251 VDPLKRATIK DIREHEWFKQ DLPSYLFPED PSYDANVIDD EAVKEVCEKF  
 301 ECTESEVMNS LYSGDPQDQL AVAYHLIIDN RRIMNQASEF YLASSPPTGS  
 351 FMDDMAMHIP PGLKPHPERM PPLIADSPKA RCPLDALNTT KPKSLAVKKA  
 401 KWHLGIRSQS KPYDIMAEVY RAMKQLDFEW KVVNAYHLRV RRKNPVTGNY  
 451 VKMSLQLYLV DNRSYLLDFK SIDDEVVEQR SGSSTPQRSC SAAGLHRPRS  
 501 SVDSSTAENH SLSGSLTGSL TGSTLSSASP RLGSHTMDFF EMCASLITAL  
 551 AR 
Figure 3.2.2.7-6: Output from the analyis of the full-length AMPK_α2_1-552 (D56A/R171E/T172D) by the 
FoldIndex prediction tool. Top panel, plot of the distribution of hydrophobicity (blue) and net charge 
(pink). Sections of the sequence with predicted folded domains are shown in green, whereas sections 
with relatively low hydrophobicity and high net charge are predicted to be unfolded (red). Bottom panel, 
amino acid sequence colored according to sections predicted to be structurally ordered (green) and 
disordered (red). The data from this analysis imply a domain/construct boundary for the core kinase at 
amino acid E251. Similar results were obtained with the DisEMBL algorithm (LINDING et al., 2003; data 
not shown). 
 
None of the core kinase constructs was found to yield soluble protein in expression tests 
in E. coli. This together with previous observations suggested that the sequence 
comprising amino acids 250 to 312 had a substantial effect on protein stability. This led 
to the decision to determine a carboxy-terminal construct boundary based on constructs 
used for the crystallization of a homologous kinase. 
Although AMPK has not been shown to be directly regulated by Ca2+/ calmodulin it is a 
member of the family of Ca2+/ calmodulin-dependent protein kinases (CAMK; MANNING 
et al., 2002). The sequences of rat AMPK_α2_1-339 and the construct of rat CAMK-1 
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whose structure had been solved (GOLDBERG et al., 1996, PDB code 1a06) possess 
31.3 % identity and 44.6 % similarity (Figure 3.2.2.7-7). 
 
                    .         .         .         .  
AMPK_α2            1        maekqkhdgrvkighyvlgdtlgvgtfgkvkigehqltghkva     43 
                            ...||..|.|   ..|...|.||.|.|.:|.:.|.:.|...|| 
CAMK_1a06          1 MPGAVEGPRWKQAEDIR---DIYDFRDVLGTGAFSEVILAEDKRTQKLVA     47 
                              .            .         .         .        
                           .         .         .         .         .    
AMPK_α2           44 vkilnrqkirslavvgkikreiqnlklfrhphiiklyqvistptdffmvm     93 
                     :|.:.::.:....  |.::.||..|...:||:|:.|..:..:....:::| 
CAMK_1a06         48 IKCIAKKALEGKE--GSMENEIAVLHKIKHPNIVALDDIYESGGHLYLIM     95 
                       .         .           .         .         .      
                          .         .         .         .         .    
AMPK_α2           94 eyvsggelfdyickhgrveevearrlfqqilsavdychrhmvvhrdlkpe    143 
                     :.||||||||.|.:.|...|.:|.||..|:|.||.|.|...:|||||||| 
CAMK_1a06         96 QLVSGGELFDRIVEKGFYTERDASRLIFQVLDAVKYLHDLGIVHRDLKPE    145 
                         .         .         .         .         .      
                              .         .         .         .         . 
AMPK_α2          144 nvl---ldaqmnakiadfglsnmmsdgefledscgspnyaapevisgrly    190 
                     |:|   ||......|:|||||.|...|..|..:||:|.|.||||::.:.| 
CAMK_1a06        146 NLLYYSLDEDSKIMISDFGLSKMEDPGSVLSTACGTPGYVAPEVLAQKPY    195 
                         .         .         .         .         .      
                              .         .         .         .           
AMPK_a2          191 agpevdiwscgvilyallcgtlpfddehvptlfkkirggvfyipey----    236 
                     : ..||.||.|||.|.||||..||.||:...||::|...     ||     
CAMK_1a06        196 S-KAVDCWSIGVIAYILLCGYPPFYDENDAKLFEQILKA-----EYEFDS    239 
                          .         .         .         .     
                             .        249        . 262/3/4 .         .  
AMPK_α2          237 -----lnrsiatllmhmlqvdplkratikdirehewfkqdlpsylfpedp    281 
                          ::.|....:.|:::.||.||.|.:...:|.|         ...|. 
CAMK_1a06        240 PYWDDISDSAKDFIRHLMEKDPEKRFTCEQALQHPW---------IAGDT    280 
                     .         .         .         .                  . 
                             .                   .301      . 312     .  
AMPK_α2          282 sydanviddeavkevcek----------fectesevmnslysgdpqdqla    321 
                     :.|.|:  .::|.|..:|          |..|                 | 
CAMK_1a06        281 ALDKNI--HQSVSEQIKKNFAKSKWKQAFNAT-----------------A    311 
                                .         .         .                   
                         326 .                  
AMPK_α2          322 vayhliidnrrimnqase            339 
                     |..|:     |.:....:         
CAMK_1a06        312 VVRHM-----RKLQLGHQPGGTGTDS    332 
                                  .         .   
Figure 3.2.2.7-7: Sequence alignment (Needle, EMBOSS, RICE et al., 2000) of rat AMPK_α2_1-
339_D56A/R171E/T172E and rat CAMK-1_1-332 as deposited in PDB entry 1a06 (CAMK_1a06). The 
carboxy-terminal residues of truncated constructs are labeled red. 
 
Alignment of the sequences emphasized that residue 326 of the α2-subunit of AMPK 
precedes a discontinuity in homology. It should be noted that CAMK-1 and AMPK_α2 
show a good overall alignment for the relevant constructs but only limited homology in 
the amino acid sequence spanning the transition from the kinase to the regulatory 
domains. However, sequence analysis with other isoforms and programs (data not 
shown) confirmed a break in local homology at postion 326 in AMPK_α2. Therefore, the 
construct AMPK_α2_1-326_D56A/R171E/T172D was generated, purified to 
homogeneity and subjected to crystallization trials, but no crystals were obtained. 
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3.2.2.8 Crystallization of the AMPK heterotrimer 
In addition to efforts to crystallize the catalytic domain of AMPK the option of 
crystallizing the holo-trimer was pursued. For this a collaboration with the group of Prof. 
T. Wallimann, ETH Zurich, had been established which granted access to cell lysates 
and purified protein of rat isoform combinations expressed from a tricistronic vector in E. 
coli (NEUMANN et al., 2003). The His6-tagged α1β1γ1 isoform combination was purified 
by H-J. Schönfeld and B. Pöschl, Roche Basel, from cell lysate provided by the 
Wallimann group. The purified protein was concentrated to 10 mg/ml in 25 mM 
HEPES/NaOH pH 7.8, 1 mM MgCl2, 200 mM NaCl, 1 mM DTT and subjected to 
commercial crystallization screens as apo enzyme and in combination with a range of 
nucleotide analogs as well as the active-site inhibitors compound C (ZHOU et al., 2001) 
and indirubin-5-sulphonate (synthesized by U. Riek, ETH Zurich; HOESSEL et al., 1999; 
DAVIES et al., 2001). Crystals of the apo enzyme could be obtained from 24 out of 48 
conditions of the PEG/Ion Screen™ (Hampton Research) using the free interface 
diffusion and modified microbatch methods. This demonstrated for the first time the 
feasibility to crystallize the heterotrimeric holoenzyme of AMPK. Optimization of the 
initial crystallization conditions proved difficult as the protein exhibited a substantial 
batch-to-batch variability with regard to its capability to crystallize, although the 
preparations were of high quality in terms of elution profiles during chromatography as 
well as final electrophoretic purity and monodispersity in dynamic light scattering (Figure 
3.2.2.8-1). 
 
A 
 
B             Rh = 6.6 nm, Polydisp. = 19.9 %
 
 
 
 
 
 
Figure 3.2.2.8-1: A, SDS_PAGE of a preparative SEC of His6-AMPK_α1β1γ1, with marker (lane M, MW 
is indicated), sample (lane S, before SEC) and fractions. Pools A and B were subjected to crystallization 
trials. B, DLS signal of His6-AMPK_α1β1γ1 (10 mg/ml).  
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Assuming a spherical protein the hydrodynamic radius of 6.6 nm corresponds to a 
molecular weight of 280 kDa. Despite the fact that a concentrated (presumably non-
ideal) sample solution was measured this demonstrated the formation of dimers of 
AMPK heterotrimers in solution, which was later confirmed by small angle X-ray 
scattering (SAXS; see 3.2.2.11). The best crystals of AMPK_α1β1γ1 were grown with 
the hanging drop technique in optimized conditions of the Index Screen™ (Hampton 
Research) and diffracted X-rays to 7 Å (Table 3.2.2-1, page 29).  
From the purified AMPK hetrotrimers delivered by the Wallimann group the isoform 
combinations α2β1γ1 and α2β2γ1 crystallized reproducibly (Table 3.2.2.8-1). 
Isoform/ Mutant Crystals/ Conditions 
His6-(TEV)-AMPK_α1β1γ1 no crystals 
AMPK_α1β1γ1 no crystals 
AMPK_α1β1γ1_D157A no crystals  
AMPK_α1β2γ1_wt no crystals  
 19 % PEGMME 2000, 0.2 M NaCl, 
0.1 M Bis-Tris pH 6.5 
(optimized from NHR-LB Screen 
Extension Kit , MDL) 
 12.5 % PEGMME2000, 0.4 M NaCl, 
0.1 M Bis-Tris pH 6.5 
(optimized from NHR-LB Screen 
Extension Kit, MDL) 
AMPK_α2β1γ1_wt 
 10 % PEGMME2000, 0.2 M NaCl 
0.1 M Bis-Tris pH 6.5 
(optimized from NHR-LB Screen 
Extension Kit, MDL) 
AMPK_α2β2γ1_wt needle-shaped crystals similar to AMPK_α2β1γ1_wt 
Table 3.2.2.8-1: Crystallization conditions of AMPK hetrotrimer isoforms obtained from Wallimann group, 
ETH Zurich. 
 
As observed with AMPK_α1β1γ1 purified in-house, the variability of the crystallization 
behavior between different batches precluded extensive optimization trials. No crystals 
were obtained of AMPK_α1β1γ1 or a derived trimer with a point mutation of catalytic 
50 µm
50 µm
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base (AMPK α1β1γ1_D157A), as opposed to the AMPK_α1β1γ1 purified in-house. This 
discrepancy emphasized the sensitivity of the trimer to minute changes in the construct 
and purification conditions (all preparations of AMPK_α1β1γ1 were performed with cell 
paste from the same fermentation).  
 
3.2.2.9 Crystallization of the AMPK regulatory subunits 
The crystals of various α2-subunit constructs, which were flawless in regard to visual 
inspection, and those of various isoform combinations of the heterotrimer were of limited 
diffraction quality. This suggested that the α-subunit might be responsible for the 
disorder of the crystals. Therefore, two constructs comprising the regulatory β- and γ-
subunits were cloned, expressed in E. coli and purified (R. Thoma, Roche Basel). These 
were AMPK_β1_∆1-67 • γ1 and AMPK_β1_∆1-185 • γ1, i.e., two amino-terminally 
truncated constructs of the β1-subunit in complex with the full-length γ1-subunits, 
respectively (Figure 3.2.2.9-1). 
 
A B                   Rh = 5.2, Polydisp. = 13.1 %
 
 
 
 
 
 
Figure 3.2.2.9-1: A, SDS-Page (red, calculated MW; M, marker with MW) and B, DLS of purified 
AMPK_β1_∆1-67 • γ1. 
 
The amino-terminal construct boundaries for the β1-subunit had been chosen according 
to the analyses performed by POLEKHINA et al. (2003; reviewed in KEMP et al., 2003) 
who had shown that residues 68 to 163 of AMPK_β1 form a functional glycogen binding 
domain (GBD). In fact, this GBD is the only domain of mammalian AMPK for which 
experimental structural information is available (POLEKHINA et al., 2005A and B). 
Neither of the purified heterodimers of the regulatory β1-subunit (in presence or 
absence of the GBD ± β-cyclodextrin) in complex with the γ1-subunit crystallized. 
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Preliminary results of limited proteolysis experiments with AMPK_α2β2γ1 (Figure 
3.2.2.9-2) suggested that further preparation of truncated AMPK constructs should be 
included in the optimization scheme. Trypsin, pronase and Staphylococcus aureus 
protease cut preferentially the catalytic α-subunit, while the regulatory β- and γ-subunits 
showed partial resistance to cleavage by these proteases. A future construct 
optimization scheme should include the analysis of the cleavage products by analytical 
SEC and native PAGE followed by SDS-PAGE and MS. This will allow the separation 
and identification of those fragments that can still form stable complexes. 
 
 M Marker 
1 Pepsin   
2 Trypsin   
3 Chymotrypsin 
4 Subtilisin    
5 Factor Xa   
6 Proteinase K 
7 Pronase 
8 St. aureus Protease 
9 CTase 
10 NTase 
11 Thrombin 
12 Control w/o protease  
Figure 3.2.2.9-2: Limited proteolysis of AMPK_α2β2γ1. The reaction was performed with a 1:10,000 
(w/w) ratio of protease to AMPK trimer for 5 h at 21°C in 50 mM HEPES/NaOH pH 8, 200 mM NaCl, 2 
mM MgCl2 and 2 mM TCEP. 
 
3.2.2.10 Interaction of the AMPK heterotrimer with the ligand binding domain of 
PPARα 
BRONNER et al. (2004) showed that the α2-subunit of (human) AMPK physically 
interacts with the ligand binding domain (LBD) of the (murine) nuclear hormone receptor 
PPARα in vitro. Nulear localization and direct phosphorylation of proteins involved in 
gene transcription were demonstrated for the AMPK-α2 subunit (SALT et al., 1998; 
LEFF, 2003). In order to assess whether this complex formation could enhance the 
crystallization of the heterotrimer, AMPK_α2β2γ1 was incubated with an equimolar 
amount of (human) PPARα. The  PPARα was a preparation of an in-house construct, 
which was 42 amino-acids shorter than that used in the study by BRONNER et al. 
(2004). Despite using a buffer system as published, no interaction of  AMPK_α2β2γ1 
with the LBD of PPARα could be detected using analytical size exclusion 
chromatography and only a very weak interaction could be demonstrated by Biacore 
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(data not shown) and this strategy for crystallization was not pursued. However, these 
results could indicate that the 42 amino acids at the amino-terminus of LBD missing in 
the in-house PPARα constructs are essential for the interaction with AMPK_α2. 
 
3.2.2.11 Small angle X-ray-scattering (SAXS) studies of AMPK 
As the AMPK crystals were not suitable for solving the structure, SAXS studies were 
performed in order to elucidate the low resolution (app. 15-20 Å) solution structures of 
wild-type AMPK_α2_1-392 and the AMPK_α2β2γ1 hetrotrimer. The SAXS 
measurements and data analyses were done in collaboaration with D. Svergun and P. 
Konarev, EMBL, Hamburg outstation. In order to visualize the shape of AMPK_α2_1-
392 an ab initio bead model was generated based on the scattering data (Figure 
3.2.2.11-1). In a second approach the AMPK_α2_1-339 homology model was used as 
input and the missing residues (aa 340-392) were modeled by minimizing the 
discrepancy of the scattering intensity calculated from the input data and the 
experimental scattering intensity (Figure 3.2.2.11-1). While these models cannot be fully 
superimposed, the elongated shapes of the models clearly accentuate that the putative 
autoinhibitory domain does not bind to the catalytic core with high affinity. This result is 
in full agreement with the Thermofluor data (3.2.2.2). 
 
A 
 
B 
 
Figure 3.2.2.11-1: SAXS analysis of AMPK_α2_1-392 (5.4 mg/ml). A, ab initio bead model generated 
with the program DAMMIN. B, homology model of AMPK_α2_1-339 (ribbon representation, green: α-
helices, blue: β-strands) with the model  of the missing part of the putative autoinhibitory domain (aa 340-
392, orange spheres), as calculated with the programs CRYSOL and CREDO (PETOUKHOV et al., 
2002). Each sphere represents one added residue, the three residues at the amino-terminus (pink 
spheres) are derived from the thrombin cleavage site of the His6-tag. 
 
86 Å 56 Å
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The scattering curves of full-length heterotrimeric AMPK_α1β1γ1 and AMPK_α2β2γ1 at 
concentrations that were used for crystallization trials (1.3-18 mg/ml) indicated that 
trimeric AMPK has a tendency to oligomerize and aggregate. Dilution of the protein  to 
lower concentrations with the stabilizing buffer (50 mM HEPES/NaOH pH 8.0, 2 mM 
MgCl2, 200 mM NaCl and 2 mM TCEP)  resulted in an decreased signal to noise ratio 
(electron density contrast), which rendered the data uninterpretable. For AMPK_α2β2γ1 
(1.3 mg/ml) the program DAMMIN was run with P1 symmetry but produced a model with 
an approximate two-fold symmetry (Figure 3.2.2.11-2). This result indicated the 
formation of dimers of heterotrimers because the AMPK heterotrimer has certainly no 
internal two-fold symmetry. The model has a volume of 3.214⋅105 Å3, which corresponds 
to a MW of 160 kDa (assuming a partial specific volume of 0.741 ml/g). As the MW 
determined by SAXS was between the theoretical MW of the AMPK_α2β2γ1 trimer (130 
kDa) and that of a dimer of such a heterotrimer, the data suggested that AMPK_α2β2γ1 
has a tendency to form higher order assemblies. Analyzing the scattering of 
AMPK_α2β2γ1 at 13 mg/ml with a P2 symmetry restriction yielded a model of 6.497⋅105 
Å3 (320 kDa, Figure 3.2.2.11-2). 
 
A B 
C D 
Figure 3.2.2.11-2: Ab initio bead models of the AMPK_α2β2γ1 heterotrimer. A, AMPK_α2β2γ1 at 1.3 
mg/ml. B, AMPK_α2β2γ1 at 13 mg/ml. C, superimposition of A and B. D, same as C but rotated 90° to the 
back. The maximal particle size (Dmax, [Å]) is indicated by the scale bars. 
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The AMPK_α2β2γ1 models calculated from the SAXS data have radii of gyration, i.e., 
root-mean square distances for all electrons in the model from their center of gravity, of 
5.43 nm for the low and 7.26 nm for the high concentration sample. This corresponds 
very well to the hydrodynamic radii Rh = 6.29 nm (13 mg/ml, 32.7 % polydispersity) and 
Rh = 6.6 nm (10 mg/ml, 19.9 % polydispersity) measured by DLS for AMPK_α2β2γ1 and 
AMPK _α1β1γ1 (3.2.2.8), respectively. Thus, the formation of oligomeric species in a 
concentration-dependent manner is likely to be a property of the AMPK heterotrimer and 
probably interferes with crystallization. Preliminary SAXS experiments with 
AMPK_α1β1γ1 and AMPK_α2β2γ1 equilibrated with an 1 mM excess of active (AMP-
PNP) and allosteric (AMP) site ligands, revealed that under these conditions the radii of 
gyration are decreased. This was interpreted as a ligand-dependent shift of the 
association equilibria towards monomeric αβγ-trimers, and has to be verified by 
measuring dilution series of ligand against different protein concentrations. 
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3.3 Crystallization and structure determination of carnitine 
palmitoyltransferase 2 (CPT-2) 
3.3.1 The CPT-system: a candidtate drug target for T2D 
The carnitine palmitoyltransferase (CPT) system imports long chain fatty acids (LCFA) 
into mitochondria, where they are metabolized by β-oxidation (reviewed in MCGARRY & 
BROWN, 1997; RAMSEY et al., 2001; BONNEFONT et al., 2004). The rate-limiting step 
of LCFA import is the transesterification of acyl-CoA to acyl-carnitine by CPT-1 
(RONNETT et al., 2005), which is integrated into the mitochondrial outer membrane 
(MOM). Several mechanisms for the delivery of acyl-carnitine esters from the cytosol 
into the mitochondrial intermembrane space have been proposed (BEBERNITZ and 
SCHUSTER, 2002). The acyl-carnitine esters are translocated through the 
mitochondrial inner membrane (MIM) via the carnitine/acyl-carnitine transporter (CACT). 
CPT-2, which is localized at the matrix side of the MIM, transforms the imported acyl-
carnitine back to acyl-CoA. 
The muscle isoform of CPT-1 (M-CPT-1), and to a lesser extent the liver isoform (L-
CPT-1), are inhibited by malonyl-CoA (ZAMMIT, 1999A), the product of the committed 
step of fatty acid synthesis. In contrast, the activity of the ubiquitously expressed CPT-2 
is not known to be directly regulated by malonyl-CoA or other intermediates of 
metabolism (MCGARRY and BROWN, 1997; NIC A'BHAIRD et al., 1993) which could 
be exploited for pharmacological modulation of CPT-2 activity. 
Pharmacological inhibition of the CPT system by the glycidic acid derivative etomoxir, 
an irreversible and non-isoform-specific active site inhibitor of CPTs, has been 
demonstrated to reduce fasting blood glucose in an animal model of type 2 diabetes 
mellitus (T2D; BARNETT et al., 1992). Oral administration of etomoxir decreased fasting 
glucose and ketone body levels in obese T2D patients (RATHEISER et al., 1991), and 
insulin-mediated glucose uptake was observed to be increased in another study with 
T2D patients (HUBINGER et al., 1992). However, specific inhibition of L-CPT-1 would 
be desirable, as this would utilize the glucose-fatty acid (Randle) cycle for restoring 
glucose homeostasis without affecting mobilization of ectopic lipid depots in skeletal 
muscle of adipose T2D patients (reviewed in ANDERSON, 1998; RANDLE, 1998; 
FRAYN, 2003; DULLOO et al., 2004).  
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The identification of L-CPT-1 as a target for the treatment of T2D is further supported by 
the finding that inhibition of L-CPT-1 has been shown to reduce gluconeogenesis 
(WOLF and ENGEL, 1985; KASHIWAGI, 1995; WAGMAN and NUSS, 2001). Inhibition 
of L-CPT-1 results in depletion of mitochondrial acetyl-CoA which is an allosteric 
activator of the gluconeogenic enzyme pyruvate carboxylase.  
In addition to etomoxir, various series of compounds have been designed that are 
competitive with substrate binding to CPT-1 (BEBERNITZ and SCHUSTER, 2002). 
These include the aminocarnitine-related family of emericidins isolated from the 
ascomycete fungus Emericella quadrilineata (SHINAGAWA et al., 1987), which were 
further developed into more L-CPT-1-specific ureidic acyl-aminocarnitine derivatives 
(GIANNESSI et al., 2001 and 2003). A representative of the latter, (R)-N-
(tetradecylcarbamoyl)-aminocarnitine (ST1326) is an analog of palmitoylcarnitine, the 
product of CPT-1 and substrate of CPT-2. The compound ST1326 is currently in clinical 
trials at Sigma-Tau Pharmaceuticals. ST1326 was shown to inhibit L-CPT-1 in isolated 
rat mitochondria with marked specificity over M-CPT-1 (GIANNESSI et al., 2003).  
Moreover, ST1326 caused a pronounced reduction of serum glucose levels when 
administered orally to db/db mice (GIANNESSI et al., 2003) and was shown to elicit an 
anorexic effect, as well as to inhibit endogenous glucose production after central 
administration to rats (OBICI et al., 2003). These features render ST1326 a model 
compound for L-CPT-1 inhibition in the treatment of diabetes mellitus.  
In order to support the discovery of novel anti-diabetic drugs that inhibit the CPT-
system,  the function and structure of CPT-2 was investigated in this thesis. Full length 
CPT-2 from rat was expressed in E. coli, solubilization and purification of membrane 
bound CPT-2 with detergent yielded homogeneous and active enzyme. Characterization 
of the activity of CPT-2 revealed inhibition of CPT-2 in vitro by ST1326, which had 
previously been reported to be a specific inhibitor of L-CPT-1 (GIANNESSIi et al., 2003). 
The binding mode of ST1326 was elucidated by solving the crystal structure of full-
length rat CPT-2 in complex with ST1326 at 2.5 Å resolution. The structure of the 
uninhibited enzyme of rat CPT-2 was solved at 1.6 Å and 2.0 Å in two different space 
groups. The amino acid sequence of CPT-2 revealed a 30 amino acid insert uniquely 
found in CPT-2 as compared to CPT-1 isoforms, carnitine acetyltransferase (CrAT) and 
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carnitine octanoyltransferase (CrOT). Based on the crystal structure of CPT-2 a model 
for membrane attachment of CPT-2 mediated by this insert could be proposed. 
The crystal structure of CPT-2 in complex with the substrate analog ST1326 revealed 
an extensive hydrogen network involving residues highly conserved between CPT-1 and 
CPT-2 that tightly interact with the hydrophilic aminocarnitine headgroup of ST1326. 
Furthermore, clear electron density for the hydrophobic tail of ST1326 accommodated in 
the acyl binding-site was visible. The structure of CPT-2 in complex with ST1326 shows 
for the first time the substrate binding mode of LCFA-specific carnitine acyltransferases, 
which are indispensible for the import of substrates for β-oxidation into mitochondria. 
The CPT-2 structure also allows the correlation of structure and function of amino acids 
mutated in CPT-2 deficiency, a hereditary disorder of lipid metabolism.  
 
3.3.2 Biophysical characterization of CPT-2 
Rat CPT-2 was solubilized in detergent micells and purified to homogeneity by a two 
step purification protocol. CPT-2 was chosen as a surrogate system because of 
markedly increased solubility (MURTHY and PANDE, 1987; WOELTJE et al., 1990) and 
crystallizability when compared to the integral membrane protein CPT-1. Human L-CPT-
1 and rat CPT-2 share 27 % identity and 43 % similarity in the amino acid sequence of 
their catalytic cores and the catalytically important residues are fully conserved (Figure 
3.3.2-1).  
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Figure 3.3.2-1: Amino acid sequence alignment (ClustalW, EMBOSS; RICE et al., 2000) of rat CPT-2 
(rCPT-2) and human L-CPT-1 (hL-CPT-1). Secondary structure elements (S.S.) are indicated. The 
residue numbering corresponds to the rCPT-2 precursor and its mitochondrial import sequence is 
italicized. The CPT-2 specific insert (amino acids 179-208) is underlined. Key residues of the acylcarnitine 
binding site of rCPT-2 are in bold letters and are labeled with an asterisk when fully conserved in hCPT-1. 
Residues are printed in red when mutations in CPT-2 deficiency have been reported. 
 
In the final preparative size-exclusion chromatography rat CPT-2 (c ≈ 14 mg/ml in 
pooled peak fractions) behaved as a monomer and no aggregates could be detected. In 
the presence of 1 % (w/v) n-octyl-β-D-glucopyranoside (βOG; app. 1.5-fold CMC 
concentration), but not in preparations with detergents at CMC-concentration (βOG; n-
dodecyl-β-D-maltoside; CHAPS), rat CPT-2 was found to be monomeric and 
monodisperse as determined by analytical ultracentrifugation (Figure 3.3.2-2).  
rCPT-2    ..........................................................................................
hL-CPT-1  MAEAHQAVAFQFTVTPDGIDLRLSHEALRQIYLSGLHSWKKKFIRFKNGIITGVYPASPSSWLIVVVGVMTTMYAKIDPSLGIIAKINRT
S.S.                                                                                    α1 
Res.                                        1        10        20        30        40        50   
rCPT-2    ..................................MMPRLLFRAWPRCPSLVLGAPSRPLSAVSGPDDYLQHSIVPTMHYQDSLPRLPIPK
hL-CPT-1  LETAN..CMSSQTKNVVSGVLFGTGLWVALIVTMRYSLKVLLSYHGWMFTEHGKMSRATKIWMGMVKIFSGRKPMLYSFQTSLPRLPVPA
S.S.      -----α2----    ------α3------  -----α4------      ----α5----         -β1-   α6
Res.         60        70        80        90        100       110        120       130       140 
rCPT-2    LEDTMKRYLNAQKPLLDDSQFRRTEALCKNFETGVGKELHAHLLAQDKQNKHTSYISGPWFD.MYLTARDSIVLNFNPFMAFNPDPKSEY
hL-CPT-1  VKDTVNRYLQSVRPLMKEEDFKRMTALAQDFAVGLGPRLQWYLKLKS..WWATNYVSDWWEEYIYLRGRGPLMVNSN.YYAMDLLYILPT
                                                                    *    * 
S.S.        --------α7-------       β2  α8  --α9--      α10    β3    α11  β4    β5
Res.          150       160       170       180       190       200       210       220       230 
rCPT-2    NDQLTRATNLTVSAVRFLKTLQAGLLEPEVFHLNPSKSDTDAFKRLIRFVPPSLSWYGAYLVNAYPLDMSQYFRLFNSTRIPRPNRDELF
hL-CPT-1  HIQAARAGNAIHAILLYRRKLDREEIKPIRLLGS.............................TIPLCSAQWERMFNTSRIPGEETDTIQ
S.S.            --β6---β7-          ----α12----           -α13-  ----α14----   --α15--  
Res.          240       250       260       270       280         290       300        310       320
rCPT-2    TDTKARHLLVLRKGHFYVFDVLDQDGNIVNPLEIQAHLKYILSDSSPVP..EFPVAYLTSENRDVWAELRQKLIFD.GNEETLKKVDSAV
hL-CPT-1  HMRDSKHIVVYHRGRYFKVWLYH.DGRLLKPREMEQQMQRILDNTSEPQPGEARLAALTAGDRVPWARCRQAYFGRGKNKQSLDAVEKAA
S.S.      -β8-              --α16--           -β9-    -β10-      ------α17------          
Res.                     330       340       350       360       370       380       390       400 
rCPT-2    FCLCLD........DFPMKDLIHLSHTMLHGDGTNRWFDKSFNLIVAEDGTAAVHFEHSWGDGVAVLRFFNEVFRDSTQTPAITPQ..SQ
hL-CPT-1  FFVTLDETEEGYRSEDPDTSMDSYAKSLLHGRCYDRWFDKSFTFVVFKNGKMGLNAEHSWADAPIVAHLWEYVMSIDSLQLGYAEDGHCK
                                                                  *   * 
S.S.           α18β11   -------α19-------  -β12-              ------α20------      -β13-
Res.             410       420       430       440       450       460       470       480       490
rCPT-2    PAATNSSASVETLSFNLSGALKAGITAAKEKFDTTVKTLSIDSIQFQRGGKEFLKKKQLSPDAVAQLAFQMAFLRQYGQTVATYESCSTA
hL-CPT-1  GDINPNIPYPTRLQWDIPGECQEVIETSLNTANLLANDVDFHSFPFVAFGKGIIKKCRTSPDAFVQLALQLAHYKDMGKFCLTYEASMTR
                                                                                            *  
S.S.            -β14- ---α22--- α22B --------α23--------      ----α24----     α25 -α26+
Res.             500       510       520       530       540       550       560       570       580
rCPT-2    AFKHGRTETIRPASIFTKRCSEAFVRDPSKHSVGELQHMMAECSKYHGQLTKEAAMGQGFDRHLYALRYLATARGLNLPELYLDPAYQQM
hL-CPT-1  LFREGRTETVRSCTTESCDFVRAMVD..PAQTVEQRLKLFKLASEKHQHMYRLAMTGSGIDRHLFCLYVVS..KYLAVESPFLKEVLSEP
              ** *                                                    * 
S.S.      +   β15                    β16     -β17-     -β18-        --------α27-------- 
Res.             590                    600       610        620          630       640       650 
rCPT-2    NHNILSTSTLNSPAVSL.............GGFAPVVPDGFGIAYAVH.DDWIGCNVSS...YSGRNAREFLHCVQKCLEDIFDALEGKA
hL-CPT-1  WR..LSTSQTPQQQVELFDLENNPEYVSSGGGFGPVADDGYGVSYILVGENLINFHISSKFSCPETDSHRFGRHLKEAMTDIITLFGLSS 
              ***                      *** 
S.S. 
Res.        658 
rCPT-2    IKT. 
hL-CPT-1  NSKK 
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The purified enzyme was active as monomer and its activity could be inhibited in a 
concentration dependent manner by ST1326 with an IC50 = 0.24 µM (Figure 3.3.2-2). 
 
A  B 
 
C 
Detergent c [% (w/v)] Monomers  
[% in supernatant] 
Oligomers  
[% in supernatant] 
Sed. Loss [%] 
β-OG 0.1 16 84 58 
β-OG 1.0 100 0 3 
DDM 0.075 97 3 70 
CHAPS 0.35 72 28 0 
Figure 3.3.2-2: Characterization of rCPT-2. The SEC elution profiles at A, app. 1 mg/ml in peak fraction 
and B, app. 40 mg/ml show that rCPT-2 eluted as a single, monomeric species in the presence of 1 % 
(w/v) βOG. C, the left panel shows the sedimentation equilibrium of rat CPT-2 in 1% βOG at 20°C and 
12,000 rpm. The absorbance at 280 nm (○) is plotted vs. radial distance. The solid line (―) shows the fit 
corresponding to an apparent single species of 73,471 Da (the theoretical MW of the construct is 
73,470.82 Da) with a partial specific volume vbar = 0.760 ml/g and a solvent density ρ = 1.092 g/ml. 
Residuals of the fitted curve are shown in the top panel. The right panel depicts the inhibition ± SD of 
purified rCPT-2 activity by ST1326 (IC50 = 0.24 µM). The 100 % activity control was determined in the 
absence of ST1326. The table at the bottom summarizes the AUC data with different detergent 
conditions. 1 % (w/v) βOG is required for stabilization of rCPT-2. 
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3.3.3 Crystallization and overall structure of CPT-2 
Rat CPT-2 crystallized in complex with the inhibitor ST1326 and as uninhibited enzyme 
within seven days after setting up the crystallization trials (Figure 3.3.3-1). The term 
"uninhibited" as opposed to "apo" is used fort the structures determined in the abscence 
of ST1326 because in the 1.6 Å high resolution structure significant electron density for 
a fortuitous ligand bound to the active site was visible (see 3.3.4). While the crystals of 
the complex from the initial screen were sufficient for determining the structure, the 
crystals of the uninhibited enzyme had to be optimized by microseeding. 
 
A 
 
 
 
 
 
ST1326 
25 % (w/v) PEG 1500 (Index 37) 
modified microbatch 
B 
 
 
 
 
 
 
 
 
Apo 
0.15 M DL-malic acid pH 7.0 
20 % PEG 3350 (Index 91)  
hanging drop vapor diffusion 
Figure 3.3.3-1: A, orthorhombic crystals of the rCPT-2 • ST1326 complex. B, tetragonal crystals of apo 
rCPT-2. Microseeding with a diluted seed stock containing vortexed preliminary crystals (inset) was 
essential for obtaining large, single diffraction quality crystals of the uninhibited enzyme. 
 
The structure of rCPT-2 was determined by molecular replacement and refined to a 
resolution of 1.6 Å (C2221) and 2.0 Å (P43212) for the uninhibited enzyme and 2.5 Å 
(P212121) for the ST1326 complex (see Table 3.3.3-1 for data statistics). The first 31 
amino-terminal amino acids, comprising the His6-tag and five residues of the actual 
rCPT-2 sequence, are disordered in all three structures. The full carboxy-terminus (Thr 
658) is visible in chain A of the uninhibited enzyme in space group C2221, while the last 
residues with interpretable electron density at the carboxy-termini are Ile 656 and Lys 
654 in the tetragonal uninhibited and the complex crystals, respectively. 
 
 
 
20 µm 200 µm
50 µm
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 uninhibited 1, 
high resolution uninhibited 2 CPT-2 / ST1316 
Data collection    
Space group C2221 P43212 P212121 
Cell dimensions     
    a, b, c (Å) 95.2, 97.3, 310.4 67.6, 67.6, 307.3 85.8, 96.2, 124.3 
    α, β, γ (°)  90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å) a 23.0 -1.6 (1.69 - 1.60) 
23.0 - 2.0 
(2.12 - 2.00) 
50.0 - 2.24 
(2.38 - 2.24) 
Rsym b 6.2 (21.2) 3.1 (7.4) 16.7 (41.1) 
I / σI 14.04 (7.24) 28.04 (14.80) 9.57 (3.20) 
Completeness (%) 99.7 (99.8) 99.9 (100) 92.9 (81.8) 
Redundancy 6.7 (5.8) 21.8 (18.5) 6.9 (6.2) 
    
Refinement    
Resolution (Å) 23-0 - 1.6 23.0 - 2.0 15.0 - 2.5 
No. reflections 179022 46957 32831 
Rwork / Rfree c 16.5 / 19.4 17.9 / 23.5 24.1 / 29.6 
No. atoms (all) 11449 5502 5143 
    Protein 10085 4977 4963 
    Ligand/ion n/a d n/a 28 
    Water 1364 525 152 
B-factors  (overall) 20.1 21.9 41.0 
    Protein 18.7 21.0 41.4 
    Ligand/ion n/a d n/a 27.6 
    Water 30.1 30.7 31.6 
R.m.s. deviations    
    Bond lengths (Å) 0.014 0.01 0.013 
    Bond angles (°) 1.225 1.161 1.502 
Table 3.3.3-1: Data collection and refinement statistics of the rCPT-2 crystals. 
a Values in parentheses are for highest resolution shells. 
b Rsym = Σ(I-<I>)/Σ(I) 
c R = ΣFobs-Fcalc/ ΣFobs; Rfree was calculated using randomly selected 5 % of reflections. 
d The βOG detergent molecule (mean B = 54.9 Å2), the two C16 alkyl-moieties (mean B = 23.3 Å2 ) and 
the two residual, unspecifically bound CoA molecules (mean B = 37.7 Å2) were not included in the 
statistic. 
 
The rCPT-2 secondary structure contains 27 α-helices and 18 β-strands. Amino-
terminal (residues 111-440) and carboxy-terminal (residues 441-658, plus 32-110) 
domains can be assigned to rCPT-2. These domains consist of a six-stranded central 
anti-parallel β-sheet and surrounding α-helices (Figures 3.3.2-1 and 3.3.3-1). Two of 
these β-strands (β1, β16) mediate the major domain contact.  
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Figure 3.3.3-1: Structure of rCPT-2 with ST1326 bound to its active site. ST1326 and its surrounding fofc 
simulated annealing omit electron density map (1000 K; 2 σ contour level) are depicted in pink, the 
amino- and carboxy-termini are labeled with blue and red spheres, respectively, in A through C. A, 
ST1326 binds at the interface of the amino-terminal (cyan) and carboxy-terminal (orange) domains of rat 
rCPT-2. Strands β1 and β16 mediate the major domain contact by forming an antiparallel sheet. B, the 
central β-strands (blue) are surrounded by α-helices (green). C, same as B but rotated 90° to the back. 
The CPT-2-specific insert (red) consisting mainly of helices α9 and α10 protrudes from the amino-
terminal domain. D, surface representation of C that shows the entry (orange) to the active site tunnel 
close to the insert. E, surface in orientation of C colored according to electrostatic potential, charges 
(blue: positive, red: negative; white: neutral) were calculated at neutral pH (MOE). Key basic residues are 
indicated. F, electrostatic potential representation identical to that in E with orientation of B.  An excess of 
positive charges is found on the surface close to the insert. The arrows indicate the entrance to the CoA-
tunnel of the active site. 
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The loop connecting helices 22 and 23 adopts a helical conformation in the uninhibited 
structures and is, therefore, designated helix 22B. The corresponding region of the 
ST1326 complex structure is located close to a crystal contact, which may interfere with 
secondary structure formation. A 30 amino acid insert (comprising helices α8-10) 
uniquely found in CPT-2 when compared to other carnitine acyltransferases (29 amino 
acids when compared to L-CPT-1, Figures 3.3.2-1 and 3.3.3-1) protrudes from the 
amino-terminal domain. Despite this insert the overall topology of rat CPT-2 resembles 
the two domain architecture found in human and mouse CrAT [PDB codes 1s5o (WU et 
al., 2003; GOVINDASAMY et al., 2004) and 1ndb (JOGL and TONG, 2003), 1t7n 
(HSIAO et al., 2003)] as well as CrOT [PDB code 1xl7 (JOGL et al., 2005)]. These 
members of the family of carnitine acyltransferases show approximately 30 % identity 
and 47 % similarity in the amino acid sequence of their catalytic core. 
Uninhibited rCPT-2 and the ST1326 complex crystallized in different crystal forms, but 
the structures have similar conformations as indicated by a r.m.s. distance of 0.38 Å 
between all equivalent Cα atoms. In all three structures the active site residue Arg 498 
is in the generously allowed region of the Ramachandran plot and Leu 129 as well as 
Asn 230 do not comply with favored geometry of the Ramachandran plot, as indicated 
by well defined electron density for these residues. Leu 129 is the second residue in a 
type II reverse turn (equivalent to Ile 116 in mouse CrAT, PDB code 1t7n), whereas Asn 
230 is located in a β-turn whose geometry is distorted due to interaction with 
neighboring Asp 297 and Arg 124. Mutation of Arg 124 is associated with inherited CPT-
2 deficiency (see below). 
 
3.3.4 Binding mode of ST1326 
The active site of CPT-2 is located in a Y-shaped tunnel at the domain interface 
(Figures 3.3.3-1 and 3.3.4-1). The tripartite (NIC A'BHAIRD et al., 1993) tunnel consists 
of binding sites for the acyl-, carnitine- and CoA moieties. In contrast to CrAT and CrOT 
the acyl-tunnel opens to the surface in rCPT-2. ST1326 is a non-cleavable analog of 
palmitoyl-carnitine, the physiological substrate of CPT-2. The acyl- and carnitine tunnels 
of the active site of CPT-2 are occupied by ST1326, whereas the CoA-tunnel can be 
assigned by homology modeling based on the complex structure of CrAT with CoA 
(PDB code 1t7q, Figure 3.3.4-1). 
_________________________________________________________Results: CPT-2 
 69
A 
 
B 
 
C 
Figure 3.3.4-1: A, stereo figure (generated with MOLOC; GERBER, 1992) of the tripartite active site 
tunnel with bound ST1326 viewed perpendicular to the domain interface. Key active site residues are 
depicted in yellow. The co-crystallized ST1326 is shown in pink, a CoA molecule (blue) was modeled 
based on the CoA coordinates from the CrAT-CoA complex structure (PDB code 1t7q). B, Fischer 
projection of ST1326 with atom numbering as used in the text. C, Fischer projection of palmitoyl carnitine, 
the natural substrate of CPT-2. 
 
The hydrophilic aminocarnitine head group of ST1326 is tightly bound in a hydrogen-
bond network. The catalytic base His 372 forms a hydrogen bond with the amino-
nitrogen (N11) of ST1326, which substitutes the ester oxygen of the native ligand 
palmitoylcarnitine.  
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Ser 590 of the Ser-Thr-Ser (STS) motif conserved among carnitine acyltransferases 
makes a hydrogen bond to the carbamoyl-oxygen (O13) of the ST1326, which confirms 
the role of this motif in positioning the substrate for catalysis to occur. Tyr 486, Ser 488 
and Thr 499 of the carboxy-terminal domain are directly hydrogen-bonded to the 
carboxyl oxygens (O9 and O10) of ST1326. Hydrogen bonds to the guanidinium group 
of Arg 554 further stabilize the orientation of Tyr 486 and Thr 499. Residues Trp 116, 
Tyr 120 and Asp 376 of the amino-terminal domain fix a conserved water molecule that 
interacts with the carboxy group of ST1326 (Figure 3.3.4-1). Arg 498 forms a strong 
hydrogen bond with the side chain of Asp 376 and its guanidinium group interacts with 
the main chain carbonyl oxygen of Ser 373 in the catalytic loop, thereby positioning the 
active site residues in a position ideal for catalysis. The positively charged tertiary amine 
of ST1326 is stabilized by cation-pi interactions with the conserved Phe 602. 
The hydrophobic tunnel that accommodates the aliphatic tetradecanoyl tail of ST1326 is 
lined by residues of β-strands 1 and 16, which form an anti-parallel β-sheet at the 
domain interface, and the two carboxy-terminal β-strands 17 and 18. A simulated 
annealing fofc omit map contoured at 2 σ shows clear continuous electron density for 
the ligand ST1326 bound to the active site (Figure 3.3.3-1). The β-strands forming the 
hydrophobic acyl-tunnel are moved apart in order to make room for the extended 
hydrophobic tail of the substrate analog ST1326 compared to the closed arrangement in 
CrAT and CrOT (PDB codes 1ndb, 1t7n and 1xl8). The glycine residue Gly 600, at a 
position where bulkier residues are found in CrAT (Met 564) and CrOT (Gln 552), allows 
binding of LCFA carnitine-derivatives in CPT-2, thereby determining substrate 
specificity. Glu 487 and Glu 500 of CPT-2, which are conserved throughout the carnitine 
acyltransferases, have been implicated in substrate binding and catalysis by means of 
mutational analysis (ZHENG et al., 2002). The crystal structure of CPT-2 reveals that 
Glu 487 is indeed located in the part of the active site tunnel that accommodates the 
(modeled) CoA. Glu 487 and the highly conserved Asp 464 form a negatively charged 
patch that is probably required for guiding substrates to the active site. The side chain of 
Glu 500 interacts with the main chain of conserved Arg 554, which is a crucial 
component of the hydrogen bond network required for binding the carnitine moiety of 
acyltransferase substrates. 
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The side chains of Tyr 120 and the catalytic His 372 have very weak electron density in 
both the uninhibited structures, but are both well defined in the structure of the ST1326 
complex. Significant electron density in the final fofc map of the 1.6 Å high resolution 
apo structure indicated the presence of a fortuitous ligand in the acyl-tunnel of both 
rCPT-2 molecules in the asymmetric unit (data not shown). This ligand shows the same 
binding mode as the alkyl-moiety of ST1326 and was interpreted as a C16 aliphatic 
chain which may be part of a palmitate molecule from the bacterial host metabolism. 
Those residues in the active site that interact with the hydrophilic aminocarnitine head 
group of ST1326, as well as Ser 590, are moved slightly away from the ligand binding 
site in the uninhibited structures, but the overall shape of the active site tunnel is 
preformed in the uninhibited enzyme. 
 
3.3.5 Membrane association 
After cleavage of the amino-terminal mitochondrial targeting sequence, the mature CPT-
2 protein is localized to the matrix site of the mitochondrial inner membrane (MIM; 
RAMSEY et al., 2001). A model for membrane association of CPT-2 had been proposed 
(WIESER et al., 2003) that predicts an α-helix (Asp 464 to Y479) inserted into the MIM 
inner leaf. The secondary structure has been predicted correctly (α21) but the crystal 
structure of rCPT-2 shows this helix to be an integral component of the carboxy-terminal 
domain that is not exposed to the surface to be accessible for membrane binding. 
Structural alignment of the amino acid sequence of rCPT-2 with other acyltransferases 
clearly accentuates the presence of a unique 30 amino acid insert in rCPT-2 comprising 
residues Asn 179 to Asn 208 (Figure 3.3.2-1). These residues form a pair of anti-parallel 
helices (α9 and α10) that protrude from the catalytic core in the vicinity of both the 
amino terminus and the CoA-tunnel leading to the center of the active site (Figure 3.3.3-
1). Helix α9 is clearly amphipathic. It carries two large hydrophobic residues, Phe 188 
and Phe 194, opposed to the three positively charged residues Lys 189, Arg 190 and 
Arg 194. Helix α10 is predominantly hydrophobic. As CrAT and CrOT lack the insert and 
are soluble proteins, the insert most likely confers the membrane association of CPT-2. 
This notion is supported by electron density that indicates the presence of a βOG 
detergent molecule interacting with Val 195, Leu 199 and Tyr 202 of helix α10 in chain 
B of the high (1.6Å) resolution rat CPT-2 structure (data not shown). 
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A second means for membrane localization by the insert could be the recruitment of 
CPT-2 to the membrane by direct interaction with CACT. A representation of the charge 
distribution on the surface of rCPT-2 reveals an excess of positive charges in the vicinity 
of the largely apolar insert and the entry of the CoA-tunnel (Figure 3.3.3-1). Like other 
integral membrane proteins, CACT is known to require the negatively charged 
mitochondrial lipid cardiolipin for activity (reviewed in RUBIO-GOZALBO et al., 2004; 
PALSDOTTIR and HUNTE, 2004). The positively charged and oblate surface of CPT-2 
facing the membrane would be ideally suited for interaction with cardiolipin molecules 
that surround CACT. With the insert bound to CACT the CoA-tunnel would be oriented 
perpendicular to the membrane, which would allow direct channeling of acylcarnitine 
substrates from CACT into the active site of CPT-2. As the acyl-tunnel does not open to 
the surface in CrAT and CrOT it seems reasonable that the substrates of carnitine 
palmitoyltransferases enter the active site via the CoA-tunnel. This mechanism for 
membrane recruitment of CPT-2 fully supports the observation that acylcarnitine esters 
transported into the mitochondrial matrix by CACT do not equilibrate with the bulk 
acylcarnitine pool in the mitochondrial matrix (MURTHY and PANDE, 1987; reviewed in 
ZAMMIT, 1999B). Physical association of CACT and CPT-2 would allow the carnitine 
released by CPT-2 to be transported back into the cytosol by CACT, whereas the newly 
formed acyl-CoA esters are directed towards β-oxidation. CPT-2 has been copurified 
with enzymes of the β-oxidation (KERNER and BIEBER, 1990). Therefore, CACT and 
CPT-2 form a microenviroment for efficient substrate channeling (Figure 3.3.5-1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.5-1: Proposed orientation of CPT-2 
towards the mitochondrial inner membrane. The 
unique insert of CPT-2 mediates membrane 
association either directly or via interaction with 
the transmembrane transporter CACT. Two 
molecules of cardiolipin are indicated. 
CACT
Insert
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The alpha carbon of Asp 32, the first ordered amino-terminal residue of the CPT-2 
structure, is situated in the vicinity of helix α10 of the insert. His 44 of the amino-
terminus directly interacts with the main chain carbonyl oxygens of Ile 192 and Val 195. 
Therefore, the amino-terminus of rCPT-2 is situated in proximity to the insert. These 
observations also argue for the insert mediating membrane localization, because all 
CPT-1 isoforms have an amino-terminal domain with two transmembrane segments 
(MCGARRY and BROWN, 1997; RAMSEY et al., 2001; PRICE et al., 2002). 
 
3.3.6 CPT-2 deficiency 
The clinically heterogeneous disease CPT-2 deficiency is caused by various mutations 
in the CPT-2 gene and is inherited in an autosomal recessive manner (BONNEFONT et 
al., 1999 and 2004). Two different manifestations of the disorder can be distinguished 
based on the time of onset, i.e., the early onset (neonatal or infantile) and the more 
frequent adult form of CPT-2 deficiency. The early onset form is characterized by a 
severe symptomatology including cardiomyopathy and hypoketotic hypoglycemia and 
has been linked to acute liver failure in sudden infant death syndrome (DEMAUGRE et 
al., 1991). Clinical signs of adult CPT-2 deficiency are recurrent myalgia and 
myoglobinuria in response to fasting and exercise. 
More than 30 point mutations in the coding region for CPT-2 leading to single amino 
acid exchanges in the enzyme have been identified (Table 3.3.6-1 and Figure 3.3.6-1; 
BONNEFONT et al., 1999; THUILLIER et al., 2003), in addition to deletions/ insertions 
causing frame shifts or truncation of the protein.  
Whereas deletions/ insertions in the CPT-2 gene inevitably lead to a severe neonatal 
presentation of CPT-2 deficiency by loss of CPT-2 function, a graduated correlation of 
genotype and severity of clinical phenotype becomes obvious for those missense 
mutations that have been described in a homozygous state (Table 3.3.6-1,). An 
exception to this correlation is the mutation of Arg 631 to cysteine, which has been 
identified in homozygous patients both with the adult as well as with the infantile form of 
CPT-2 deficiency. The crystal structure of rCPT-2 allows mapping and interpretation of 
the effects of the described mutations (summarized in Table 3.3.6-1). Most (60 %) 
cases of adult CPT-2 deficiency are associated with a mutation Ser 113 to leucine 
(TARONI et al., 1993). Ser 113 is located at the amino-terminus of helix α5 close to the 
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domain interface. Mutation of Ser 113 residue to a larger, hydrophobic Leu alters the 
interaction with the neighboring Phe 117. This changes the position and environment of 
the catalytically important residues Trp 116  and Arg 498, rendering the enzyme less 
active. 
Conservation Category Mutation Clinical phenotype CPT-1 CrAT CrOT 
S113L A    
Y120C     
E174K A    
E454X   D  
E487K     
Substrate binding 
I502T  V  V 
P50H A    
L72F  (M/B)   
R161W A    
Structure/ domain 
contact of amino-
terminus residues 
D32 to S110 K164X  R or H   
R124Q/R124X     
N146T     
R151Q I    
P227L I    
K274M     
Y290X     
R296Q/R296X     
D328G I E  E 
R382K I H   
Amino-terminal 
domain 
F383Y I    
D213G     
M214T     
P604S     
Domain interface 
Y628S I    
F448L     
Y479F     
R503C     
G549D     
Q550R  (B)   
D553N     
D608H  (L/M)   
Carboxy-terminal 
domain 
R631C I/A    
Insert Y210D     
Internal salt bridges affected by mutations (bold face) described for CPT-2 deficiency 
R124 - D232 
R161 - D390 
R296 - D353 
R350 - D328 
R382 - E174 
R503 - D553 
R631 - D608 
D608 - H584 
Table 3.3.6-1: Residues mutated in human CPT-2 deficiency.  All the affected residues are conserved 
between rat and human CPT-2, residue numbering for the human and rat isoforms of CPT-2 are identical. 
Homozygous mutations labeled A are associated with the late onset, adult form of CPT-2 deficiency, 
those labeled I with the early onset, infantile phenotype. Residues that are conserved in other carnitine 
acyltransferases are highlighted by a gray box. B, L or M in parentheses indicate conservation limited to 
brain, liver or muscle CPT-1, respectively. Conservative amino acid exchanges are indicated with one 
letter code abbreviations.  
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Asp 213 and Glu 487 are affected by naturally occurring mutations and have been 
determined to be important for CPT-2 function by biochemical analyses (ZHENG et al., 
2002; LIU et al., 2005). Asp 213 is located in a loop between β3 and α10 of rCPT-2 and 
aligns with a cysteine conserved in all human CPT-1 isoforms. Mutation of this cysteine 
to Ala fully abolishes enzyme activity in human M-CPT-1, indicating that this position is 
crucial for structural integrity in all CPT isoforms. In CPT-2 the side chain of Asp 213 
makes a strong interaction with the main chain nitrogen of His 496. This is important for 
the positioning Arg 498 and Arg 499 which are involved in substrate binding.  Mutation 
of Glu 487 in β13 to aspartic acid leads to an almost complete loss of CPT-2 activity. 
This mutation could interfere with CoA binding as Glu 487 is part of the CoA-tunnel 
surface. From the rCPT-2 crystal structure it can be predicted that an aspartic acid at 
position 487 would form a strong hydrogen bond with the side chain of Thr 589 of the 
conserved STS motif, thereby distorting the geometry of the active site. A Glu 487 Lys 
exchange is one of 6 mutations identified in CPT-2 deficiency that cause disruption of 
internal salt bridges or hydrogen-bond interactions which are fully conserved in CPT-1, 
CrAT and CrOT (Table 3.3.6-1). A guanidinium nitrogen of Arg 296 makes a strong (2.7 
Å) contact with a side chain oxygen of Asp 353, which is conserved in carnitine 
acyltransferases. The equivalent residue in M-CPT-1, Asp 454, has been proposed to 
be part of a catalytic triad (LIU et al., 2005), whereas the CPT-2 crystal structure 
implicates this residue to form a conserved salt bridge. None of the reported mutants 
identified in CPT-2 deficiency is located in the insert mediating membrane localization, 
although they are distributed uniformly in the rest of the structure (Figure 3.3.6-1). 
 Figure 3.3.6-1: Locoalization of amino acid exchanges (red 
spheres) reported for hereditary CPT-2 deficiency. So far no 
mutations of catalytically important residues or of residues lining the 
ligand binding cavity have been reported. This suggests that only 
mutations associated with residual activity of CPT-2 are tolerated 
whereas a complete loss of function would not be compatible with 
life. 
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4 Discussion 
4.1 Insulin receptor 
Although the GST-tagged insulin (and IGF-1) receptor kinase domains proved to be 
valuable tools for the examination of the reaction kinetics of these enzymes (BAER et 
al., 2001), they were not adequate for solving the structures of the respective dimeric 
kinase domains. The insufficient crystallization behavior of the constructs containing the 
entire intracellular domains might be attributed to flexibility of the linker regions as well 
as to high mobility of the amino- (juxtamembrane domain) and carboxy termini. Based 
on the results of activity assays, DLS and mass spectrometry analyses, abberrant 
folding, aggregation or covalent modification could be ruled out as factors that hindered 
crystallization. The formation of tetramers of GST observed with AUC (≤ 10 % in 
supernatant mass distribution at 5 µM GST) is apparently negligible as free GST and 
various fusion proteins were reported to crytallize readily (ZHAN et al., 2001). In the 
case of the GST-tagged core kinases, instability of these constructs was shown to 
interfere with proper crystallization (Rufer et al., 2005). Therefore, future attempts to 
stabilize and crystallize the dimeric kinase domains of IR (and IGF1-R) may comprise 
the formation of tyrosine phosphorylation-dependent complexes with high affinity 
effector or regulatory proteins. The structure of the IR core kinase domain in complex 
with the SH2 domain of APS (HU et al., 2003) as well as two PDB entries awaiting 
release of coordinates showing complexes with downstream signaling proteins (Table 
4.1-1) emphasize in principle the feasibility of this approach.  
 
PDB code Author Title 
2b4s LI et al., 2005  Crystal structure of a complex between PTP1B and the insulin receptor tyrosine kinase 
2auh DEPETRIS et al., 2005 Crystal structure of the Grb14 BPS region in complex with the insulin receptor tyrosine kinase 
Table 4.1-1: Stoichiometric complexes of the IR core kinase domain with effector proteins whose 
coordinates are deposited but on not yet publically available. An  helix αC-mediated dimer of IRK is visible 
in the asymmetric unit of IRK • PTP1B structure by LI et al. (2005), but the kinase domains are not 
aligned in an orientation compatible with autophosphorylation. 
 
Direct interaction of the IR with the SH2 domains of the p85 regulatory subunits of PI3K 
and the PTB domain of IRS-1 has been shown in vitro and in cell-based assays 
(SANCHEZ-MARGALET et al., 1995; BACKER et al., 1997; SUNG et al., 1998, and 
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references therein). These interactions could potentially be exploited for binding and 
stabilizing the juxtamembrane and carboxy-terminal domains of GST-IRTK, 
respectively. Moreover, interaction of the intrinsically dimeric 14-3-3γ protein with GST-
IGFK phosphorylated on its carboxy-terminal serine residues (LIU et al., 1995; XIAO et 
al., 1995; PARVARESCH et al., 2002), could provide a means to prepare complexes 
amenable to crystallization. SAXS studies have been successfully used by other groups 
in order to characterize the linker peptide of GST-fusion proteins and their overall 
topology (PETOUKHOV et al., 2002). Therefore, optimization of the linker peptide of 
GST-IRTK_∆NT/CT (GST-IRK) in order to enhance the stability while retaining the 
enzymatic activity and fitting the existing structures of GST and IRK into low resolution 
SAXS envelopes could advance the understanding or IRTK dimerization. Exchange of 
GST with the FK506-binding protein 12, which forms dimers upon binding of the ligand 
FK1012  (Keenan et al., 1998; ROLLINS et al., 2000; GAZDOIU et al., 2005), would 
allow to investigate a different dimerization motif. This chemically induced dimerization 
has been shown to yield active fusion proteins of IR or platelet-derived growth factor 
receptor (PDGFR) constructs with FK506 (YANG et al., 1998). 
Examination of the concentration-dependent sedimentation equilibria of 
unphosphorylated, apo His6_IRTK by AUC revealed that the full-length intracellular 
domain of the IR has an intrinsic capability to form dimers in solution with an EC50 = 
11.8 µM. As the core kinase construct is less active than the full-lenght intracellular 
domain of the IR (THIEBACH, 2003, diploma thesis, University of Cologne) and mutual 
substrate recognition is a prerequisite for trans-autophosphorylation, it is reasonable to 
argue that the juxtamembrane and carboxy-terminal domains of IRTK are important for 
productive dimerization. This hypothesis could be verified by performing AUC analyses 
with the core kinase constructs or constructs lacking either the amino- or carboxy- 
terminal domain. Dimers of IRTK need not to be symmetrical, i.e., possess an internal 
two-fold axis, but could consist of one molecule of IRTK in an enzyme conformation and 
another in a substrate conformation, assuming intra-dimer phosphorylation. Along these 
lines, the formation of both symmetric and asymmetric dimers have been suggested for 
the epidermal growth factor receptor (EGFR; GROENEN et al., 1997) and it has been 
shown for the EGFR that a basic 13 amino acid peptide (aa 645-657) in the 
juxtamembrane region is crucial for dimerization of its intracellular domain (AIFA et al., 
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2005). The available crystal structures of the monomeric kinase domain of the EGFR 
(STAMOS et al., 2002; PDB accession codes 1m14 and 1m17) do not contain this 
putative dimerization motif. As the IR switches from auto- to substrate phosphorylation 
under physiological conditions, it would be interesting to investigate if the activity states 
are correlated with distinct dimers (as implied by LI et al., 2005) or if the kinase domain 
becomes independent of dimerization upon full activtion. 
Limited proteolysis and AUC studies with His6_IRTK and the Merck1 compound 
(RO0716631, L-783,281) showed for the first time that this compound indeed alters the 
conformation (as opposed to other IR agonists) and promotes the dimerization of His6-
IRTK. However, the Merck and Telik compounds were also observed to cause 
aggregation of His6_IRTK, tend to form particles/micelles and display promiscuous 
protein binding. This rendered these compounds unusable for attempts to crystallize 
dimeric IRTK and constitutes a significant disadvantage for the use of these compounds 
as reference IR activators/sensitizers in the drug discovery process. The use of 
dertergents for solubilizing the holo IR in activity assays or inclusion of other 
proteinacious assay components (e.g., BSA, IR substrates) is likely to further complicate 
the distribution of free, soluble compound vs. compound particles and compound-
protein complexes or mixed micelles with detergent molecules. A 50 % decrease in 
dimer formation of apo His6_IRTK was observed in the presence of 1 % (w/v) DMSO 
under the conditions examined by AUC. This effect of DMSO, which was indispensible 
for solubilization of the Merck and Telik compounds, interferes with dimer-promoting 
activity of the compounds. AUC analysis accompanied by activity assays would provide 
a means to identify solvents that are inert with regard to dimerization of His6_IRTK. 
Furthermore, examination of the interacation of the Merck and Telik compounds with 
full-length (IRTK) vs. truncated (IRK) constructs would allow to map the actual site of 
interaction. 
As attempts to crystallize dimeric IRTK (or IGFK) using the established constructs failed, 
hydrogen/deuterium exchange coupled with mass spectrometry could provide a 
valuable tool for mapping the interface of the IRTK dimer and planning novel constructs 
for crystallization (LANMAN and PREVILEGE, 2004; PANTAZATOS et al., 2004). With 
the same technique conformational changes upon ligand binding and sites on the 
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surface of IRTK that interact with small-molecule ligands might be identified (GARCIA et 
al., 2004). 
 
4.2 AMPK 
Crystals of constructs comprising the kinase domain of AMPK including various parts of 
the putative auto-inhibitory sequence as well as the intact heterotrimer were obtained. 
Despite setting up over 36,000 individual crystallization drops containing 20 different 
AMPK constructs, isoform combinations and mutants thereof in combination with app. 
750 precipitant solutions, these crystals could not be optimized to meet the diffraction 
quality needed for structure determination by X-ray crystallography. This is entirely in-
line with the results communicated by other laboratories (D. Alessi, D. Carling, G. 
Hardie, B. Kemp; 2nd Annual Upstate Cell Signaling Symposium on "Implications of the 
LKB1 and AMPK Systems", 2005).  
However, in two recent reports by POLEKHINA et al. (2005B) and RUDOLPH et al. 
(2005) the feasibilty to obtain diffraction quality crystals of distinct domains of the 
mammalian and yeast AMPK heterotrimer, respectively, was demonstrated. Therefore, 
future attempts to crystallize AMPK (-constructs) should be expanded to screening 
alternative isoforms and AMPK orthologs from different species. Exchanges of exposed 
residues and deletion/ insertion of loops in these orthologs can be understood as 
complex surface mutations that might support crystallization. This approach can be 
combined with limited proteolysis of the AMPK heterotrimer in order to identify compact 
domains. As AMPK is conserved from yeast to man, the in-depth elucidation of the 
structural details of the allosteric activation for any ortholog is likely to advance the 
understanding of mammalian (and human) isoforms. 
The SAXS studies on full-length, heterotrimeric AMPK clearly demonstrated that an 
equlibrium of different oligomeric species of the trimer exists. Characterization of 
conditions effecting this equilibrium and accumulation of a distinct oligomeric state is 
expected to improve the crystallization behavior. 
In addition, chemical modification of the molecular surface by reductive methylation of 
lysine residues could provide a means to improve the formation of crystal contacts 
(RAYMENT, 1997; JBS Methylation Kit). This technique was evaluated with the 
construct AMPK_α2_1-339_D56A/R171E/T172D which crytallized best and most 
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reproducibly. While the protein was quantitatively precipitated by addition of ammonium 
sulfate, which is recommended for quenching unreacted alkyl-donor, the amino acids 
glycine and arginine were found to serve as efficacious substitutes for the quenching 
ammonium ion without adverse effects on AMPK stability. Therefore, investigation of the 
effect of reductive methylation on the crystallization behavior of different AMPK 
constructs can now be included in the optimization strategy. 
Despite the phosphorylation of T172 by upstream kinases the effect of post-translational 
modification, i.e., autophosphorylation and myristoylation of the β-subunit, on AMPK 
structure and function is so far inadequately defined. All experiments within this thesis 
assignment were conducted with unmodified protein. Preparation of homogeneously 
phosphorylated and/or myristoylated AMPK constructs (in combination with appropriate 
ligands) might allow to accumulate a discrete (active) conformation and, thereby, 
improve crystallization. 
The generation of antibodies against flexible loops (as defined by proteolysis, D/H 
exchange and available structural information) would also provide a rational means for 
optimization of AMPK crystals. Co-crystallization with antibody fragments was 
demonstrated to enhance the crystallization of several proteins (KOVARI et al., 1995). 
 
4.3 CPT-2 
The crystal structure of rCPT-2 in complex with ST1326 reveals the molecular details of 
protein-substrate interactions of a LCFA-specific acylcarnitine transferase. The key 
residues of the active site that form an extensive hydrogen network with the 
aminocarnitine-headgroup of ST1326 (or a physiological LCFA-acylcarnitine substrate) 
are fully conserved between rCPT-2 and the candidate diabetes drug-target L-CPT-1. 
The sequence alignment of rCPT-2 and human L-CPT-1 shows, that human L-CPT-1 
contains an extended loop between β15 and β16, which forms part of the acyl tunnel, 
and human L-CPT-1 has discrete amino acid exchanges in the acyl-tunnel when 
compared to human and rat CPT-2. Therefore, the structure of rCPT-2 with bound 
ST1326 is valuable for guiding the development of novel drugs for the treatment of 
diabetes mellitus in terms of optimizing affinity and isoform specificity of pseudo 
substrates as inhibitors of human L-CPT-1.  
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Investigation of the tissue (liver) exposure and distribution of ST1326 as well as its 
capability to be transported into mitochondria by CACT are needed to elucidate the 
effect of this compound on inhibition of the ubiquitous CPT-2. Accumulation of ST1326 
in hepatocytes or negligible transport via CACT would greatly increase the safety of 
ST1326. 
The complete inhibition of the CPT system could potentially inflict symptoms of CPT-
deficiency on diabetic patients. Therefore, it should be emphasized that downregulation 
rather than complete inhibition of the activity of L-CPT-1 in diabetic patients should be 
anticipated in order to restore their gluconeogenesis rate to normal levels. 
The proposed mode of membrane association of CPT-2 via its unique insertion is in line 
with the observation that acylcarnitine esters are transported into the mitochondrial 
matrix by CACT and are directly conveyed to β-oxidation through CPT-2 (reviewed in 
Zammit, 1999B). Furthermore, the carnitine released from CPT-2 does not equlibrate 
with the mitochondrial carnitine pool but is transported back into the cytosol by CACT. 
This also strongly supports the hypothesis that CPT-2 physically interacts with CACT. 
Docking the crystal structure of rCPT-2 to the molecular model of CACT (TONAZZI et 
al., 2005) may be useful to verify a possible direct interaction of CPT-2 and CACT. 
The crystal structure of CPT-2 allows the precise allocation of mutants identified in CPT-
2 deficiency. The absence of mutations of active site residues in CPT-2 deficiency 
emphasizes the essential function of CPT-2 for fatty acid metabolism as a complete loss 
of function might not be compatible with life. Determining the correlation of the effect of 
an amino acid exchange to CPT-2 function (i.e., its residual activity) could provide a 
means to link a given genotype to the severity of the corresponding clinical phenotype. 
CPT-2 deficiency can be detected in a newborn-screening. In the case of a positive 
diagnosis a correlation of structure and function could help to suggest appropriate 
dietary measures to ameliorate the clinical symptoms. 
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5 Materials and Methods 
5.1 Materials 
5.1.1 Chemicals 
All chemicals used for the preparation of media, buffers and solutions for expression, 
purification, characterization and crystallization were of the highest purity grade 
commercially available and purchased from AppliChem (via Axon Lab AG, Baden-
Dättwil, CH), Bio-Rad Laboratories (Reinach, CH), Fluka (Buchs, CH), 
Calbiochem/Novabiochem/Novagen (Merck Biosciences, via VWR International Life 
Science, Lucerne, CH), Jena Bioscience (Jena, D), Hampton Research (Aliso Viejo, CA, 
USA), Molecular Dimensions (Soham, UK), Pierce (Lausanne, CH), Roche Diagnostics 
(Rotkreuz, CH) Sigma-Aldrich (Buchs, CH) and Upstate (via Biomol, Hamburg, D). 
 
5.1.2 Enzymes 
DNase I    Roche Diagnostics,Rotkreuz, CH 
Lysozyme    Serva, Heidelberg, D 
Pfu DNA-Polymerase  Stratagene, LaJolla, CA, USA 
Restriction Enzymes  New England Biolabs,via BioConcept, Allschwil, CH 
Shrimp Alkaline Phosphatase USB, via GE Healthcare, Otelfingen, CH 
T4 DNA Ligase   New England Biolabs, via BioConcept, Allschwil, CH 
Trypsin (mod. sequencing grade) Roche Diagnostics, Rotkreuz, CH 
Thrombin    GE Healthcare, Otelfingen, CH 
 
5.1.3 Kits 
BigDye Terminator Sequencing Kit Applied Biosystems, Foster City, CA, USA 
DyeEx™ 2.0 Spin Kit   Qiagen, Hombrechtikon, CH 
HiSpeed® Plasmid Maxi Kit  Qiagen, Hombrechtikon, CH 
NucleoSpin® Extract II   Macherey-Nagel, Oensingen, CH 
QickChange® Multi    Stratagene, LaJolla, CA, USA 
JBS Methylation    Jena Bioscience, Jena, D 
S.N.A.P. MiniPrep Kit   Invitrogen, Basel, CH 
 
5.1.4 Specialty chemicals 
[γ32P]-Adenosin-5´-triphosphate, 5000 Ci/mmol NEN, Zeventem, Belgien 
Sypro® Orange, 5000X concentrate in DMSO Molecular Probes, Eugene, OR, 
USA 
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5.1.5 Bacterial strains (chemically competent E.coli) 
Cloning, plasmid propagation: DH10B (TOP10®) Invitrogen, Basel, CH 
Expression: Bl21(DE3) (One Shot®)   Stratagene,LaJolla, CA, USA, 
Selenomethionine labelling: B834(DE3) Novagen (via VWR International 
Life Science, Lucerne, CH) 
 
5.1.6 Consumable supplies and hardware 
AbiPrism™ 310 Genetic Analyzer Perkin Elmer, Boston, MA, USA 
Absorption Chromatography 
- Cary 100 Bio UV-Visible Spectroph. Varian, Zug, CH 
- NanoDrop® ND-1000 Spectroph. Witec AG, Littau, CH 
AlphaImager™ 340 Alpha Innotech, via Witec AG, Littau, CH 
Cell disruptor Basic Z Model  Constant Systems, Warwick, UK 
Centrifuges Sorvall/Heraeus, via Kendro, Zurich, CH; 
Kontron Instruments, via Hemotec, 
Gelterkinden, CH; Eppendorf, via Dr. Vaudeaux 
AG, Schönenbuch, CH 
Chromatography  
- Columns, Resins    GE Healthcare, Otelfingen, CH 
Qiagen, Hombrechtikon, CH 
- Static light scattering   Wyatt, Santa Barbara,CA, USA 
Crystallization tools & plates Hampton Research, Aliso Viejo, CA, USA; 
Greiner Bio-One, via Huber AG, Reinach, CH 
Crystallography 
- Rotating anode FR591 Nonius, via Bruker AXS, Karlsruhe, D 
- Confocal Max-Flux Optics™ Osmic, Auburn Hills, MI, USA 
- dtb 345 image plate detector MarResearch, Hamburg , D 
Filtration     Millipore, Bedford, MA, USA 
Dynamic Light Scattering DynaPro™ (Protein Solutions™) via Wyatt, 
Santa Barbara,CA, USA 
Incubators Kühner AG, Birsfelden, CH; Sanyo, via Labtech 
Services AG, Wohlen, CH 
T3000 Thermocycler for PCR  Biometra, Goettingen, D 
Precast electrophoresis gels  Invitrogen, Basel, CH 
Robotic Crystallization Systems 
- Freedom Evo    Tecan, Zurich, CH 
- Impax I-5     Douglas Instruments, Hungerford, UK 
- Topaz FID™ Crystallizer   Fluidigm, San Francisco, CA, USA 
Scintillation Counter   Beckman-Coulter, Munich 
Spectra/Por® Dialysis Membrane  Spectrum Lab., via Socochem, Lausanne, CH 
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5.2 Methods 
5.2.1 Molecular biology methods 
5.2.1.1 Transformation of chemically competent E. coli  
- 100 µl E. coli suspension is thawed on ice 
- addition of 1 µl of plasmid preparation (c > 1 ng/µl) 
- incubation on ice for 20 min 
- heat shock at 42°C for 30 s 
- incubation on ice for 2 min 
- addition of 250 µl SOC-AMP-- media 
- incubation in shaker for 1 h at 37°C/ 220 rpm 
- aliquots > 5µl on LB-Amp+-agar 
- incubation of plates at 37°C until colonies visible 
 
5.2.1.2 PCR for sequencing 
1. PCR:  5 µl Plasmid stock 
5 µl mod. dNTP BigDye® Terminator v1.1 Cycle Sequencing Kit 
    1 µl Sequencing primer (T7P, α1, α2, T7T; 4 tubes) 
        + 9 µl H2O 
         20 µl                                         
 
Sequencing PCR Programs 
Primer α1 / α2 AMPK T7Promotor / T7Terminator 
Steps T [°C] t [min] T [°C] t [min] 
1X 95 2 95 2 
Cycle 
30X 
95 
45 
60 
0.5 
0.5 
4 
95 
50 
60 
0.5 
0.5 
4 
 
2. Processing of PCR-samples over EDGE BIO-SYSTEMS Centriflex Gel Filtration 
Cartridge 
- resuspension of column resin with 400 µl H2O 
- centrifugation 2 min/ 700 g 
- discard flow-through 
- centrifugation 2 min/ 700 g 
- column into sterile tube 
- application of 20 µl  PCR-sample 
- centrifugation 2 min/ 700 g 
- flow-through is lyophilized in Speedvac for 15 min/ 60°C 
- addition of 17 µl Template Suppression Reagent (Applied Biosystems, Foster City,  
CA, USA) 
- 2 min at 95°C 
- transfer of sample into sequencing tubes 
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5.2.1.3 Cloning of AMPK point mutations 
Starting with the vector pET-15b_AMPK_α2_1-339_T172D the triple mutant 
AMPK_α2_1-339_D56A/R171E/T172D was generated by site-directed mutagenesis 
using the QickChange® Multi kit (Stratagene) according to the manufacturer´s 
specifications. The annealing temperature was chosen app. 5°C below the lowest 
primer melting point and strand synthesis was performed at 65°C for 3 min/kBp (30 
cycles plus a 15 min final completion step at 65°). The three point mutations were 
introduced into the sequences coding for AMPK_α2_1-301_wt and AMPK_α2_1-312_wt 
by restriction fragment cloning. 
 
1. Restriction cut of vectors, 4 h at 37°C 
 
20 µl pET-15b- AMPK_α2_1-339_D56A/R171E/T172D 
  3 µl 10X restriction enzyme buffer (#4) 
  1 µl NdeI (CA/TATG) 
  1 µl PmeI (GTTT/AAAC) 
         +  5 µl 6X BSA 
30 µl ⇒ Insert 
 
20 µl pET-15b- AMPK_α2_1-301_wt 
  3 µl 10X restriction enzyme buffer (#4) 
  1 µl NdeI (CA/TATG) 
  1 µl PmeI (GTTT/AAAC) 
         +  5 µl 6X BSA 
30 µl ⇒ Vector 301 
 
20 µl pET-15b- AMPK_α2_1-312_wt 
  3 µl 10X restriction enzyme buffer (#4) 
  1 µl NdeI (CA/TATG) 
  1 µl PmeI (GTTT/AAAC)  
         +  5 µl 6X BSA 
30 µl ⇒ Vector 312 
 
2. Preperative agarose-gel electrophoresis 
The fragments released during the restriction cut were separated by electrophoresis 
of the entire reaction (30 µl) in a 1 % (w/v) agarose-gel, detected under UV-light and 
isolated by cutting out of the band with a scalpel. 
 
3. Extraction of DNA from agarose-gel with NucleoSpin®Extract II kit (Machery-Nagel) 
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4. Dephosphorylation of cut and purified vectors with Shrimp Alkaline Phosphatase 
(SAP) 
48 µl DNA solution (eluate of step 3) 
  6 µl 10X SAP-buffer 
         +  6 µl 1:10 SAP (in SAP dilution buffer) 
60 µl, inkubation 1 h at 37°C, thereafter inaktivierung of SAP 15 min at 65°C 
       
5. 10 µl  of the purified and dephosphorylated fragments were quantified via analytical 
agarose-gel electrophoresis with size and molecular mass markers. 
 
6. Ligation was performed for 1 h at RT followed 14 h at 16°C 
 
  9 µl Insert 
  3 µl Vector 1-301 
  2 µl 10X T4-buffer 
  1 µl T4-ligase 
         + 5 µl H2O 
20 µl ⇒ AMPK_α2_1-301_D56A/R171E/T172D 
 
  9 µl Insert 
  3 µl Vector 1-312 
  2 µl 10X T4-buffer 
  1 µl T4-ligase (NEB) 
         + 5 µl H2O 
20 µl ⇒ AMPK_α2_1-312_D56A/R171E/T172D 
 
  3 µl Vector 1-302 
  2 µl 10X T4-buffer 
  1 µl T4-ligase (NEB) 
       +14 µl H2O 
20 µl, control 
 
3 µl Vector 1-312 
  2 µl 10X T4-buffer 
  1 µl T4-ligase (NEB) 
       +14 µl H2O 
20 µl, control 
 
7. Transformation of 3 µl  of the ligation reaction 
 
__________________________________________________Materials and Methods 
 87
5.2.2 Expression and purification of GST-fusion proteins 
Pellets and lysates from Sf9-cell expression were prepared by M. Gompert and K. Baer 
(Klein group, University of Cologne; BAER et al., 2001).  Pellets were processed 
accordingt o the following protocol: 
- Lysis buffer:  50 mM Tris/HCl pH 7.5                      
0.25 M Sucrose    
4 Tbs./ 100 ml Roche Complete Protease inhibitor (+EDTA) 
5 mM DIFP 
1 mM DTT 
 
- frozen pellets are thawed, resuspended, homogenized in lysis buffer (108 cells/ 10 ml) 
- cells disruption with ultrasound 5 X 5 s (interval 0.5 s, 80 % power) 
- addition of Triton-X-100 to 1 % (w/v) f.c., solubilization for 30 min at 4°C 
- centrifugation for 10 min at 10,000 g/ 4°C 
- preparative ultracentrifugation for 1h at 150,000 g/ 4°C 
 
A two step protocol yielded GST-fusion proteins devoid of any covalent modification. 
DTT was used during binding of the fusion proteins because decreased affinity was 
observed with TCEP. The GST-affinity chromatography (25 ml GSH-sepharose FF, GE 
Healthcare) was carried out in the cold room using a peristaltic pump for sample 
application. 
 
Purification Step Buffer 
A Equilibration 
DTT 
 
50 mM Tris/HCl pH 7.5 
4 Tbs./l RocheComplete (+EDTA) 
2 mM DTT  
B Wash 
TCEP 
50 mM Tris/HCl pH 7.5 
4 Tbs./l RocheComplete (+EDTA) 
2 mM TCEP 
C Wash 
High Salt 
50 mM Tris/HCl pH 7.5 
4 Tbs./l RocheComplete (+EDTA) 
2 mM TCEP 
1 M NaCl 
C Wash 
TCEP 
50 mM Tris/HCl pH 7.5 
4 Tbs./l RocheComplete (+EDTA) 
2 mM TCEP 
GST-affinity 
chromatography at 
4°C 
D Elution 
GSH / TCEP 
50 mM Tris/HCl pH 7.5 
4 Tbs./l RocheComplete (+EDTA) 
2 mM TCEP 
20 mM GSH 
SEC 
at 21°C  
20 mM Tris/HCl pH 7.5 
2 Tbs./l Roche Complete (+EDTA) 
150 mM NaCl 
0.02 %(w/v) NaN3 
2 mM TCEP 
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5.2.3 Expression and purification of AMPK constructs 
The following constructs were purified with the protocol mentioned below: 
- AMPK_α2_1-339_D56A/R171E/T172D and _wt 
- AMPK_α2_1-326_D56A/R171E/T172D 
- AMPK_α2_1-312_D56A/R171E/T172D 
- AMPK_α2_1-301_D56A/R171E/T172D 
For simplicity, the mutant combination D56A/R171/T172D is hereafter called „triple“.  
Buffer adjustments for short constructs are indicated in red. 
 
5.2.3.1 Expression 
- inoculation of 4 X 1 l LBamp+ with 25 ml each of a over-night culture of E. coli BL21DE3 
carrying a pET-15b vector with the relevant construct 
- incubation at 30°C/ 230 rpm until A600 = 0.45, then incubation at 20 °C/ 230 rpm until 
A600 = 0,75  
- induction with 0.5 mM f.c. IPTG, incubation at 20°C/ 230 rpm/ 20 h 
- harvesting of cells by centrifugation at 5000 g/ 4°C, resuspension/ washing of cells in 5 
ml/g buffer Ni-NTA A at 4°C, centrifugation at 5000 g/ 4°C, storage of pellet at -20 °C 
 
5.2.3.2 Cell lysis 
- resuspension and homogenization of cells in 3 ml/g buffer Ni-NTA A 
Buffer Ni-NTA A 
AMPK_α2_1-339triple & wt 
AMPK_α2_1-326triple AMPK_α2_1-312triple AMPK_α2_1-301triple 
50 mM TRIS/HCl pH 7,8 
300 mM NaCl 
2 mM TCEP 
2 mM MgCl2 
 
 
 
4 Tbs /100 ml   RoComplete-
EDTA 
3 mg/100ml DNase I 
5 mM DIFP 
50 mM TRIS/HCl pH 7,8 
300 mM NaCl 
2 mM TCEP 
2 mM MgCl2 
20 mM Imidazol 
10 % (v/v) Glycerin 
 
4 Tbs /100 ml RoComplete-
EDTA 
3 mg/100ml DNase I 
5 mM DIFP 
50 mM TRIS/HCl pH 7,8 
300 mM NaCl 
2 mM TCEP 
2 mM MgCl2 
20 mM Imidazol 
10 % (v/v) Glycerin 
 
4 Tbs /100 ml RoComplete-
EDTA 
3 mg/100ml DNase I 
5 mM DIFP 
 
- cell disruption at 0.6 bar in continuous precessing disruptor 
- centrifugation of flow-through at 30,000 g/ 4°C/ 45 min, filtration of supernatant through 
0.2 µm Filter 
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5.2.3.3 Chromatography 
IMAC on 25 ml Qiagen Ni2+-NTA resin 
- Buffer B = Buffer A + 300 mM imidazole, no protease inhibitors 
- sample is applied via sample pump at 4 ml/min, washing with buffer A until A280 < 10, 
gradient of 0 % to 100% buffer B over 10 column volumes, 10 ml fractions 
 
Thrombin cleaveage of His6-tag and dialysis 
- 10 U Thrombin per 1 mg AMPK, ad 2.5 mM CaCl2 f.c. from 50 mM stock solution and 
dialysis 16 h/ 4°C in MWCO 8000 tube in 5 l of: 
AMPK_α2_1-339triple & wt 
AMPK_α2_1-326triple AMPK_α2_1-312triple AMPK_α2_1-301triple 
15 h 
50 mM TRIS/HCl pH 7,8 
2 mM TCEP 
2 mM MgCl2 
2,5 mM CaCl2 
20 mM Imidazole 
18 h 
50 mM TRIS/HCl pH 7,8 
2 mM TCEP 
2 mM MgCl2 
2,5 mM CaCl2 
3 h 
50 mM TRIS/HCl pH 7,4 
2 mM TCEP 
2 mM MgCl2 
2,5 mM CaCl2 
20 mM Imidazole 
18 h 
50 mM TRIS/HCl pH 7,8 
2 mM TCEP 
2 mM MgCl2 
2,5 mM CaCl2 
20 mM Imidazole 
 
Anion-IEX on Resource Q Superflow (30 ml) 
- AMPK_α2_1-339_D56A/R171E/T172D & wt; AMPK_α2_1-326triple 
- AMPK_α2_1-312_D56A/R171E/T172D 
 AMPK_α2_1-339triple & wt AMPK_α2_1-326triple AMPK_α2_1-312triple 
Pu
ffe
r A
 50 mM TRIS/HCl pH 7,8 
2 mM TCEP 
2 mM MgCl2 
50 mM TRIS/HCl pH 7,4 
2 mM TCEP 
2 mM MgCl2 
Pu
ffe
r B
 50 mM TRIS/HCl pH 7,8 
2 mM TCEP 
2 mM MgCl2 
500 mM NaCl 
50 mM TRIS/HCl pH 7,4 
2 mM TCEP 
2 mM MgCl2 
500 mM NaCl 
- application of sample from dialysis at 2.5 ml/min, chromatography at 4 ml/min 
1. Wash 1 CV with 0% B 
2. Wash 4 CV with 10 % B    120 ml, 30 min 
3. Gradient to 50 % Buffer IEX B over 15 SV  450 ml, 115 min 
4. Gradient to 100 % Buffer IEX B over 4 SV  140 ml, 35 min 
- the united elution fractions are concentrated in Amicon stirring cell (MWCO 10,000) 
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HIC on Phenylspharose HP (5 ml) 
- AMPK_α2_1-301_D56A/R171E/T172D 
- adjustment of sample from dialysis to 1 M (NH4)SO4 (4 M stock solution) 
 AMPK_α2_1-301triple 
Pu
ffe
r A
 50 mM TRIS/HCl pH 7,8 
2 mM TCEP 
2 mM MgCl2 
20 mM Imidazol 
1 M (NH4)SO4 
Pu
ffe
r B
 50 mM TRIS/HCl pH 7,8 
2 mM TCEP 
2 mM MgCl2 
20 mM Imidazol 
 
Gelfiltration (Biosec) 
- centrifugation 20,000 g/ 4°C/ 20 min before injection 
AMPK_α2_1-339triple & wt 
AMPK_α2_1-326triple AMPK_α2_1-312triple AMPK_α2_1-301triple 
50 mM TRIS/HCl pH 7,8 
2 mM TCEP 
2 mM MgCl2 
50 mM NaCl 
50 mM TRIS/HCl pH 7,8 
2 mM TCEP 
2 mM MgCl2 
50 mM NaCl 
20 mM HEPES/NaOH pH 7,8 
2 mM TCEP 
2 mM MgCl2 
150 mM NaCl 
 
Concentration 
- step gradient elution (100 % Buffer B) from 1ml ResourceQ IEX 
 
 AMPK_α2_1-339triple & wt AMPK_α2_1-326triple AMPK_α2_1-312triple AMPK_α2_1-301triple
Pu
ffe
r A
 20 mM HEPES/NaOH pH 7,8 
2 mM TCEP 
2 mM MgCl2 
20 mM HEPES/NaOH pH 7,8 
2 mM TCEP 
2 mM MgCl2 
Pu
ffe
r B
 20 mM HEPES/NaOH pH 7,8 
2 mM TCEP 
2 mM MgCl2 
500 mM NaCl 
20 mM HEPES/NaOH pH 7,8 
2 mM TCEP 
2 mM MgCl2 
500 mM NaCl 
Milipore Concentrator 
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5.2.4 Expression, purification and activity test of rat CPT-2 
The DNA coding for amino acids 27-658 of rat CPT-2 (provided by Prof. V.A. Zammit, 
Hannah Research Institute, Ayr, Scotland) was amplified by PCR and subcloned into a 
Novagen pET-28a vector by using NdeI and NotI (New England Biolabs) restriction 
sites. This construct was used to express full-length CPT-2 (without the mitochondrial 
import sequence, amino acids 1-26 of the CPT-2 precursor) in E. coli strain BL21(DE3) 
at 20°C. After cell disruption the lysate (in 50 mM HEPES/ NaOH pH 8, 0.15 M NaCl, 5 
mM TCEP, 10 mM MgCl2, 30 mg/l DNase I, 30 Tbs./l Roche Complete protease 
inhibitor) was adjusted with 0.1 % (v/v) Triton-X-100 final concentration. Solubilization 
and centrifugation (30.000 g, 45 min) was followed by immobilized metal affinity 
chromatography (IMAC) on a HIS-Select™-HC Nickel Affinity Gel. The detergent was 
exchanged to 1 % (v/v) n-octyl-β-D-glucopyranoside (βOG) on the column. The eluate 
from the IMAC step was subjected to a size exclusion chromatography column (S200, 
Amersham Bioscences/GE Healthcare) equilibrated with 25 mM Tris/ HCl pH 8, 0.15 M 
NaCl, 2 mM TCEP, 1 % (v/v) βOG, 0.02 % (w/v) NaN3. ESI-MS confirmed the identity of 
CPT-2 and showed that the protein was modified by amino-terminal α-N6-
phosphogluconoylation (Geoghegan et al., 1999, data not shown). The His6-tag was not 
cleavable with thrombin. A 10 l fermentation (45 g of biomass) yielded 300 mg of 
electrophoretically pure, monomeric and monodisperse protein. 
 
The activity of rat CPT-2 expressed in E. coli (30 nM enzyme concentration) was 
measured for the reverse reaction with a spectrophotometric assay using 5,5’-dithio-bis-
(2-nitrobenzoic acid), DTNB. The HS-CoA released on the formation of acylcarnitine 
from carnitine (500 µM) and palmitoyl-CoA (80 µM) reduced DTNB (300 µM). The 
resulting 5-mercapto-(2-nitrobenzoic acid) absorbs at 410 nm with a molar extinction 
coefficient of 13,600 M-1cm-1. The assay buffer contained 120 mM KCl, 25 mM Tris/ HCl 
pH 7.4, 1 mM EDTA and various concentrations of the inhibitor ST1326. 
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5.2.5 Thermofluor assay 
Assay contents: 
Construct 
33
9a
po
 
39
2a
po
 
33
9P
N
P 
39
2P
N
P 
33
9P
C
P 
39
2P
C
P 
33
9S
ta
u.
 
39
2S
ta
u.
 
Protein [µl] 2.8 3.0 2.8 3.0 2.8 3.0 2.8 3.0 
SEC buffer [µl] 47.2 47.0 45.2 45.0 45.2 45.0 45.2 45.0 
5X Sypro Orange [µl] 50.0 50.0 50.0 50.0 50.0 50.0 50.0 50.0 
ligand stock [µl] n/a n/a 2.0 2.0 2.0 2.0 2.0 2.0 
f.c. ligand [mM] n/a n/a 1 1 1 1 0.004 0.004 
 
Stock solutions: 
1) AMPK_α2_1-339wt: 1.44 mg/ml = 36 µM ( f.c. = 1 µM) 
2) AMPK_α2_1-392wt: 1.49 mg/ml = 33 µM (f.c. = 1 µM) 
3) SEC – Buffer: 20 mM HEPES pH 7.8, 2 mM MgCl2, 2 mM TCEP, 150 mM NaCl 
4) Sypro Orange: 5X / SEC – Buffer (f.c. = 2.5X) 
5) AMP-PNP / SEC – Buffer: 50 mM 
6) AMP-PCP / SEC – Buffer: 50 mM 
7) Staurosporine / SEC –Buffer: 200 µM 
 
Blank samples contained all components despite protein.  
 
Derivation of equations for fitting of the Thermofluor® data 
Assuming that the temperature-dependent unfolding of a protein is described by the 
two-state equilibrium (i.e., there is no significant population of intermediate states) 
N U
k1
k-1  
, with the equilibriun constant un UK =
N
 
where N and U are the native and unfolded states, respectively, and 1k  and - 1k  are 
the apparent rate constants of protein unfolding and folding, the respective mole 
fractions are given by 
N
un
1X =
1+K
 and  unU
un
KX =
1+K
, with the partition function unQ = 1+K  
Based on these equations the process of unfolding can be followed and quantified by 
recording the change in fluorescence upon protein unfolding (EFTINK, 1994; EFTINK 
and SHASTRY, 1997). If the protein states N and U have a relative fluorescence of 
NF  and UF , the accumulative temperature-dependent fluorescence signal is given by 
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Σ(T) i i N N U U
N U
N U
U
N U
U
un
F = X F = X F + X F
F (Q -1)F= +
Q Q
F F= +F -
Q Q
F -F= F +
1+K
 
As unK  is the temperature dependent equilibrium constant with 
∆ (T) unG = -RTlnK  ⇔ ∆ (T)un GK = exp -
RT
 
the increase in fluorescence upon binding of the probe Sypro® Orange to a protein 
undergoing thermal unfolding is described by 
∆
N U
(T) U
(T)
F -FF = F + G1+exp-
RT
(Equation1). 
The change in the Gibbs free energy (∆ (T)G ) for a two-state thermal unfolding 
process is also dependent on the differences of the enthalpy (∆ unH ) and heat 
capacity (∆ p, unC ) of the native and the unfolded protein states as well as the melting 
point ( mT , midpoint of the unfolding process), as described by the Gibbs-Helmholtz 
equation 
   ∆ ∆ ∆      (T) un p, un mm m
T TG = H 1- - C T - T +Tln
T T
 
⇒    ∆ ∆      un un p, un mm m
T T-RTlnK = H 1- - C T - T +Tln
T T
 
⇔ ∆ ∆         
un p, un m
un
m m
H 1 1 C T TlnK = - - + ln + -1
R T T R T T
 (Equation 2). 
Substitution of equation 2 into equation 1 yields the formula which was used for fitting 
the Thermofluor® data by non-linear regression (Levenberg-Marquardt algorithm, 
Prism 3.0, GraphPad Software) in order to determine the protein melting points: 
 ∆ ∆            
N U
(T) U
un p, un m
m m
F -FF = F +
H 1 1 C T T1+exp - - + ln + -1
R T T R T T
 
⇒     m U N(T ) F +FF =
2
, with [N] =[U]; Kun = 1. 
The fluorescence signal was recorded on a Bio-Rad iCycler iQ Real Time PCR 
machine with an excitation wavelength of 490 nm and an emission wavelength of 530 
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nm (the absorption and emission maxima of Sypro® Orange are 470 nm and 570 
nm, respectively). The heating rate was 1°C/min which was found to be sufficiently 
slow to allow complete equilibration of dye adsorption to denatured protein. As 
opposed to published studies (PANTOLIANO et al., 2001; LO et al., 2004; MATULIS 
et al., 2005; CARVER et al., 2005) the fluorescence signal was corrected for baseline 
drift due to thermal disintegration and photo bleaching of the fluorescence probe. The 
excellent fit of the derived curves to the measured data (R > 99 %; p < 0.0001) 
confirmed that the above mentioned assumption (two-state unfolding process) is valid 
to describe the thermal unfolding of AMPK_α2_1-339 and AMPK_α2_1-392. 
The ligand concentration ( mTL ) dependent shift of the protein melting point to higher 
temperature was used to calculate the ligand binding constant mL(T )K  at mT  (LO et al., 
2004, based on BRANDTS et al., 1989) 
 ∆∆            
00
m
m
TT
mp,unun
m m
L(T )
T
CH 1 1 T Texp - - + ln + -1
R T T R T T
K =
L
, 
with m 0T = T ,∆ ∆ 0Tun unH = H  and∆ ∆ 0Tp, un p,unC = C in the absence of ligand (reference 
curve). Finally, the ligand binding constant L(T)K  at the crystallization temperature 
(294 K) was calculated according to LO et al. (2004): 
 ∆      m
L(T)
L(T) L(T ) 
m
H 1 1K = K exp - -
R T T
, 
using the approximation of ∆ L(T)H  ≈ -60 kJ/mol for the ligand binding enthalpy 
(PANTOLIANO et al.,2001). 
 
5.2.6 Phosphorylation assay 
Auto- and substrate phosphorylation of GST-IRTK was examined in order to exclude 
any detrimental effects on enzymatic activity by the strong reducing agent TCEP, 
which was used for purification and characterization instead of the established DTT. 
The SI unit for radioactive decay is Becquerel (Bq [s-1]), whereas the unit generally 
used in the literature is Curie [Ci [s-1]; 1 Ci = 3.7·1010 Bq]. 
 
5.2.6.1 Autophosphorylation 
[γ32P]-ATP with a specific activity of app. 250 cpm/pmol was used as co-substrate for 
the autophosphorylation reaction of 1 µM GST-IRTK. The reaction was initiated by 
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addition of 10X phosphorylation buffer. Aliquots of 10 µl (10 pmol GST-IRTK; 2 µCi) 
were withdrawn at indicated time points and the reaction was stopped with SDS-
PAGE buffer. 
10X phosphorylation buffer: 5 µl 1 M MgCl2 
50 µl 0.1 M MnCl2 
10 µl 100 mM ATP 
20 µl 50 mM TCEP, 0.5 mM Tris/HCl pH 7.5 
10 µl 1 mg/ml BSA 
+  5 µl MQ H2O 
100 µl 
 
5.2.6.2 Substrate phosphorylation 
The substrate GST-IRS-1_p30 (6 µM f.c.) was mixed with [γ32P]-ATP (250 cpm/pmol 
specific activity) in phosphorylation buffer. The reaction was initiated by addition of 
0.3 µM f.c. GST-IRTK, which had been autophosphorylated for 3 min. Aliquots (10 µl, 
with 60 pmol GST-IRS-1_p30; 2 µCi) were withdrawn at indicated time points and the 
reaction was stopped with SDS-PAGE buffer. 
 
5.2.6.3 Quantitation of [γ32P]-incorporation 
After the phosphorylation reaction kinase, substrate and excess [γ32P]-ATP were 
separated by SDS-PAGE. The gel was fixed for 15 min in destain solution [50 % (v/v) 
methanol, 7 % (v/v) acetic acid], dried and used for autoradiography. [γ32P]-
incorporation was determined by measuring the Cerenkov radiation of excised gel 
bands in a scintillation counter. The data of the time course of phosphorylation were 
fit to an equation describing a one phase exponential association with pseudo-first 
order kinitics as implemented in the program Prism 3.0 (GraphPad Software): 
(t) maxY = Y [1- exp(-kt)]  ; where k is the association rate constant in [s-1], t is the time 
[s] an Y is  the [γ32P]-incorporation [mol/mol]. 
 
5.2.7 Limited Proteolysis 
The proteases subtilisin, Staphylococcus aureus protease, amino-peptidase, 
carboxy-peptidase, proteinase K, pronase, factor Xa, thrombin, trypsin and 
chymotrypsin were stored at -20°C in buffers recommended by the manufacturer and 
supplemented with 50 % (v/v) glycerol. The concentrations of target protein and 
protease were determined based on the cleavage kinetics with initial screens 
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containing a 1:80 - 1:10,000 mass ratio in target protein storage buffer at 21°C. The 
conditions for the cleavage of His6_IRTK were adapted from BAER et al. (2001). 
 
5.2.8 Analytical ultracentrifugation (AUC) 
The AUC measurements were performed in collaboration with F. Mueller and E. 
Kusznir (Roche, Basel). The partial specific volume of the protein to be analyzed was 
determined as the arithmetic mean of the value derived from the amino acid 
sequence (EDSALL, 1943; EMBOSS program suite, Rice et al., 2000) and the value 
for a hydrated protein (RICKWOOD and CHAMBERS, 1984). The buffer density was 
measured by the mechanical oscillator techique (ELDER, 1979) on an Anton Paar 
DMA 4500/RXA density meter. The results from AUC runs on Optima XL-A/I 
centrifuges (Beckman-Coulter) were analyzed by the program DISCREEQ 
(SCHUCK, 1994) implemented in the Beckman-Coulter AUC software package. 
Curve simulation for the determination of the association constants of His6-IRTK was 
accomplished with Prism 3.0 (GraphPad Software). 
 
5.2.9 Mass spectrometry (MS) 
MS measurements and accompanying Edman microsequencing of peptides (see 
MATSUDAIRA, 1989, for methodology) were performed by A. Friedlein (Roche 
Center of Medical Genomics, Basel). 
 
5.2.9.1 Nanoelectrospray Ionization (Nano-ESI) MS of intact proteins 
The electrospray ionisation approach was used for determining the molecular mass 
of full-length protein molecules. Comparison of the determined mass and the 
calculated mass deduced from the amino acid sequence allows the detection of 
covalent modifications. The protein samples were desalted and, if necessary, 
concentrated on a pulled capillary containing app. 100 nl POROS R1 reverse phase 
material (Perseptive Biosystems, Framingham, MA) and eluted with 1 µl of aqueous 
50 % (v/v) acetonitrile/ 5% (v/v) formic acid directly into the nanoelectrospray needle 
(WILM and MANN, 1996). Electrospray mass spectra were acquired on a QSTAR 
Pulsar i quadrupole TOF tandem mass spectrometer (Applied Biosystems/MDS-
Sciex, Toronto, Canada) equipped with a nano electrospray ion source as described 
by WILM and MANN (1996). All data were acquired with a mass range from 600 to 
1600 (m/z, amu). The average molecular masses of the proteins were calculated 
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from the m/z peaks in the charge distribution profiles of the multiply charged ions. 
The reconstructed molecular mass profiles were obtained by using a deconvolution 
algorithm (MDS Sciex). 
 
5.2.9.2 Characterization of in-gel digested proteins 
A) Analysis of tryptic peptides by matrix-assisted laser desorption-ionization 
time of flight (MALDI-TOF) MS 
MALDI MS  achieves a direct desorption of gas-phase ions from the target by pulse-
laser irradiation of a sample. Ions are all formed at the same time and placed in the 
ion source and then accelerated through a fixed potential into the TOF drift tube. The 
reflectron compensates for the differences in the velocities of ions with the same m/z 
and, therefore, increases the resolution of TOF spectrometry. 
The in-gel digestion of Coomassie Brilliant Blue-stained protein bands with trypsin 
was performed according to FOUNTOULAKIS and LANGEN (1997). Following 
overnight digestion app. 1 µl sample was mixed with 1 µl of the saturated matrix 
[alpha-cyano cinnamic acid in aqueous 50 % (v/v) acetonitrile/ 0.1 % (v/v) 
trifluoroacetic acid] and applied to the MALDI-target. The samples were analyzed 
with a Bruker Daltonics (Bremen, Germany) Ultraflex TOF/TOF mass spectrometer. 
An acceleration voltage of 25 kV was used. Calibration was internal to the samples 
with the peptides des-Arg-bradykinin and ACTH(18-38) purchased from Sigma. 
 
B) Analysis of tryptic peptides by nano-ESI tandem MS 
For this approach the peptides obtained after tryptic digestion were desalted and 
concentrated on a pulled capillary column containing approximately 100 nl POROS 
R2 reverse phase material (Applied Biosystems, Foster City, CA). The peptides were 
eluted with app. 1 µl of aqueous 60 % (v/v) acetonitrile/ 5 % (v/v) formic acid directly 
into a nanoelectrospray capillary needle. Mass spectra were acquired on a QSTAR 
Pulsar i quadrupole TOF tandem mass spectrometer (Applied Biosystems/MDS-Sciex, 
Toronto, Canada) equipped with a nano electrospray ion source (Proxeon, Odense, 
Denmark). Fragmentation by tandem MS yields a stretch of amino acid sequence 
together with its location in the peptide (sequence tag). With this sequence tag 
information appropriate databases (Swissprot) were searched using MASCOT Search 
software (Matrix Science, London, UK). 
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5.2.10 Biacore 
The Biacore (surface plasmon resonance) measurements were conducted in 
collaboration with W. Huber and J. Kohler (Roche, Basel). Stock solutions of the 
constructs AMPK_α2_1-339_wt, AMPK_α2_1-339_D56A/R171E/T172D and 
AMPK_α2_1-392_wt with concentrations of 1 mg/ml in 20 mM HEPES/NaOH pH 7.8, 
250 mM NaCl, 10 mM MgCl2 and 2mM TCEP were diluted to 40 µg/ml in 10 mM 
NaOAc/AcOH pH 5.0, 10 mM MgCl2 and 200 µM Merck compound C (RO4499487) 
shortly prior to immobilization. Incubation with the ligand compound C was 
indispensible for stabilization of the AMPK constructs during immobilization by amine 
coupling on Biacore CM5 sensors. The coupling was carried out according to the 
manufacturer's instructions (Amine Coupling Kit, Biacore). The integrity of the 
immobilized AMPK constructs (app. 6000 RU, or 6 ng/mm2) were tested by recurrent 
injection of the active site binder AMP-PNP and comparing the corresponding sensor 
responses. All measurements were performed on Biacore 2000 and 3000 
instruments. KD values were determined by plotting the steady-state equilibrium 
binding response units, i.e., the signal obtained when no net association or 
dissociation of ligand is observed over time, against the respective ligand 
concentration. The binding curves were calculated by fitting the sensorgram data to 
an equation describing a Langmuir adsorption isotherm (Biaevaluation software, 
Biacore). For this fitting procedure one-class of independent binding sites, i.e., 
absence of lateral protein-protein interactions, in a 1:1 stoichiometry of protein to 
ligand was assumed. 
 
5.2.11 Small angle X-ray scattering (SAXS) 
For a dilute and monodisperse protein solution the X-ray scattering intensity is 
proportional to the spherically averaged single-particle scattering, i.e., the scattering 
of randomly oriented protein molecules. The average electron density of a typical 
biopolymer sample is only 30 % higher than that of the buffer system. Therefore, care 
must be taken with regard to the choice of buffer system (< 0.5 M salt or glycerol) in 
order to maximize the electron density contrast. The scattering data is plotted as the 
logarithm of the scattering intensity against the square of the momentum transfer, s2 
= [(4π/λ)sinθ]2 (Guinier plot), where λ is the X-ray wavelength [Å] and 2θ the 
scattering angle. From this linearized representation the molecular weight and the 
radius of gyration RG of a particle in solution can be determined. At a given 
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concentration the scattering intensity at zero angle (extrapolation to y-intercept) is 
propotional to the molecular mass of the scatterer, while the slope is inversely 
proportional to the square of RG. Deviation from linearity in the Gunier plot indicates 
solution non-ideality or significant deviation from globular shape of the scatterer, i.e., 
polydispersity due to interparticle interference (oligomerization or aggregation). As 
the signal of intensity vs. s decays rapidly the maximal resolution of SAXS is limited 
to s = (4π/λ)sinθ = 2π/d, where d ≈ 15 Å (reviewed in SVERGUN and KOCH, 2002 
and 2003). 
The SAXS measurements were performed in collaboration with the group of D. 
Svergun, EMBL Hamburg outstation, on beamline X33 in the HASYLAB (DORIS III 
storage ring at DESY). A temperature controlled (21°C) mica flat cell (V = 100µl) was 
used as sample cuvette. The X-ray wavelength was 1.5 Å and data were collected on 
a conventional Mar345 image plate detector (data range 0.012 < s < 0.45 Å-1) with a 
2.7 m sample-detector distance. A 5 mg/ml BSA standard (66 kDa monomer) in 50 
mM HEPES pH 7.5 was measured before and after the set of AMPK samples for 
calibration purposes. Standard and sample protein concentrations were measured in 
denaturing buffer in order to obtain exact values for the normalization of dilution 
series. As the X-ray beam intensity at the DORIS III synchrotron decays in between 
of injection cycles, AMPK storage buffer was measured immediatelly before and after 
each protein sample in order to allow precise baseline substraction. The PRIMUS 
program package (KONAREV et al., 2003) was used for raw data reduction and 
processing. 
The shape of AMPK_α2_1-339 and trimeric AMPK_2α2β1γ was calculated with the 
program DAMMIN (P. Konarev, EMBL Hamburg Outstation; SVERGUN, 1999). This 
program constructs a sphere of densely packed dummy atoms encompassig the full 
protein volume and its maximal diameter. Each of the dummy atoms is assigned to 
either protein or solvent. The DAMMIN ab initio algorithm then selects a continuous 
and compact set of dummy atoms that fits the scattering data by minimizing the 
discrepancy of calculated and measured scattering curves. The resulting structure is 
optimized by simulated annealing. 
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5.2.12 Crystallographic methods (CPT-2) 
5.2.12.1 Protein crystallization 
Crystals of uninhibited rCPT-2 and (R)-N-tetradecylcarbamoyl-aminocarnitine 
(ST1326, IUPAC: (3R)-3-[(tetradecylaminocarbonylamino]-4-(trimethylazaniumyl) 
butanoate, synthesized in-house by Med. Chem. Dept.) complex were obtained at a 
protein concentration of 10-20 mg/ml and 21°C using hanging drops with 0.15 M DL-
malic acid pH 7.0, 20 % (w/v) PEG 3350 or the modified microbatch (D'ARCY et al., 
2003) method with 25 % (w/v) PEG 1500, respectively (Index 91 and 37, Hampton 
Research). For complex formation rCPT-2 was incubated with an 3-fold molar excess 
of the inhibitor ST1326 for 3 h on ice prior to crystallization. The crystals were flash 
frozen in liquid nitrogen after 30 s soaks in mother liquor supplemented with 25 % 
(w/v) PEG 200 (uninhibited) or exchanging excess mother liquor and Al's oil against 
100 % (v/v) paraffin oil (ST1326). 
 
5.2.12.2 Data collection and processing 
Datasets for uninhibited rCPT-2 and the ST1326 complex were collected on beam 
line X10SA at SLS, Villigen, Switzerland. The measurements were performed at 100 
K with λ = 0.97853 Å (uninhibited tetragonal, Se peak wavelength), λ = 97899 
(uninhibited orthorhombic) and λ = 1.008 Å  (ST1326). The datasets were processed 
and scaled with XDS (KABSCH, 1993). The space groups were determined as 
P43212 (unnhibited tetragonal; a = b = 67.6 Å, c = 307.3 Å; α = β = γ = 90°;  
Matthew's Coeff. =  2.4 (Matthews, 1986); 1 mol/AU), C2221 (uninhibited 
orthorhombic; a = 95.2 Å, b = 97.3 Å, c = 310. 4 Å; Matthew's Coeff. = 2.4; 2 mol/AU) 
and P212121 (ST1326; a = 85.8 Å, b = 96.2 Å, c = 124.3 Å; α = β = γ = 90°; Matthew's 
Coeff. = 3.5; 1mol/AU). The diffraction of first crystals of uninhibited rCPT-2 from 
conventional bacterial expression was not sufficient for structure determination. In 
contrast, apo crystals obtained from material that was seleno-methionine labeled by 
standard procedures (CHENE et al., 1995) were of superior diffraction quality, which 
could be attributed to improved protein quality due to the different media composition 
and bacterial host protein expression profile during labeling. When the P43212 
crystals were soaked in mother liquor containing CoA the space group was changed 
to the maximal non-isomorphic subgroup C2221. In the resulting high resolution 
structure one partial molecule of CoA per molecule rCPT-2 could be assigned to 
__________________________________________________Materials and Methods 
 101
electron density at a crystal contact distant from the physiological CoA binding site. 
The XDS rejection statistics report merely 0.26 % rejected misfits which fully supports 
the choice of P212121 as the correct space group for the complex crystal despite the 
rather high value for Rmerge of 16.7% .  
 
5.2.12.3 Structure solution and refinement 
Molecular replacement was performed using AMoRe in the CCP4 interface 
(NAVAZA, 1992; Collaborative Computational Project, Number 4, 1994). For the 
ST1326 complex a rCPT-2 homology model built with XSAE (C. Broger, Roche, 
Basel) based on mouse CrAT (JOGL and TONG, 2003; PDB code 1t7n) served as 
search model. The solution was refined by simulated annealing with CNS 
(BRÜNGER, 1992). The final model was built using iterative cycles of model building 
in MOLOC (GERBER, 1992), solvent building in autoBUSTER (ROVERSI et al., 
2000) and refinement in Refmac (MURSHUDOV et al., 1999). Despite Se-labeling 
the structures of the uninhibited enzyme were also solved by molecular replacement 
using the refined complex structure as search model, followed by automated model 
building with Arp/wArp (PERRAKIS et al., 1999) and iterative Refmac and MOLOC 
cycles. For the orthorhombic (tetragonal) uninhibited structure 94.0 % (92.7 %) of the 
residues lie in the most favored and 5.4 % (6.8 %) in the additionally allowed regions 
of the Ramachandran plot. For the ST1326 complex structure these values are 88.2 
% and 11.3 %, respectively. Arg 498 (generously allowed region) and Leu 129 as 
well as Asn 230 (Ramachandran outliers) account for the differences to 100 %. 
PyMOL (DELANO, 2002) was used for preparing structure representations. 
Calculation of the electrostatic potential  surface of rCPT- 2 was performed with MOE 
(Chemical Computing Group, Inc.). 
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The crystal structure of the 26 kDa glutathione S-transferase from Schistosoma
japonicum (SjGST) was determined at 3 A˚ resolution in the new space group
P212121. The structure of orthorhombic SjGST reveals unique features of the
ligand-binding site and dimer interface when compared with previously reported
structures. SjGST is recognized as the major detoxification enzyme of
S. japonicum, a pathogenic helminth causing schistosomiasis. As resistance
against the established inhibitor of SjGST, praziquantel, has been reported these
results might prove to be valuable for the development of novel drugs.
1. Introduction
A fusion protein of the constitutively dimeric 26 kDa glutathione
S-transferase from Schistosoma japonicum (SjGST) with the full-
length intracellular domain of the human insulin receptor facilitates
investigation of receptor tyrosine kinase activation mediated by
dimerization (Baer et al., 2001). As the structures of both the core
kinase domain of the human insulin receptor (IRK; Hubbard et al.,
1994) and SjGST (McTigue et al., 1995) are known, we attempted to
crystallize the corresponding fusion protein, SjGST-IRK, by means of
carrier-protein-driven crystallization (Carter et al., 1994; Lim et al.,
1994; Zhan et al., 2001; Smyth et al., 2003). The construct SjGST-IRK
was shown to be stable during purification and kinase activity was
demonstrated in both auto- and substrate-phosphorylation assays
(Baer, personal communication).
Crystallization experiments with the fusion protein yielded crystals
that were shown to consist of SjGST only. The fusion protein is
obviously cleaved under the crystallization conditions and the
released SjGST crystallizes in a new crystal form (P212121), showing
distinctively novel features of the dimer interface and ligand-binding
site. Coordinates and structure factors have been deposited in the
PDB (PDB code 1y6e).
2. Experimental methods
Cloning of the construct GST-IRK will be described elsewhere (Baer
et al., manuscript in preparation). A PCR product comprising the
coding region of IRK (residues Val966–Lys1271, C969S, Y972F) was
cloned into pAc-G2T, resulting in a fusion protein containing a
thrombin-cleavage site as a linker between GSTand IRK. Expression
in Sf9 cells and purification was performed according to Baer et al.
(2001), with the exception that the crude lysate was incubated for
30 min at 277 K after adding Triton X-100 in order to solubilize
SjGST-IRK and Tris-(2-carboxyethyl)-phosphine hydrochloride
(TCEP) was used as a reducing agent during purification and
subsequent crystallization. 109 cells from a 1 l fermentation typically
yielded 10 mg of GST-IRK, which was found to be electrophoretically
pure (Fig. 1).
Prior to crystallization, GST-IRK was concentrated to 10 mg ml1
in 20 mM Tris–HCl pH 7.5, 150 mM NaCl, 2 mM TCEP in a 30 kDa
concentrator (Amicon, Millipore). Crystallization trials were set up
directly after purification at 294 K with the modified microbatch
method (D’Arcy et al., 2003) and crystals appeared within 7 d with
0.1M Bis-Tris pH 5.5, 25%(w/v) PEG 3350 (Index Screen condition
No. 42; Hampton Research) and 0.1M sodium acetate pH 5.5,
# 2005 International Union of Crystallography
All rights reserved
36%(w/v) PEG MME 5000 (Stura Footprint Screen 2 condition No.
20; Molecular Dimensions Ltd) as precipitant solutions. Crystals grew
to a maximum diameter of 15 mm within 7 d and were flash-frozen in
liquid nitrogen directly from the screening plates.
Data were collected at the Swiss Light Source beamline X06SA at
100 K using a 165 mm MAR CCD detector with a 260 mm crystal-to-
detector distance and an oscillation range of 1. 180 frames were
collected and processed with DENZO and SCALEPACK (Otwi-
nowski, 1993). Despite their small size, the crystals diffracted to 3.0 A˚
resolution and analysis of the systematic abscences revealed that they
belong to space group P212121. A noncrystallographic twofold axis
generates one GST dimer per asymmetric unit. The crystallographic
parameters are summarized in Table 1.
A molecular-replacement solution was found with the program
MOLREP (Vagin & Teplyakov, 1997; Collaborative Computational
Project, Number 4, 1994) using the modified PDB entry 1dug (Ware et
al., 1999), i.e. an unligated dimer of GST comprising residues 1–217.
Following rigid-body refinement in REFMAC (Murshudov et al.,
1997; Collaborative Computational Project, Number 4, 1994), the
structure of orthorhombic GST was refined by iterative conjugate-
gradient minimization with subsequent grouped B-factor refinement
in CNX (Bru¨nger, 1992) and manual model building with MOLOC
(Gerber, 1992; refinement statistics in Table 1). The two carboxy-
terminal amino acids Pro217 and Lys218 have been omitted from
refinement because no clear electron density was visible for these
residues. Based on the same argument, six residues (i.e. SDLVPR) of
the linker peptide encoded by pAc-G2T that were still attached at the
carboxy-terminus of the SjGST moiety according to mass spectro-
metry and amino-terminal sequencing (data not shown) were also left
out from refinement. Finally, 16 water molecules were added manu-
ally based on electron density and hydrogen bonding.
3. Results and discussion
Analysis of the X-ray data resulted in determination of the space
group as orthorhombic P212121, with unit-cell parameters a = 161.22,
b = 50.75, c = 57.50 A˚. The calculated volume of the asymmetric unit,
117 622.3 A˚3, was obviously incompatible with the presence of the
intact fusion protein with a molecular weight of 61 kDa. Conse-
quently, we concluded that only a fragment of SjGST-IRK had
crystallized. Although the fusion protein had been purified to
homogeneity, it was realised that the protein spontaneously degraded
to SjGST and IRK during prolonged storage on ice (i.e. within 10 d),
independent of the purification protocol employed (Fig. 1). Addition
of protease inhibitors (RoComplete, Roche; diisopropyl fluorophos-
phate, Fluka) to the storage buffer did not prevent degradation and
no proteases could be detected using a sensitive spectroscopic assay
with resorufin-labelled casein as substrate (Universal Protease
Substrate assay, Roche). We assume that spontaneous autocatalytic
cleavage as described for nucleolin (Chen et al., 1991), which also
undergoes degradation independent of both exogenous and endo-
genous protease activity, could be the reason for the degradation.
Replacement of the pAc-G2T linker with a thrombin-cleavage site by
a more rigid connection according to Smyth et al. (2003) was not
pursued as the introduction of a (Gly-Ala)5 linker resulted in
significant loss of activity in autophosphorylation assays indicating
suboptimal alignment of the kinase domains.
Molecular-replacement trials with a high-resolution structure of
SjGST (PDB code 1dug) were performed which yielded marked
peaks for both the rotation and translation functions. Given the
crystal packing and electron density, the crystals were determined to
consist of SjGST crystallized in space group P212121 (Table 1). To our
knowledge these are the first orthorhombic crystals of SjGST, as
exclusively tetragonal and hexagonal crystal forms have been
reported so far (Table 2; for a review, see Zhan et al., 2001). For the
deposited SjGST structures no correlation exists between space
group and crystallization conditions in terms of protein fusion or
presence of ligand (Table 2). Inspection of the crystal packing in
orthorhombic SjGST leads to the conclusion that the solvent-channel
cavity around the carboxy-termini could potentially accommodate
covalently linked peptides but no larger protein domain for carrier-
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Table 1
Data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
Beamline X06SA, SLS
Wavelength (A˚) 0.90006
Resolution (A˚) 30.0–3.0 (3.14–3.0)
Space group P212121
Unit-cell parameters (A˚) a = 161.22, b = 50.75, c = 57.50
VM† (A˚
3 Da1) 2.2
Solvent content (%) 44.8
Total reflections 114066
Unique reflections 9910
Average redundancy 11.5 (8.6)
I/(I) 8.1 (5.5)
Completeness (%) 99.6 (99.4)
Wilson B (A˚2) 43.2
Rmerge‡ 12.3 (43.7)
hBi (A˚2) 36.7
(B) (A˚2) 14.8
Rcryst (%) 21.1
Rfree (%) 27.9
R.m.s.d. bond lengths (A˚) 0.008
R.m.s.d. bond angles () 1.44
Ramachandran plot (%)
Most preferred regions 85.9
Allowed regions 12.8
Generously allowed regions 1.3
Disallowed regions 0.0
† Matthews (1968). ‡ Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IðhklÞ.
Figure 1
SDS–PAGE. Lane 1 shows the pooled elution fractions of SjGST-IRK from a gel-
filtration column. In lane 2 the same preparation is depicted after storage on ice for
10 d. The molecular weights (kDa) of the marker proteins are indicated.
Table 2
26 kDa SjGST (EC 2.5.1.18) structures in PDB.
Unit-cell parameters
PDB entry Space group a (A˚) b (A˚) c (A˚) Apo/ligand Fusion protein
1dug P41212 105.78 105.78 137.23 l Yes
1b8x P43212 93.40 93.40 57.60 a Yes
1bg5 P43212 92.17 92.17 57.57 a Yes
1gne P43212 94.74 94.74 58.13 l Yes
1ua5 P43212 92.53 92.53 57.66 l No
1gta P6322 125.20 125.20 70.20 a No
1gtb P6322 123.80 123.80 70.20 l No
1m99 P6322 115.07 115.07 78.28 l No
1m9a P6322 114.99 114.99 78.35 l No
1m9b P6322 116.57 116.57 78.75 l No
protein-driven crystallization. Although the overall structure of
orthorhombic SjGST is similar to previously reported SjGST struc-
tures solved in different space groups (r.m.s.d.s for main- and side-
chain atoms are 0.51 and 1.34 A˚ for chain A and 0.86 and 1.47 A˚ for
chain B using residues 1–217 of 1dug as reference), a unique contact
in the dimer interface was identified in the present structure.
The Fo  Fc simulated-annealing omit electron-density map
contoured at 4 clearly indicates that the side chains of Tyr103 are
rotated by approximately 100 around the C—C bond and the
positions of the side chains of Arg107 are considerably different
compared with all previously published SjGST structures (Fig. 2). The
phenyl hydroxy group of Tyr103 in chain A is at a hydrogen-bonding
distance from the guanidinium group of Arg107 of chain B (and vice
versa), thereby establishing a reciprocal dimer contact. Interestingly,
residue Tyr103 of SjGST is a critical part of the hydrophobic binding
site (H-site) for endogenous substrates, xenobiotics and the only
effective anti-schistosomial drug praziquantel, which additionally
contacts Arg107 (McTigue et al., 1995; Cardoso et al., 2003; Hu et al.,
2004). In the structure presented here, Tyr103 partially occupies the
praziquantel-binding site. Although the structure of SjGST with
bound praziquantel and its corresponding apo-structure (PDB codes
1gtb and 1gta, respectively; McTigue et al., 1995) imply a preformed
binding site for the drug, our data reveal a conformational flexibility
for the critical residues Tyr103 and Arg107. This, together with the
absence of a homologous tyrosine residue in mammalian GSTs
(McTigue et al., 1995), might support the design of specific drugs
targeting the 26 kDa GST of Schistosoma spp., which have already
been shown to develop resistance against praziquantel (Hu et al.,
2004, and references therein). The need for novel highly potent drugs
is also emphasized by the finding that an estimated 250 million people
are infected with Schistosoma spp.
The authors would like to thank the staff of X06SA at SLS,
Villigen, Switzerland for support during data collection, A. Friedlein
(F. Hoffmann–La Roche Ltd, Basel) for MS analysis, M. Gompert
(University of Cologne) for maintaining Sf9 cell cultures and Anke
Klose (University of Cologne) for constructing the linker mutant.
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Figure 2
Stereoview of the reciprocal dimer contact between Tyr103 and Arg107 of chains A (blue) and B (magenta). The distance of the hydroxy O atom of Tyr103A to the terminal
amino N atom of Arg107B is 3.3 A˚ and N" of Arg107A is 3.5 A˚ away from the hydroxy O atom of Tyr103B. Residues Arg107 of chains A and B each hydrogen bond (3.3 and
3.1 A˚ distance to W16 and W15, respectively) to water molecules.
__________________________________________________________Appendix 7.1 
  124
 
__________________________________________________________Appendix 7.2 
 125
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
7 
 
8 
 
9 
 
10
 
 
11
 
 
12
 
13
 
 
14
 
 
15
 
 
16
 
 
17
 
 
18
 
X-
ra
y 
st
ill 
im
ag
es
 (3
0 
se
c 
ex
po
su
re
s 
on
 P
ro
te
ro
s 
eq
ui
pm
en
t) 
sh
ow
in
g 
th
e 
di
ffr
ac
tio
n 
of
 A
M
P
K
_α
2_
1-
33
9_
D
56
A
/R
17
1E
/T
17
2D
 c
ry
st
al
s 
du
rin
g 
de
hy
dr
at
io
n/
re
hy
dr
at
io
n.
 T
he
 lo
ss
 o
f d
iff
ra
ct
io
n 
af
te
r f
ra
m
e 
10
 (8
8 
%
 re
l. 
hu
m
id
ity
) w
as
 fu
lly
 re
ve
rs
ib
le
. C
on
tin
ue
d 
on
 p
ag
e 
12
6.
 
__________________________________________________________Appendix 7.2 
 126
 
 Co
nt
in
ue
d 
fro
m
 p
ag
e 
12
5 
19
 
 
20
 
 
21
 
 
22
 
 
23
 
 
24
 
25
 
 
26
 
 
27
 
 
28
 
 
   
   
   
  
 
0
60
0
12
00
18
00
8788899091929394959697
t [
s]
rh [%]
I
fr
am
e 
10
0
60
0
12
00
18
00
8788899091929394959697
t [
s]
I
fr
am
e 
10
__________________________________________________________Appendix 7.3 
 127
 
__________________________________________________________Appendix 7.3 
 128
       
 
 
 
 
 
__________________________________________________________Appendix 7.3 
 129
 
__________________________________________________________Appendix 7.3 
 130
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
__________________________________________________________Appendix 7.3 
 131
 
 
 
M
ut
ag
en
es
is
 p
rim
er
s 
M
ut
at
io
n 
aa
 
co
do
n 
Se
qu
en
ce
 
T M
 
[°
C
] 
D
up
le
x 
En
er
gy
 
at
 5
5°
C
 [k
ca
l/m
ol
] 
En
er
gy
 c
os
t o
f 
m
is
m
at
ch
es
 [%
] 
D
56
A 
G
AT
JG
C
T 
5'
- G
AC
AG
A
AG
A
TT
C
G
C
A
G
TT
TA
G
C
TG
TT
G
TT
G
G
AA
AA
A
TA
A
AA
C
G
AG
 -3
' 
79
.8
 
-4
9.
1 
6.
3 
R
17
1E
 
C
G
A
JG
A
G
 
5'
- G
A
TG
TC
AG
A
TG
G
TG
A
A
TT
TC
TA
G
AG
G
A
TA
G
C
TG
TG
G
A
TC
G
C
C
 -3
' 
78
.1
 
-5
4.
7 
10
.8
 
I3
27
* 
A
TC
JT
A
G
 
5'
- C
TC
G
C
AG
TG
G
C
TT
A
TC
A
TC
TC
TA
G
A
TT
G
AC
A
A
TC
G
G
A
G
A
A
TA
A
TG
AA
C
C
 -3
' 
79
.2
 
-5
7.
7 
9.
9 
H
26
5*
 
C
A
TJ
TA
G
 
5'
- C
AA
C
TA
TC
A
AA
G
AC
A
TA
C
G
AG
AG
TA
G
G
AA
TG
G
TT
TA
A
AC
A
G
G
A
TT
TG
C
 -3
' 
79
.5
 
-5
4.
5 
11
.2
 
E2
64
* 
G
AG
JT
A
G
 
5'
- G
C
A
AC
TA
TC
A
A
AG
AC
A
TA
C
G
A
TA
G
C
A
TG
A
A
TG
G
TT
TA
AA
C
AG
G
 -3
' 
78
.9
 
-4
9.
5 
7.
7 
R
26
3*
 
C
G
A
JT
G
A
 
5'
- C
G
A
G
C
AA
C
TA
TC
AA
AG
AC
A
TA
TG
A
G
AG
C
A
TG
AA
TG
G
TT
TA
AA
C
A
G
 -3
' 
79
.8
 
-5
2.
8 
5.
1 
Q
25
0*
 
C
A
G
JT
A
G
 
5'
- C
TG
A
TG
C
AC
A
TG
C
TG
TA
G
G
TG
G
AC
C
C
C
TT
G
 -3
' 
79
.0
 
-4
5.
2 
7.
5 
Se
qu
en
ci
ng
 p
rim
er
s 
α1
 
5'
- g
ac
ta
ca
tc
tg
ta
aa
ca
cg
gg
 -3
' 
α2
 
5'
- g
gc
tg
ta
tg
cg
gg
tc
ct
ga
gg
 -3
' 
Pr
im
er
s 
us
ed
 fo
r i
nt
ro
du
ct
io
n 
of
 p
oi
nt
 m
ut
at
io
ns
, g
en
er
at
io
n 
of
 tr
un
ca
te
d 
co
ns
tru
ct
s 
an
d 
nu
cl
eo
tid
e 
se
qu
en
ci
ng
. 
____________________________________________________Appendix 7.4 
   132
Abbreviations 
A 
A  Deoxyadenosine 
monophosphate 
Å Ångström (10-10 m) 
ACC  Acetyl-CoA Carboxylase 
AcNPV  Autographa californica 
Nuclear Polyhedrosis Virus 
ADA  N-(2-Acetamido)-2-
iminodiacetic acid 
ADP  Adenosinediphosphate 
AMP  Adenosinemonophosphate 
Amp  Ampicilline 
Amp-  Ampicilline added 
Amp+  Ampicilline not added 
AMPK  5'-Adenosinemonophosphate 
activated protein kinase 
AMP-PCP Adenylyl-
methylenediphosphonate 
AMP-PNP Adenylyl-imidodiphosphate 
app.  approximately 
ATP  Adenosinetriphosphate 
AU  Arbitrary units 
AUC  Analytical ultracentrifugation 
 
B 
βOG  Octyl-β-D-glucoside 
Bis-Tris bis(2-Hydroxyethyl)amino-
tris(hydroxymethyl)methane 
bp  Basepair 
BPS  between PH and SH2 
 
C 
C  Deoxycytidine 
monophosphate 
CACT  Carnitine/ Acylcarnitine 
translocase 
CAMKK Ca2+/calmodulin dependent 
kinase kinase 
cAMP  3´-5´-cyclic adenosine 
monophosphate 
 
CAPS  3-(Cyclohexylamino) -1-
propanesulfonic acid 
cDNA  copyDNA 
CHAPS  
CHES  2-(N-Cyclohexylamino) 
ethanesulfonic acid 
B/L/M-CPT-1 Brain/ liver/ muscle carnitine 
palmitoyltransferase 1 
CPT-2  Carnitine palmitoyltransferase 2 
CrAT  Carnitine acetyltransferase, 
also abbreviated as CAT in 
literature 
CrOT  Carnitine oktanoyltransferase,  
also abbreviated as COT in 
literature 
CT  Carboxy-terminus 
 
D 
Da  Dalton 
DBM  Dodecyl-β-D-maltoside 
DLS  Dynamic light scattering 
DNA  Deoxyribonucleic acid 
dNTP  Deoxyribonucleoside 
triphosphate (N≡A; C; G; T) 
dsDNA  double stranded DNA 
DTT  Dithiothreitol 
 
E 
E.coli  Escherichia coli 
EDTA  Ethylene diamino 
tetraacetate 
EPPS  N-(2-Hydroxyethyl)piperazine-
N´-(3-propanesulfonic acid 
et al.  et alii 
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F 
FPLC  Fast Performance Liquid 
Chromatography 
 
G 
g  Gram 
G  Deoxyguanosine 
monophosphate 
X g  fold gravity accelaration  
(9,81 m/s2) 
Grb14  growth factor receptor-bound 
protein 14 
GSH  Glutathione (reduced) 
GST  Glutathione S-Transferase 
(from Schistosoma 
japonicum) 
 
H 
h  hour 
HEPES  N-(2-Hydroxyethyl)piperazin-
N´-2-ethansulfonsäure 
HIC  Hydrophobic Interactionn 
Chromatography 
 
I 
IEF  Isoelectric focusing 
IEX  Ion Exchange 
Chromatography 
IGF-1  Insulin-like Growth Factor 1 
IGF-1R Insulin-like Growth Factor 1 
Receptor 
IGFK  Insulin-like Growth Factor 1 
Kinase Domain (entire 
intracellular part of IGF-1R) 
IMAC  Immobilized metal affinity 
chromatography 
IPTG  Isopropyl-β-D-thiogalactoside 
IR  Insulin receptor 
IRK  Core insulin receptor kinase 
domain  
IRK3P  trisphosphorylated IRK 
(pY1146/50/51)  
IRS-1  Insulin receptor substrate 1 
IRTK  Insulin Receptor Tyrosine 
Kinase (entire intracellular 
part of IR) 
 
J 
JM  Juxtamembrane domain of 
receptor tyrosine kinases 
 
K 
K  Equilibrium constant of mass 
action 
KM  Michaelis-Menten-Konstante 
kbp  Kilo basenpairs 
kDa  Kilo dalton 
 
L 
LB  Luria-Bertani 
LCFA  Long chain fatty acid 
 
M 
M  molar, mol/l 
mA  Miliampere 
MES  2-(N-Morpholino) 
ethanesulfonic acid 
µg  Mikrogram 
µl  Microliter 
ml  Milliliter 
MIM  Mitochondrial inner 
membrane 
MOM  Mitochondrial outer 
membrane 
MOPS  3-(N-Morpholino)-
propansulfonsäure 
MW  Molecular weight 
 
N 
ng  Nanogramm 
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NT  Amino-terminus 
NTA  Nitrilo-triacetic acid 
 
O 
ori  Origin of replication 
 
P 
PBS  Phosphate Buffered Saline 
PC  Pyruvate carboxylase 
PCR  Polymerase Chain Reaction 
PDB  Protein Data Bank 
PEG  Polyethylene glycol 
PEG-MME Polyethylene glycol 
monomethyl ester 
pH   potentium hydrogenii  
pI  isoelectric point 
PIPPS  Piperazine-N,N´-bis(2-
propanesulfonic acid 
PKA  protein kinase A (cAMP-
dependent proteinkinase, 
here: catalytic domain of PKA) 
PMSF  Phenylmethylsulfonylfluoride 
 
R 
RNA  Ribonucleinsäure 
rpm   Revolutions per minute 
RT  Room temperature 
RTK  Receptor tyrosine kinase 
 
S 
s  Second 
SAXS  Small angle X-ray scattering 
SEC  Size exclusion 
chromatography 
SDS  Sodium Dodecyl Sulfate 
SDS-PAGE SDS-polyacrylamide gel-
electrophoresis 
Sf9  Spodoptera frugiperda cell 
  line 9 
cell line9 
SLS  Swiss Light Source 
  (synchrotron) 
STAU  Staurosporine 
 
T 
T  Deoxythymidine 
monophosphate 
T1D Type 1 diabetes mellitus 
T2D Type 2 diabetes mellitus 
TCEP Tris-(2-carboxyethyl)-
phosphine 
TRIS  Tris-(hydroxymethyl)-
aminomethan 
tRNA  transfer RNA    
 
U 
UV  ultraviolett 
 
V 
V  Volt; Volume 
v/v  Volume per volume 
 
W 
wt  Wild-type 
w/v  Weight per volume 
 
 
Amino acids were abbreviated according to 
the one and three letter codes recommended 
by IUPAC. 
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Zusammenfassung 
Eingeschränkte Insulinwirkung aufgrund peripherer Insulinresistenz oder 
unzureichender pankreatischer Insulinsekretion ist ein entscheidender Faktor für die 
Entstehung und Manifestation von Typ 2 Diabetes mellitus (T2D). Es befinden sich 
Insulin Rezeptor (IR) Agonisten in der Entwicklung, welche die cytoplasmatische IR 
Kinaseaktivität direkt aktivieren. Zwei Klassen solcher Verbindungen wurden von den 
pharmazeutischen Unternehmen Merck & Co., Inc., und Telik, Inc., entwickelt, aber 
weder in Patenten noch in der Literatur befinden sich Angaben, wie diese Verbindungen 
die Kinaseaktivität des IR aktivieren. 
Versuche, die Kristallstruktur dimerer IR Kinasedomänen oder von Komplexen 
derselben mit IR Agonisten innerhalb dieser Dissertation zu lösen, sind fehlgeschlagen. 
Allerdings zeigte die biophysikalische Charakterisierung des gesamten intrazellularen 
Abschnitts des IR einschließlich der Kinasedomäne ein intrinsisches Vermögen, 
unabhängig von den Enzym-Substrat-Wechselwirkungen der Autophosphorylierung zu 
dimerisieren. Die Ausbildung dieses Dimers wird durch die Anwesenheit eines 
spezifischen IR Agonisten verstärkt 
Kristalle verschiedener Konstrukte und Isoformen der AMP-aktivierten Proteinkinase 
(AMPK), einem wichtigen Zielmolekül für potentielle antidiabetische Substanzen, 
konnten gezüchtet werden. Trotz ausgiebiger Optimierungsversuche waren diese 
Kristalle nicht hinreichend für die Lösung der Kristallstruktur der AMPK. 
Die Kristallstruktur der Carnitinpalmitoyltransferase 2 (CPT-2), ein Protein in der durch 
AMPK ausgelösten Metaboliten-Signalkaskade, konnte dagegen gelöst werden. CPT-1 
und -2 importienen langkettige Fettsäuren in Mitochondrien. Die Modulation der 
katalytischen Aktivität des CPT-Systems wird derzeit für die Entwicklung von neuartigen 
Medikamenten gegen T2D untersucht. Die Kristallstruktur des vollständigen 
mitochondrialen Membranproteins CPT-2 konnte mit einer Auflösung von 1.6 Å gelöst 
werden. Die Struktur von CPT-2 im Komplex mit dem generischen CPT-inhibitor 
ST1326 [(R)-N-Tetradecylcarbamoylaminocarnitine], einem Palmitoylcarnitin-
nachahmendes Substratanalogon, derzeit in klinischen Studien für die Behandlung von 
T2D, wurde mit einer Auflösung von 2.5 Å gelöst. Diese Strukturen gewähren Einsicht in 
die Funktion von Aminosäuren, die in die Bindung von Substrat und die Determination 
der Substratspezifität involviert sind, und erlauben somit die Entwicklung neuartiger 
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antidiabetischer Wirkstoffe. Eine Insertion in der Sequenz der CPT-2 vermittelt die 
Membranlokalisation. Die Kartierung der für die CPT-2 Defizienz (eine vererbte 
Fettstoffwechselstörung) beschrieben Mutationen impliziert Effekte auf 
Substraterkennung und strukturelle Integrität der CPT-2. 
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